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Abstract 
 
The premise of this project was to engineer a novel viral platform with the capacity to 
enhance antitumour immunity. To this effect, the N1L gene was disrupted in a Lister 
strain vaccinia viral backbone that had previously been engineered to be tumour 
selective (VVL15∆N1L) and armed with transgenes encoding murine and human 
versions of GMCSF and IL12.   
 
In vitro, they retained potency for infecting, replicating in and killing a panel of murine, 
Syrian hamster and human cancer cells; all viruses were able to express their transgenes 
to detectable levels upon infection of every tumour cell line.  
 
In comparison to the parental virus (VVL15), VVL15∆N1L administration into immune 
competent in vivo tumour models (of pancreatic and lung cancer) led to enhanced intra-
tumour (IT) infiltration of neutrophils as well as markedly elevated circulating numbers 
of natural killer (NK) cells. VVL15∆N1L also enhanced the tumour infiltration of 
CD8+ cells. Functional immunoassays and flow cytometric analysis of T cells provided 
evidence of enhanced tumour specific adaptive immunity.  
 
In comparison to VVL15, IT VVL15∆N1L significantly reduced the growth of 
subcutaneously implanted syngeneic pancreatic tumours. This effect was predominantly 
due to cytotoxic lymphocytes, evidenced by the complete abrogation of efficacy upon 
repeating the experiment in mice that had been depleted of CD8+ cells. A similar 
treatment schedule reduced the formation of lung metastases from a primary 
spontaneously metastasising syngeneic lung cancer model; and translated into 
prolonged short-term post-operative survival when used as neoadjuvant to surgical 
resection. Efficacy in this context was contrastingly, due to an elevation in systemic NK 
cells; concurrent depletion of NK cells (but not CD4+ or CD8+ cells) completely 
abrogated the survival advantage.  
 
The IL12 transgene armed recombinant was the most effective antitumour therapeutic. 
Its IT administration into pancreatic tumours led to complete tumour eradication in over 
80% of tumour bearing mice and was effective in slowing the growth of other 
aggressive flank tumours. Neoadjuvant administration of VVL15∆N1L-mIL12 into 
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metastatic lung cancers dramatically prolonged long-term post-surgical survival, with 
apparent cure of 88% of mice.  
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Chapter 1 Introduction 
 
Vaccinia virus (VV) played a prominent role in one of the greatest achievements in 
medical history; the eradication of smallpox (caused by Variola virus). This occurred in 
the late 1970s, having claimed the lives of half a billion people worldwide in the 
preceding three centuries (2, 3).  
 
The origin of VV remains obscure. Whilst the related cowpox virus was used for initial 
immunization; by the early 20th century VV had become the foremost smallpox vaccine 
(3, 4). Although Variola is no longer present in any population, threats of bioterrorism 
from laboratory-preserved derivatives maintain the potential need for rapid widespread 
vaccination. Vaccine development therefore still remains active. In addition, VV has 
found utility in other roles, including the immunotherapeutic prevention of other 
infectious diseases (5) as well as in the treatment of cancer (6). With regard to the latter, 
the earliest studies (which mainly used replication-attenuated VV recombinants for fear 
of toxicity) were relatively disappointing in clinical trials.  
 
Second generation replication-competent VVs retain their ability to lyse tumour cells 
and spread through tumour tissue. Recent advances in deoxyribonucleic acid (DNA) 
recombinant technology (facilitating rational manipulation of the viral backbone), 
coupled with knowledge gains in the fields of molecular virology and cancer cell 
biology, have aided the development of safe and efficacious replication-competent 
oncolytic VVs. These are currently at the forefront of the most promising novel 
anticancer agents.  
 
Different VV strains were used in different areas of the world for mass vaccination. The 
anticancer potential of the Lister strain (VVL), which was popular in Europe has been 
the focus of our research group and is the platform upon which the current project is 
based.  
 
This introduction aims to review oncolytic virotherapy (OVT) using VV as an 
archetypal example. As our group has chosen to develop the Lister strain platform, 
studies using this strain will feature prominently. However illustrative lessons from 
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studies that have utilised other viral platforms will be also be referred to where 
appropriate. 
 
 
 Advantages of vaccinia virus as an onco-therapeutic agent 1.1
 
VV is a member of the poxvirus family, which can be broadly divided into those that 
infect vertebrates (Chordopox) and those that infect insects (Entomopox). VV belongs 
to the group Orthopoxvirae, a genus of the Chordopox subdivision. Structurally, its 
protein core surrounds a double-stranded linear sequence of DNA that approximates 
192 kbp (see http://www.ncbi.nlm.nih.gov/genbank and http://www.poxvirus.org) with 
its free ends linked by hairpin loops. This contains approximately 200, largely non-
overlapping genes, some of which are duplicated due to their position in inverted 
terminal repeat sequences (7). 
 
The capacity of VV strains to stably accommodate up to 25 kbp of exogenous DNA 
with little hindrance to infectivity makes it an ideal vector for use in vaccination and 
gene therapy (8). VVs have several other inherent features that make them particularly 
suitable for development as oncolytic agents for cancer treatment.  
 
VVs have an efficient life cycle, leading to the rapid destruction of infected cells and 
indeed tissue via local dissemination (9). Viral replication occurs in juxtanuclear 
“factories,” commencing one to two hours following infection. During this time, host 
cell nucleic acid synthesis completely shuts down as cellular resources are diverted 
toward viral production (10). The initial viral replication cycle is usually complete by 
eight hours, at which time the first extracellular virions are shed. Infected cells are 
usually lysed approximately 48 hours post infection. Up to 10,000 viral genome copies 
per cell may ultimately be produced, of which half will be packaged into infectious 
particles (11-13). 
 
VV strains have a broad tumour cell tropism. Unlike other oncolytic viruses (OVs), 
cellular entry is not dependent on specific surface receptors (that would otherwise limit 
entry to those select tumour cells expressing these) but appears to involve a number of 
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nonspecific membrane fusion pathways (14, 15). During its life cycle, VV may appear 
in four infectious forms, differing in the number of layers and composition of the 
encapsulating lipoprotein membrane(s) (9) (figure 1.1) 
 
 
 
Figure 1.1 The different morphological forms of vaccinia virus during replication (16) 
TGN: trans golgi network; MT: microtubules; IV: immature virus; IMV: intracellular mature virus; IEV: 
intracellular enveloped virus; CEV: cell associated enveloped virus; EEV: extracellular enveloped virus. 
 
 
Cellular entry of the two major forms, IMV (intracellular mature virion) and EEV 
(extracellular enveloped virion), is morphologically different (17). The single IMV 
envelope fuses with the cell membrane, releasing its naked core directly into the 
cytoplasm, whereas the double-layered EEV particle is first engulfed by endocytosis. Its 
outer membrane is subsequently disrupted by the low endosomal pH allowing the inner 
membrane to fuse with the endosomal membrane to release the nucleoprotein core into 
the cytoplasm.  
 
The relative molecular independence of the life cycle of VV, in comparison to other 
OVs such as the adenovirus genre makes it more resistant to alterations in host cell 
biology (18, 19). Uniquely, infectious vaccinia virions are pre-packed with virally 
encoded proteins; notably a virus-specific ribonucleic acid (RNA) polymerase 
accompanied by enzymes responsible for further mRNA processing and various early 
transcription factors (9). Viral transcription can therefore commence almost 
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immediately after cellular entry, within the cytoplasm. The minimal reliance on host 
cellular proteins for replication makes it difficult for the host cell to effect defensive 
manoeuvres based on alteration of its gene transcription profile. VVs may be genetically 
safer compared with other virus families, because their life cycle is entirely cytoplasmic, 
with little possibility of host chromosomal integration. 
 
VVs have the potential to be efficacious following systemic administration, a feature 
that would enable targeting of metastatic disease (20). VVs have acquired various 
mechanisms to evade host defences (discussed later) and their different morphological 
forms are antigenically distinct. Following infection, the relatively stable IMVs form the 
majority of virion particles in a host. They are brick shaped and measure 300 × 200 × 
120 nm. IMVs may be released only upon cell lysis. Upon release via cellular burst, 
abundant immunogenic viral proteins on their single lipoprotein envelope rapidly 
stimulate both innate and adaptive host defence mechanisms. A cell-associated virion 
(CEV) (figure 1.1) resembles a particle just about to bud off from the host cell and 
affords a means of direct cell-to-cell dissemination. If it does bud off into the systemic 
circulation, in contrast to IMVs, it maintains the additional host cell lipoprotein bilayer, 
which enables the resulting particle (EEV) to be (relatively) antigenically quiet (16). 
This, coupled with viral transmembrane proteins that antagonize components of innate 
(complement) and adaptive (neutralizing antibodies) systemic host defence, permits 
widespread dissemination of EEVs (21-26). Current mass viral production techniques, 
which depend on co-culture in a standard cell line, produce mainly IMVs. Strategies to 
induce the intra-host production of proportionately more EEV forms of VV are an 
active area of research (27). 
 
Advanced solid tumours often harbour areas of hypoxia secondary to outgrowth from 
and/or destruction of local vasculature. This contributes to the aggressive, treatment-
resistant phenotype of several cancers (28, 29). Hypoxia is detrimental to the efficacy of 
other types of OVs (30-32). In contrast, our group has demonstrated that hypoxia does 
not impair the replication or oncolysis mediated by VVL; its oncolytic potency against 
some tumour cells may even be enhanced in such an environment (33). 
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As described for other OVs VVL appears not to discriminate between “normal” cancer 
cells and cancer “stem like” cells (CSCs) (34, 35). In one study, a VVL recombinant 
demonstrated enhanced infectivity and replication in human breast CSCs compared to 
their non-stem like counterparts (34). There is accumulating evidence that at least some 
human solid tumours are initiated and driven by CSCs. CSCs are thought to be 
chemotherapeutic and radiation resistant and have been causally linked to failure of 
these modalities to prevent recurrence (36-38). 
 
Finally, a wealth of historic clinical data, accrued mainly from its use as a vaccine, 
confirms the excellent safety profile of VV. Nevertheless, in the extremely unlikely 
event of unchecked viral replication, effective antiviral treatment options are currently 
available (39, 40). 
 
 
 Vaccinia virus cancer selectivity 1.2
 
1.2.1 Inherent tumour selectivity 
 
Several VV strains have demonstrated tumour specificity and antitumour efficacy in 
preclinical models of malignancy (6, 20, 41, 42). Molecular drivers of oncogenesis are 
often conducive to viral replication. Indeed the hallmarks of cancer could almost be 
renamed as those that enable successful viral infection (43, 44). For example many 
tumour cells contain mutations that inactivate common cellular defence mechanisms 
that in normal cells act to counter both invading pathogens and tumourigenesis. These 
include defects in interferon (IFN) and apoptotic pathways (20, 45, 46).  Tysome et al. 
(19) compared the replication of a VVL recombinant in cultured normal human 
keratinocytes with that in its malignant counterpart (SCC25). There was minimal viral 
replication in the former, even when infected with five times the dose of virus used to 
infect the SCC25 cells.  
 
Oncogenic mutations that result in excess stimulation of the cell cycle may promote 
viral replication, mainly due to the provision of a large nucleotide pool. For example, 
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the epidermal growth factor receptor (EGFR) pathway is overactive in many, if not all, 
solid malignancies (47). Interestingly, VV may actively drive this pathway as part of its 
infectious cycle: VV DNA encodes a secreted epidermal growth factor (EGF) 
homologue, vaccinia growth factor (VGF), which binds to EGFRs on neighbouring 
cells, stimulating their replication; effectively priming them for imminent virus invasion 
(48, 49). 
 
Tumours usually harbour very rich but disorganized and “leaky” blood supplies (50). 
Large gaps between endothelial cells readily allow the large VV particles to leave the 
circulation at these junctures (42). Vascular permeability may be increased by 
elevations in temperature. Chang et al. demonstrated a 100-fold increase in uptake of 
systemically delivered VV by tumour following localized heat treatment (51). Some VV 
strains have tropism for ovaries (49), which has been at least partially attributed to their 
relatively permeable blood supply. 
 
Another potential mechanism for the inherent tumour selectivity of VV may relate to 
the overexpression of vascular endothelial growth factor (VEGF) within tumour micro 
environment(TME)s. VEGF is a major effector of angioneogenesis (50). Our group has 
recently demonstrated enhanced VVL uptake by various solid tumour cell models in the 
presence of VEFG. This appears to be effected by stimulation of the AKT signalling 
pathway, that ultimately leads to enhanced viral endocytosis (52). 
 
1.2.2 Engineered selectivity 
 
In general however, viral tumour selectivity is the exception rather than the rule. Viral 
infection of and replication in normal cells is enhanced by their phylogenetic acquisition 
of host genes that stimulate cell division, inactivate growth suppression or apoptosis and 
facilitate the high-jacking of cellular energetics in normal cells.  
 
Investigators have attempted to enhance tumour selectivity and thus safety of VV by 
genetic manipulation. Traditionally, strategies have relied on disrupting viral genes that 
are essential for replication in normal cells but not required for replication in cancer 
cells. The most popular of these in VV, has been disruption of the gene encoding the 
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vaccinia thymidine kinase (VTK) enzyme. VTK is essential for the synthesis of 
deoxyribonucleotides particularly in cells with low nucleotide pools, as is the case in 
most normal, well-differentiated mammalian cells. Tumour cells, however, usually have 
an abundance of nucleotides. VTK gene-deleted recombinant VVs have demonstrated 
enhanced tumour selectivity in a number of in vivo tumour models (6). For example, 
disruption of the VTK gene in the neurovirulent laboratory-derived Western Reserve 
(WR) VV strain reduced viral colonization and replication in the mouse central nervous 
system following intravenous (IV) administration, without affecting tumour tropism 
(20, 49).  
 
The VVL derivative from Moscow (LIVP) used by our group and others (53, 54) has a 
premature stop codon in the locus that encodes VTK (the J2R gene) (55). Interestingly, 
near complete deletion of the J2R locus, in our case by replacing a significant section of 
the coding sequence with marker transgenes encoding luciferase and lacZ enzymes 
(forming the VVL recombinant, VVL15), further enhanced the tumour selectivity of 
LIVP (Hughes et al., in press, Gene Therapy). 
 
Other candidate genes that could be disrupted include those involved in combatting host 
cell defence mechanisms. Numerous tumour types have defective apoptotic pathways 
and could thereby facilitate the selective replication of viruses harbouring mutations in 
anti-apoptotic genes. Specific candidates include the anti-apoptotic serpin proteins SP1 
and SP2 (56); F1L, which inhibits the release of cytochrome c; and N1L, a structural B 
cell lymphoma(Bcl)-2 homologue with additional  functions (57) (discussed later). 
Although deliberate disruption of these and other genes should theoretically enhance 
tumour selectivity, viral replication and oncolytic potency often deteriorate in 
proportion to the extent of genetic manipulation (58). Thus, a VV in which both SP1 
and SP2 coding sequences were disrupted was severely attenuated compared to viruses 
harbouring deletions in either sequence alone (55, 59). In our experience, a disruption in 
the J2R locus of LIVP is all that is required to strike a good balance between tumour 
selectivity and antitumour efficacy. For other strains however, particularly the more 
virulent ones such as WR, additional genetic disruption may be required prior to 
potential clinical use. Indeed the WR strain of VV required deletions of both VTK and 
VGF genes (49) (WR double deleted mutant (WRDD)) to obtain a tumour specific 
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variant that was significantly less virulent than either single deleted or wild-type viral 
counterparts.  
 
Finally, other innovative strategies have been utilised more recently to enhance tumour 
specificity. One such includes the genomic incorporation of tissue or hypoxia specific 
promoters, to conditionally drive key viral gene products upon infection of target tissue 
(60) or hypoxic environments (61, 62) respectively. Along similar principles, tissue 
specific post translational targeting strategies have also been recently used. Hikichi et al. 
(63) illustrated this with an attenuated VVL virus in which the B5R gene (essential for 
intracellular viral trafficking) was reconstituted with an additional 3’ sequence 
complementary to the microRNA, Let-7a. Let-7a is commonly down-regulated in 
tumour cells, whereas normal cells contain it in abundance. Translation of the 
recombinant B5R mRNA (and consequent virus production) could therefore only take 
place in tumour cells. 
 
 
 Unique characteristics of the Lister strain of VV  1.3
 
Different strains of VV were used in different areas of the world in mass vaccination 
campaigns in the 1900s. The New York City Board of Health (NYCBOH) strain and its 
derivative, Wyeth, were popular in the United States, whereas Copenhagen (CPN) and 
Lister found prominence in Europe. Historical records trace the origin of the Lister 
strain to Elstree, UK (1961), where the original master stock was prepared from calf 
lymph and distributed to centers in France, Moscow, Tokyo, and Atlanta. Early animal 
studies with VVL suggested a superior safety profile, particularly with regard to 
neurological sequelae (64-66). During the 1970s, in Japan, an attenuated Lister strain 
mutant, LC16m8, selected for its extremely low neurovirulence, was used to safely 
vaccinate more than 50,000 infants against smallpox (67). 
 
In the past decade, the WR strain of VV, a virulent laboratory-derived NYCBOH 
derivative with potent tumour lytic ability, has been the most extensively studied and 
genetically manipulated oncolytic VV. It is currently thought to be the most superior 
oncolytic strain, although this assumption was made on the basis of its replication and 
 
 
26 
 
oncolysis in only two human cancer cell lines in an early comparative study (20). In that 
study, the WR strain was selected to be rationally engineered to be more tumour 
selective with preservation of its oncolytic potency (WRDD) by deletion of the TK and 
VGF genes. Despite these alterations concerns remain regarding its safety and it 
obviously lacks the advantage of previous clinical usage. Furthermore, we recently 
discovered that VVL15 (table 1.1) actually replicated in and lysed tumour cells 
significantly better than WRDD in 11 of the 14 tested human cancer lines, although 
WRDD did perform better in similar in vitro analyses using murine cancer cell lines 
(Hughes et al., in press, Gene Therapy). Despite the latter, VVL15 demonstrated 
significantly better antitumour potency (compared to WRDD) in several immune-
competent murine cancer models (Hughes et al., unpublished data). Given the potency 
of WRDD against murine cancer lines in vitro, the improved effect of VVL15 against in 
vivo tumours must have been mediated by indirect mechanisms; for example, through 
modulation of host immunity or vascular compromise. The investigation of possible 
underlying mechanisms responsible for this effect is an ongoing focus of our group. 
 
Many of the open reading frames (ORFs) in VV are involved in viral genome 
transcription, replication, structure, and assembly. These are located centrally in the 
viral genome and are highly conserved among all Orthopoxviruses. Peripherally located 
genes are responsible for modulation of host antiviral defence and are strain specific. 
The function and indeed expression status of many of these have yet to be delineated, 
but genes encoding proteins that interfere with IFN pathways seem to be over 
represented, indicating their significance in host defence. Although there is only an 8% 
difference between the genomes of Lister and other strains (68), phenotypic and 
functional differences between strains must be a consequence of these differences. 
 
1.3.1 Genetic differences between Lister and other strains of VV 
 
Garcel et al. (68) sequenced a clonal isolate of a VVL substrain. The vast majority of 
the 201 possible VVL ORFs (192) had more than 98% sequence homology to those 
previously identified in other strains, including CPN and WR strains. L172 (A53R) 
encodes a tumour necrosis factor (TNF) receptor homologue found in VVL but is absent 
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in WR. An extra interleukin (IL)-18 binding protein gene (L013) is again present in 
VVL but missing in the WR strain. 
 
Genomic comparison between Lister, CPN, and WR strains conspicuously revealed a 
short sequence that encodes completely different proteins in the Lister genome (68). 
Part of this sequence (L196) bears resemblance to that encoding a transmembrane Bax 
(a cellular pro-apoptotic protein) inhibitor motif, found in various mammalian species 
and may therefore have been acquired by a historic recombination event with 
mammalian DNA. L196 therefore unsurprisingly encodes an apoptosis inhibitor (69). 
Another unique gene in this region, which is not present in CPN and WR strains 
encodes a TNF binding protein (L195) (70). In contrast its neighbouring gene, L194 
encodes a truncated version of a type-1 IFN binding protein that appears intact in the 
WR strain.  
 
Alternative sequences in the corresponding section of CPN and WR genomes include a 
gene encoding an IFNα/β binding protein (B19R/WR200) and a different anti-apoptotic 
gene, WR195 that encodes the serpin protein SPI-2 (an IL-1β converting enzyme 
inhibitor that ultimately inhibits Fas-mediated apoptosis).  
 
Finally, the gene encoding a semaphorin-like protein, L156 (A39R) (which stimulates 
monocytes and enhances production of proinflammatory cytokines (55)) is frame-shift 
mutated in the WR strain. That this plays a role in the immunogenicity of VV is 
dramatically demonstrated by the induction of systemic inflammation and pulmonary 
oedema in mice administered a WR recombinant expressing this transgene. 
 
To summarise, VVL therefore codes for at least two extra TNF binding proteins (L172 
and L195) in comparison to WR and CPN strains and could thus be better armed against 
the host TNF response. On the other hand, it lacks at least one IFN binding protein gene 
(WR200). There are also qualitative differences in genes encoding anti-apoptotic 
proteins. How these features relate to differences between the strains of VV with 
regards: the generation of antiviral or antitumour immunity, host toxicity and 
antitumour efficacy, remains to be elucidated. 
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1.3.2 Differences in virulence between Lister and other VV strains 
 
The most commonly reconstructed Lister strain variant for the purposes of antitumour 
therapy has been the Moscow derivative, LIVP. The WR VV is particularly 
neurovirulent, reflecting its origin from multiple passages through the murine brain 
(71). Although systemic inoculation with a VTK gene-deleted WR virus reduced viral 
recovery from off-target organs, titres in these organs were still significantly higher in 
comparison to that with LIVP (54). In one study, there was no viral recovery from the 
brain or ovaries of nude mice following an IV dose of 1 × 107 plaque-forming units 
(PFU) of VVL (54). Other organs also had a higher affinity for WR VV compared to 
VVL. Pulmonary titres were consistently higher at any given time-point following 
intranasal inoculation of similar doses of viruses (72). Indeed, as little as 5 × 105 PFU of 
intranasally inoculated WR caused severe signs of toxicity (including significant weight 
loss) and 50% death in immune-competent BALB/c mice (73). Similar toxicity was 
only observed with VVL if administered in doses 100-fold higher (74). 
 
Further characterization of the expression and functional aspects of individual VV genes 
will enable the rational engineering of more selective, safer, and potentially more 
effective recombinants. Table 1.1 outlines the range of VVL constructs that we and 
other groups have used as potential anticancer therapeutics.  
 
 
 Tumour targeted Lister strain derivatives that have demonstrated antitumour 1.4
efficacy 
 
In order to enhance VVL as an anticancer therapeutic, it is necessary to review its 
previous successes and shortcomings.  
 
VV, like other OVs mediates antitumour efficacy via both direct and indirect 
mechanisms. These include (a) direct viral oncolysis, (b) local vascular destruction, 
and/or (c) focusing of the effector host immune defence (both innate and adaptive) into 
the TME. All of these mechanisms may be augmented by incorporation of relevant 
therapeutic transgenes into the viral backbone.  
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As with other strains, VVL derivatives have demonstrated tropism for a variety of 
different tumour types both in cell culture and in animal models. Ascierto et al. (75) 
investigated whether molecular signatures within a particular tumour cell could predict 
permissivity of infection by the Lister strain recombinant GLV-1h68 (table 1.1). They 
screened the NCI 60 panel of human cancer cell lines (76), which covers a broad 
spectrum of human malignant cancers. Three genes were found to be consistently up-
regulated in permissive versus non-permissive lines: GDF15, a member of the 
transforming growth factor (TGF) superfamily that regulates inflammatory and 
apoptotic pathways; cluster of differentiation (CD)9, a transmembrane protein that 
promotes cell growth, activation, and mobility; and integrin β5, which plays a role in 
cell movement and adhesion. In contrast, far more genes were conspicuously down-
regulated. In general they included genes involved in stimulating nuclear factor (NF)-
κB or IFNα/β signalling and/or the activation of the RNA polymerase complex. In other 
words, the most permissive cell lines to GLV-1h68 had favourably pre-dampened host 
cell antiviral defence and gene transcription.  
 
Chen et al. (58) demonstrated a positive correlation between the replication efficiency 
of VVL derivatives in tumour cell culture and antitumour efficacy in the corresponding 
xenograft model. Although the latter largely reflected higher titres of replicating virus 
and thus oncolysis, they also postulated a significant bystander contribution from the 
innate immune system which should have been preserved in these animal models. 
Expression profile analysis post infection revealed up-regulation of characteristic 
“innate” cytokines, chemokines, and growth factors in tumour tissue, associated with a 
cellular infiltrate consisting of dendritic cells, NK cells, monocytes, and neutrophils (54, 
77-79). Thus even in animal models deficient in components of adaptive immunity, 
mechanisms additional to viral oncolysis contribute to antitumour efficacy. It is these 
mechanisms that will require optimisation as viral oncolysis is likely to be rapidly 
curtailed in immune competent models and human patients.   
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Table 1.1 A list of tumour targeted oncolytic vaccinia viruses derived from the Lister Strain  
Virus name Disrupted genes Transgene expression References 
GLV-1h68 J2R (VTK), F14.5L, A56R 
(haemagglutinin) 
Renilla luciferase-GFP fusion protein 
(RLUC-GFP), β-galactosidase,  
β-glucoronidase 
(54) 
GLV-1h99 J2R (VTK), F14.5L, A56R 
(haemagglutinin) 
Human norepinephrine transporter 
(into F14.5 instead of RLUC-GFP),  
β-galactosidase, β-glucoronidase 
(80) 
GLV-1h153 J2R (VTK), F14.5L, A56R 
(haemagglutinin) 
Human sodium iodide transporter (into 
A56R instead of β-glucoronidase) 
(81, 82) 
GLV-1h107, 
1h108, 
1h109 
J2R (VTK), F14.5L, A56R 
(haemagglutinin) 
VEGF single-chain antibody (GLAF-1) 
under different promotors, RLUC-GFP 
fusion protein 
(83) 
VVL-15 J2R (VTK) Luciferase, E. coli lacZ (84) 
VV-TK-P53 J2R (VTK) P53, E. coli lacZ (84) 
VVhEA F14.5L  Fused human endostatin and 
angiostatin  
(19) 
VVlacZ F14.5L E. coli lacZ  (19) 
VVRG F14.5L RLUC-GFP (85) 
VV-2-12 J2R (VTK), N region mIL-2, mIL-12, E. coli lac Z, luciferase (53) 
VV-mIL12 J2R (VTK) mIL-12, E. coli lacZ (53) 
VV-mIL2 J2R (VTK) mIL-2, E. coli lacZ (53) 
 
 
1.4.1 VVL as an anti-cancer gene therapeutic platform 
 
The unique properties of VV outlined previously make it particularly appealing for use 
as an anticancer gene therapeutic vector. In the context of cancer, the term gene therapy 
has traditionally referred to the replacement of or curtailment of dysfunctional tumour 
suppressor or promoting genes. The tumour protein(TP)53 tumour suppressor gene is 
commonly mutated in solid tumours and has therefore been targeted for replacement 
(86). Other transgenes that have been similarly used include pro apoptotic genes 
including death receptors/ ligands (e.g. Fas/Fas-Ligand(L)) (86) or those coding for 
products (e.g. short hairpin RNAs) that disrupt overexpressed growth-factors (87). 
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Traditionally, replication-impaired viruses have been utilised as the delivery vehicle 
amid concerns of potential toxicity. A VVL recombinant in which a TP53 transgene 
replaced the VTK gene locus was rendered replication inactive by mild psoralen and 
UV treatment. It successfully infected tumour cells in culture and induced cell death 
mediated by apoptosis in cell lines with dysfunctional TP53 (88). However in vivo, it 
was only effective following the ex vivo infection of tumour cells prior to their 
subcutaneous (SC) implantation, a situation which has little translational validity. Its 
replication-competent counterpart however, demonstrated superior tumour growth 
inhibition compared to the control virus in a pre-established xenograft model; an affect 
that was further enhanced by combination treatment with radiotherapy (89). Similarly, 
in a syngeneic orthotopic model of bladder cancer, instillation of the same replication-
competent VVL-TP53 virus decreased tumour incidence and improved survival 
compared to the control virus (90). 
 
Second generation oncolytic VVs that are replication-competent are currently being 
investigated as oncolytic biological agents capable of delivering transgenes. However, 
even with a potently replicating virus such as VV, several barriers within the TME may 
prevent spread to and transduction of all tumour cells, which in themselves will be 
genetically heterogeneous (91). The latter in particular means that restoring the function 
of a single gene is unlikely to succeed in curbing tumour growth.  
 
1.4.2 Combination with cytotoxic agents to enhance antitumour efficacy of VVL  
 
A population of tumour cells is genetically heterogeneous and will often harbour cells 
resistant to a single treatment modality. Although VV as an antitumour therapeutic 
operates through multiple mechanisms (92, 93), it is unlikely that every single tumour 
cell will be infected and lysed. Combination with other cytotoxic modalities may be 
more efficacious. 
 
For example, cisplatin and gemcitabine are commonly used for the treatment of 
advanced pancreatic cancer. Cisplatin binds to and cross-links double-stranded DNA. 
Gemcitabine is a nucleoside analogue that terminates DNA strand extension and thus 
replication. Both work by ultimately triggering apoptosis. These have been used in a 
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pancreatic xenograft model in conjunction with GLV-1h68 (94). Both demonstrated 
synergistic antitumour efficacy, although in the gemcitabine combination study, the 
final tumour size in the “virus only” group eventually caught up with that of the 
combination group. Possible mechanisms for this synergy include alterations in 
nucleotide pools, DNA repair pathways, and apoptosis. Additionally, changes in the 
local tumour vasculature associated with viral infection may have improved delivery of 
drug into the TME. Although synergism was demonstrated in this particular study, 
chemotherapeutics that target nucleotide production and DNA replication could 
adversely affect the viral life cycle (95). 
 
Tumour targeted OVs armed with transgenes may be used to locally deliver high 
concentrations of the translated product into the TME. For example, they have been 
used to deliver enzymes that mediate the conversion of a relatively safe prodrug into a 
highly potent cytotoxic one (96). One advantage of doing this is that not all cells need to 
be infected, because the active toxic drug may spill over onto neighbouring uninfected 
tumour cells to cause a bystander effect. A replication-competent VV armed with the 
transgene for the cytosine deaminase (CTD) enzyme, which converts 5-fluorocytosine 
(5-FC) into the active metabolite 5-fluorouracil (5-FU), demonstrated efficacy in animal 
models (95). Seubert et al.(97) employed a different prodrug/enzyme system in 
conjunction with the GLV-1h68 recombinant. GLV-1h68 contains a lacZ transgene that 
encodes β-galactosidase. The prodrug in this case was derived from a seco-analogue of 
the highly cytotoxic natural antibiotic duocarmycin (98) which is activatable by β-
galactosidase. Systemic addition of prodrug enhanced the antitumour effect of GLV-
1h68 in a xenograft model of human breast cancer. Viral replication in this study was 
not affected by the presence of either inactive or active metabolite, in contrast to a study 
in which a VV CTD/5-FC system was used (95). 
 
Similar to combination with chemotherapeutics, several preclinical studies have 
demonstrated mutual antitumour synergy afforded by combination of OVT with 
radiation (99). Most such studies, however, were conducted with adeno and herpes 
viruses. Timiryasova et al. (89) demonstrated that a TP53-ve glioma xenograft was 
more sensitive to a replication-competent VVL armed with a TP53 transgene in 
conjunction with radiotherapy compared to either treatment alone. As predicted, this 
effect was mediated by a superior level of apoptosis (89, 100). 
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Finally, VVL has also been armed with transgenes coding for receptors or transporters 
for radionuclides, to ensure their localization into tumour (101). Indeed, such a strategy 
could even render traditionally radio-resistant tumours more responsive. Gholami et al. 
(81) used a GLV-1h68 VVL backbone armed with the human sodium iodide symporter 
to effect uptake of radio-iodide tracer and exacerbate cell death in human anaplastic 
thyroid cancer cells in vitro. These cells are usually radio-resistant due to lack of the 
sodium iodide symporter on their cell membranes. The tracer concentrated in tumours in 
a xenograft model, although efficacy was not studied this particular experiment (102). 
 
A further discussion of OVT in combination with chemotherapeutic agents will be 
continued in the discussion chapter, in the context of synergistically enhancing 
antitumour immunogenicity (section 4.2.1).  
 
1.4.3 Enhancing VVL-mediated compromise of the local tumour vasculature  
 
Tumour angiogenesis is one of the hallmarks of malignancy (47). All cells must be 
within 200 µm of a blood vessel (the limit of diffusion of oxygen) for survival. Solid 
tumours therefore need to be highly vascularized, and this is generally mediated by an 
imbalance between tumour-produced endogenous pro and anti-angiogenic factors (103). 
Soluble growth factors such as VEGF and fibroblast growth factor (FGF)β are key 
molecules in this regard and are overexpressed by many tumour cells. However, the 
resulting neovasculature within a tumour is often poorly organized, with patchy areas of 
collapse and leakiness. This leakiness may contribute to the tumour selectivity of the 
relatively large vaccinia virions. Furthermore, VV may directly interfere with the local 
tumour vasculature. Kirn et al. (104) demonstrated that a WR recombinant infected and 
destroyed tumour-associated vascular endothelial cells. Our group has also witnessed 
this phenomenon with a VTK gene-deleted VVL derivative (VVL15). In addition, as 
previously mentioned, the infectivity of VVL15 for tumour cells appeared to be 
enhanced by the presence of VEGF (52).  
 
Tysome et al. (19) demonstrated that LIVP armed with a gene encoding a fusion protein 
comprising two potent endogenous angiogenesis inhibitors, endostatin and angiostatin 
(VVhEA), selectively inhibited tumour angiogenesis in a xenograft pancreatic cancer 
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model. This was associated with enhanced antitumour regression and animal survival, 
an affect that was reproduced in a similar model of head and neck cancer (105). 
Similarly, Frentzen et al. (83) created a recombinant Lister strain virus based on the 
GLV-1h68 platform in which a single-chain antibody against both human and murine 
VEGF (GLAF-1) replaced the VTK gene locus (GLV-1h108). This also demonstrated 
enhanced antitumour efficacy in xenograft models of human lung and prostate cancer; 
again, efficacy was associated with a significant reduction in microvessel density. 
Interestingly, in this study, the backbone virus GLV-1h68, when combined with the 
licensed monoclonal anti-VEGF-A inhibitor Avastin, demonstrated a regression pattern 
similar to treatment with GLV-1h108 alone. Stabilization of the haphazard tumour 
vasculature by independent angiogenesis inhibition may aid oncolytic viral delivery. In 
some circumstances, VV may in turn be mutually beneficial to drug delivery by 
decompressing and “normalizing” pre-existing intratumoural vessels (106, 107). 
 
 
 Oncolytic viruses and immunotherapy 1.5
 
Traditionally tumourigenesis was perceived as being consequent to the accumulation of 
a number of genetic misendeavours confined to the level of the cell. Clearly this was an 
oversimplification, with multiple mechanisms, including defects in regulatory systems 
external to the cell now known to be important. A relatively new addition to the 
“Hallmarks” of cancer is evasion of host immunity, acknowledging the significant role 
that immune surveillance plays in curtailing cancer ontogeny (43, 108). 
 
Throughout the life of an organism, the host immune system is thought to play an 
intimate surveillance mechanism seeking out and destroying genetically and thus 
antigenically deviant cells (109, 110). In most cases this should result in successful and 
clinically covert “elimination” of such cells. However, if the tumour is not particularly 
immunogenic or indeed the host lacks the capacity to mount a strong immune response, 
a stalemate “equilibrium” state occurs with little or no tumour progression; a situation 
often associated with markers of chronic inflammation. Eventually host immunity may 
be overwhelmed or completely bypassed leading to tumour “escape” with escalation of 
growth and dissemination. This phase is characterized by a TME containing 
 
 
35 
 
immunosuppressive cells and cytokines and supported by a relatively impenetrable 
structural framework (111).  
 
Although the latter picture implies a bleak outlook, the host immune system may retain 
the capacity to reject an “escaped” tumour. Thus reports of spontaneous cures have 
dotted the cancer literature and tumour infiltrating cells of both innate (e.g. NK) and 
adaptive (e.g. lymphocytes) immunological origin are positive prognosticators of 
survival (112). 
 
1.5.1 Why host immunity is often incapable of eradicating an advanced tumour 
 
In 1989, Janeway proposed that for the productive activation, processing and 
presentation of antigenic peptides, resting antigen presenting cells (APCs) require 
concurrent and independent binding of infectious non-self pathogen associated 
molecular patterns (PAMPs) to their cognate cellular pattern recognition receptors 
(PRRs)  (113, 114). PAMPs include nucleic acid intermediates (e.g. viral DNA, dsRNA, 
defective viral genomes (115)) or non-self protein derivatives (including glyco and lipo-
proteins that are often membrane associated (116, 117). These are recognised by a wide 
range of PRRs expressed in APCs and other cells and include toll-like (TLR), retinoic 
acid inducible gene-1 (RIG 1) like, and nucleotide oligomerisation domain (NOD) like 
receptors (118, 119).     
 
Later, Matzinger modified Janeway’s theory and introduced the “danger hypothesis” 
which proclaimed that the prime role of the immune system is to respond to cellular and 
tissue distress and not necessarily to non-self per. se.  APCs could  be stimulated by 
endogenously generated “danger” signals  in whose presence even tolerance to self-
antigens may be reversed (120). Endogenous danger signals from damaged cells may 
signal through PRRs in the absence of pathogen particles (121). Damage associated 
molecular patterns (DAMPs) include deranged host DNA or RNA, metabolic 
intermediates like uric acid (122), stress related proteins like high-mobility group 
protein B1 (HMGB1) (123, 124) and heat shock proteins (HSPs). Therefore, in the 
context of virotherapy, both self and pathogen (viral) related “danger” signals ultimately 
up-regulate genes coding for molecules that promote antigen presentation as well as  
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inflammatory mediators, that are designed to eliminate the offending pathogen or 
damaged cells (125).  
 
Both these theories agree on the importance of favourable APC activation to initiate an 
immune response and both might predict the relative inadequacy of the immune system 
to reject an untreated tumour. According to Janeway’s model (with the exception of 
pathogen induced tumours) there are no foreign PAMPs, whereas stably growing 
tumours were thought not to provide the requisite threshold of “danger signals” 
according to Matzinger’s hypothesis. Chronic inflammation, a feature of many TMEs 
(126) is however associated with perpetual tissue destruction and should theoretically 
provide a continuous supply of “danger signals”. Matzinger’s hypothesis will therefore 
need to incorporate the notion that individual DAMPs may differ in their potency to 
activate APCs and/ or that immune priming may only occur if DAMP mediated APC 
activation can overcome regulatory forces within the TME (see later). 
 
An obvious problem that host immunity is faced with is that tumour associated antigens 
(TAAs) are essentially peptides derived from variants of normal host proteins. There are 
of course exceptions and these include antigens associated with tumours causally linked 
to an infectious agent (e.g. human papilloma virus associated cervical cancer), those that 
are normally expressed in an immunologically privileged site such as in germ cells, or 
antigens that were only transiently expressed during embryogenesis (127). Furthermore, 
theoretically central thymic selection should have eliminated high affinity self-reacting 
T cell receptor (TCR) containing clones, whereas the few weakly self-reacting T cell 
clones that have escaped into the periphery should be curtailed from expansion by 
peripheral tolerance mechanisms.  
 
There are a number of well characterized immune evasion strategies that a tumour may 
employ both at the level of the cell and externally. Tumour cells often down-regulate 
components of antigen-presenting pathways i.e. the molecular events leading to the 
presentation of peptide on the class I major histocompatibility complex (MHC) (128-
130). In addition many tumour cells resist external cell killing strategies for example by 
impairing perforin or Fas binding (130). Some tumour cells secrete the stress induced 
ligands, MHC class I-related chains A or B (MIC A/B) whose prolonged secretion may 
down-regulate activating receptors on NK (NKG2D) and Cytotoxic T cells (131). 
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Furthermore, should a tumour antigen specific TCR bind to its cognate peptide-MHC on 
the tumour cell, some tumours also express inhibitory ligands (e.g. programmed death-
ligand(PD-L)1) whose concurrent binding to inactivating receptors on T cells may 
compel them to anergise or apoptose (132).  
 
Tumour cells may secrete non-specific immunosuppressive soluble mediators that 
directly inhibit cytotoxic T cells (129). These include prostaglandin E2, histamine, 
hydrogen peroxide and adenosine (133). Inhibitory cytokines and chemokines such as 
TGFβ (134) and IL10 (135) may also be expressed by many tumour cells. These 
directly or indirectly inhibit APCs and cytotoxic T cells; promote the development of an 
unfavourable T helper(Th)-2 skew in the ensuing effector immune response and play a 
role in the recruitment, maintenance and activation of modulatory cells. The latter  
include myeloid derived suppressor cells (MDSCs), T regulatory cells (T-regs), and 
tumour associated macrophages (TAMs) (111). These in turn may promote tumour 
growth through secreted growth factors and positively amplify the immunosuppressive 
TME (136). TMEs may also be characterised by the presence of immature APCs 
lacking co-stimulatory signals. Antigen presentation by these cells have been 
demonstrated to anergise de novo T cells but perhaps more importantly to induce the 
conversion of infiltrating T helper cells into regulatory ones (137).  
 
1.5.2 Shortcomings of traditional cancer immunotherapeutic strategies 
 
Although it is possible to vaccinate against pathogens causally linked to tumours, cancer 
immunotherapy, with a few notable exceptions has not yet made a successful transition 
into the clinic (138).  
 
Just as with vaccination against infectious diseases, cancer immunotherapy may be 
classified into passive or active. The former includes administration of preformed 
effector molecules such as cytokines and antibodies against TAAs, but it also 
encompasses adoptive immune cell therapy (i.e. autologous NK and T cells that are 
manipulated and expanded ex vivo and reintroduced into the patient).  
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In general, such “passive” therapies are designed to act directly on the tumour cell. This 
means that unless they encounter every single cancer cell, complete tumour eradication 
can only occur through bystander killing mechanisms, a situation that is unlikely to be 
achieved with mono therapy. With the possible exception of adoptive T cell therapy 
(139), long term memory and thus tumour surveillance is not a feature of passive 
immunotherapy (110).  
 
On the other hand “active” immunotherapy (often used synonymously with the term, 
tumour vaccination) refers to therapeutic (treating existing tumour) and prophylactic 
(preventing future tumours) strategies to boost host immunity to eradicate residual 
disease and generate tumour specific memory. Single or multiple TAAs, xenoantigens 
(homologous antigens derived from another species) and whole tumour cell lysates have 
been used in this regard. They have been delivered alone, along with various adjuvants; 
encoded as DNA or RNA on different vectors or delivered in autologous APCs (110).  
 
Both modalities have suffered from being targeted to a single or relatively few tumour 
specific epitopes (the exception being whole cell lysates). Even within a single patient, 
the tumour cell population can be extremely heterogeneous with the inevitability of 
tumour escape if such narrowly focused therapy is used. Of course multiple tumour 
epitopes may be exposed following targeted tumour cell destruction, but the 
surrounding immunosuppressive TME, coupled with the relative paucity of co-
stimulatory danger signals may hinder their ability to prime a response. 
 
For these reasons, research has recently focused on combining existing 
immunotherapies with non-targeted agents designed to counter some of the 
aforementioned hurdles. For example, co administration of cytokines (Th-1 associated) 
or antibody mediated eradication of T-reg and other suppressive cells (132). Likewise, 
at the effector end of the immune response, the survival of those effector T cells that 
have been successfully stimulated can also be prolonged. Ipilimumab has proved 
relatively effective in malignant melanoma trials using this approach.  Ipilimumab is an 
antibody against the CTLA4 receptor on activated T cells and prevents CTLA4 
mediated T cell inactivation (140).  
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Systemically administered non-specific immunomodulators such as IL12 or IFNγ 
showed initial promise as anti-tumour immunotherapeutic agents, however, their 
efficacy was limited  by the induction of host tolerance (141), as well as dose limiting 
toxicity (142). 
 
Finally, perhaps the biggest hindrance to success in previous trials of cancer 
immunotherapy were the patients themselves. As with all novel treatment modalities, 
enrolled patients have carried advanced stage solid tumours that have likely been further 
selected by failed traditional treatment modalities. Additionally, patients at this stage 
were likely to be globally immunosuppressed, either by progression of their disease or 
due to therapy. Therefore, to have any chance of success, immunotherapeutics should 
ideally be implemented at relatively earlier stages in the disease process.   
 
1.5.3 Hurdles for immunotherapy with OVT 
 
Based on their potency to infect and lyse tumour cells, the developmental focus with 
earlier generations of replication selective OVs was to enhance their in vivo tumour 
selectivity (35). A number of recombinant platforms for this purpose were developed, 
culminating in the first government approved OV, H101/Oncorine (Shanghai Sunway 
Biotech, China), for use as adjuvant therapy in head and neck cancer (143-145). This 
was an attenuated adenovirus in which the E1B55K gene (encoding an anti-apoptotic 
protein) had been deleted and was demonstrated to be tumour selective and safe; 
however to date, there has been no published data demonstrating long term survival 
benefit. 
  
Much preclinical and clinical data confirmed that regardless of the route of 
administration, OVs often infect cancers incompletely (146), a fact that would preclude 
the success of a therapeutic that solely relied on its ability to infect and lyse every single 
tumour cell. Despite being injected directly into the heart of an immunosuppressive 
TME (as with IT administration) an immune competent host generally retains the 
capacity to mount a strong antiviral immune response. Antigen presenting cells take up 
viral particles in the context of strong co-stimulation through PRRs. These mobilise to 
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local lymphoid tissue whence they are in a position to prime Th1 and 2 cells which 
direct the generation of effector antiviral cytotoxic T lymphocytes (CTLs) and 
antibodies respectively. Innate cellular (NK cells, monocytes and neutrophils) and 
humoral (complement) effectors are also mobilised and activated by virally infected 
cells or viral particles (147-149). These features are likely to lead to the relatively rapid 
clearance of virus. 
Furthermore, cancer patients may have pre-existing immunity to many of the commonly 
used oncolytic viral platforms including VV. Newly generated or pre-existing antiviral 
immunity may be expected to preclude multiple dosing and thus efficacy, if indeed 
antitumour efficacy was based solely on viral oncolysis. On the other hand, it is 
theoretically possible that pre-existing antiviral immunity could actually aid tumour 
clearance. Infected tumour cells could stimulate the rapid expansion, mobilization, and 
infiltration of virus-specific memory CD8+ T cells into the TME to inadvertently 
supplement viral oncolysis. Hu et al. (150) demonstrated that IT injection of adeno or 
vaccinia virus in hosts pre-immunized against these, led to enhanced tumour shrinkage 
and greater infiltration of lymphocytes into the tumour, compared to naïve tumour 
bearing hosts. Our group has also observed a similar phenomenon when VVL15 was 
administered into a syngeneic CT26 (murine colorectal cancer) model (Chard et al. 
unpublished data). Unfortunately, such bystander tumour cell destruction is generally 
not enough to eradicate tumour, especially when aiming to treat widespread metastases 
that often elude  systemically delivered viral infection (151). Certainly in the case of 
H101, clinical efficacy was partially impeded by a host antiviral response that 
eradicated virus at a faster rate than viral oncolysis (143, 152).  
 
The developmental focus in OVT subsequently shifted to establishing methods of 
minimising the induction of antiviral immunity. Concurrent administration of global 
leucocyte depletors such as high dose cyclophosphamide or more focused depletion of 
antiviral cellular effectors e.g. clodronate liposome mediated depletion of macrophages 
were demonstrated to enhance tumour viral load, that in some models were paralleled 
by efficacy (151, 153).  
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However, notwithstanding the risk of fulminant viral dissemination when 
immunosuppressing an already immunocompromised host, other barriers within the 
TME exist that are likely to limit widespread permeation within the tumour. These 
include multiple layers of connective tissue and extracellular matrix (69-70), high intra-
tumour interstitial pressure (71), poorly organized vasculature and non-cancer stromal 
cells that may not be permissive to viral infection (91, 111). Large tumours will also 
contain areas of overt necrosis or calcification (154) with patchy areas of low pH and 
hypoxia. These are generally not conducive to OV infection, although as previously 
mentioned, VVL appears to be able to  replicate in hypoxic conditions (33).  
 
Whilst, the concurrent IT administration of enzymes that degrade matrix (e.g. 
collagenases, matrix metalloproteinases) or antifibrinolytics or indeed arming larger 
OVs with transgenes encoding such enzymes (155) could aid the breakdown of 
components of this framework (156), the likelihood is that despite our best efforts, 
attempts at infecting and directly lysing every single tumour cell are likely to be futile. 
  
Nevertheless, efficacy with OVs has been demonstrated in numerous syngeneic primary 
and disseminated models of tumour when intralesional virion particles were few or even 
absent (157). Furthermore, we and others have consistently noted the absence of tumour 
regrowth upon re-challenge with the same syngeneic tumour cells following successful 
OV mediated tumour eradication (158). That this effect was often abrogated by 
depletion of certain lymphocyte subsets, pointed strongly to a prominent immune 
effector role.   
 
Rather than being problematic, we would therefore argue that it is the very ability of VV 
and other OVs to elicit a potent antiviral immune response that may ultimately be the 
key to their success. By virtue of their tumour selectivity, the finite immune resources 
of the host should theoretically be focussed into the tumour bed. Live replicating viruses 
should release multiple TAAs through oncolysis, against which tolerance may be 
reversed in the context of powerful, non-specific co-stimulatory signals, even in the face 
of an immunosuppressed TME (44, 159). In such a scenario infection and lysis of every 
single tumour cell would no longer be necessary. 
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1.5.4 Replication competent OVs and the induction of antitumour immunity 
 
A virus that strongly elicits a viral specific CD8+ T cell response would be expected to 
provide the best chance to cross-prime a favourable antitumour CD8+ T cell response. 
In monotherapeutic regimes, highly replication-competent viruses promote better CD8+ 
T cell responses than their attenuated and non-replicative counterparts (74). Tumour 
lysis induced by replicating viruses releases multiple sequestered TAAs but it also 
creates greater numbers and diversity of DAMPs. Replicating viruses may also go some 
way to breaking down some of the physical and physiological immunosuppressive 
barriers previously discussed (see section 1.5.3) as well as debulking the tumour mass. 
APCs should therefore be able to prime the immune response against otherwise 
unavailable TAAs in the context of superior co-stimulation and the subsequently 
generated effector response might be faced with an easier task in clearing lower volume 
residual tumour.  
 
In a comparison study that included Lister and NYCBOH derivatives, wild-type WR 
virus demonstrated the strongest level of replication in animal models and also elicited 
the strongest CD8+ T cell responses following both intraperitoneal and intranasal 
infection (74). This phenomenon was attributed to the engagement of the co-stimulatory 
receptors, OX40 and CD27 (both TNF receptor family members) on T cells; a 
phenomenon that was only observed with the more virulent strains and recombinants of 
VV.  
 
There are however two potential problems with using an extremely potent replicating 
virus as an antitumour therapeutic. First, such viruses are likely to be dose limited by 
toxicity, especially in the context of the likely need to use relatively high doses in 
patients with advanced cancer. The wild type WR strain persisted significantly longer in 
off-target organs such as lungs and ovaries and afflicted considerable toxicity in both 
immune-competent and  nude animal hosts (74). In contrast, as mentioned previously, 
the Lister strain was cleared more than two times faster and was 100-fold less toxic 
following intranasal administration. Second, although a stronger CD8+ effector 
response is likely with potently replicating viruses; when they are used as monotherapy 
(i.e. for both prime and boost phases), the antiviral effector response is likely to 
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dominate the antitumour response as viral antigens are likely to be vastly more 
immunogenic than TAAs (see section 1.5.8). 
  
1.5.5 Oncolytic viruses and immunogenic cell death  
 
Certain individual or combinations of “danger” signals may be more or less effective at 
initiating and propagating immune responses. This concept of immunogenic vs non 
immunogenic cell death (ICD) is a necessary modification to the “danger” model of 
immunity, as despite the potential release of multiple different types of endogenous 
damage associated molecular signals, immune tolerance clearly does not reverse every 
time a cell dies. There is currently intense research activity in identifying whether 
different modes of cell death induced by therapeutic agents including OVs, could be 
characterised by combinations of danger of signals that either positively or negatively 
favour the stimulation of an adaptive immune response (160-162).  
 
Much work in this field has been generated by teams that have previously investigated 
chemotherapeutic induced ICD  with the discovery that some agents like mitoxantrone 
appear to induce antitumour immunity independent of their direct  mechanism of action 
(163, 164). Classically the dichotomy between apoptotic and necrotic cell death was 
synonymous with immune tolerant versus inflammatory/immunogenic death 
respectively. This we now know was an oversimplification. Certainly, other modes of 
death have also been described based on morphological features and activation of 
certain death pathways and are encompassed by terms such as necroptosis, pyroptosis 
and autophagy (44, 165, 166). These modes as described do not fit neatly into 
immunogenic versus non- immunogenic subcategories (164); thus apoptosis for 
example, contrary to traditional dogma may also be immunogenic.  
 
The definition of ICD is currently in a state of flux but presently includes the surface 
expression of pre-apoptotic calreticulin (167), the surface translocation of uric acid 
(122), expression and release of HSPs (124, 164), adenosine triphosphate (ATP) and/ or 
the nuclear protein, HMGB1 (164, 168). Calreticulin binds to LDL receptor related 
protein on APCs to drive their cellular activation (169). HMGB1 is released following 
both apoptotic and necrotic cell death and binds to activating TLR2/ 4, receptor for 
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advanced glycation end products (RAGE) and T cell immunoglobulin and mucin 
(TIM)-3 receptors in APCs (165). ATP released from cells that die through a phase of 
autophagy, binds to the purinoceptor P2X7 in dendritic cells (DCs). This leads to the 
activation of the NLRP3-ASC (see index of abbreviations) inflammasome that drives 
the secretion of activated IL1β which ultimately polarises the developing adaptive 
immune response toward the generation of IFNγ secreting CD8+ T cells (44, 170).  
 
OVs are capable of killing tumour and some associated stromal cells through multiple 
different classically defined modes of cell death, in association with some of the 
aforementioned immunogenic molecular markers. Often a single mode of death tends to 
dominate, depending on the virus, tumour and host. Thus VV has been demonstrated to 
kill human cancer cells through apoptosis, necrosis or necroptosis in association with 
HMGB1 release (59, 171-173). Autophagy (which refers to the sequestration, 
degradation and recycling of organelles and proteins within the antigen donor cell) 
associated cancer cell death has been shown to be effected by adenovirus (174), 
Newcastle disease virus (175), reovirus (176) and herpes simplex virus (HSV) (177) and 
appears to be a particularly immunogenic mode of cell death. It is associated with the 
release of HMGB1 (178) and uric acid (179) in addition to ATP, by which it is more 
commonly defined (180, 181). Interestingly, antigens from cells undergoing autophagy, 
may be processed through both MHC pathways in APCs (i.e. cross presented) (182-
185). 
 
Throughout the course of their evolution, cancer cells often acquire mutations in key 
components of apoptosis (and other death pathways). The success of an anticancer 
therapeutic might lie in its ability to induce death through alternative, relatively intact 
death modes within the cancer cell, e.g. necroptosis (186) or autophagy. This is more 
likely to be exploited by OVs that have plasticity in their induced modes of cell death. 
VV for example may kill cells by apoptosis, necroptosis or necrosis (165). Furthermore, 
the deliberate disruption of certain virulence genes, which inhibit strategic points in 
certain death pathways, could persuade the infected cell to die in a potentially greater 
immunogenic mode of death. Arming OVs with transgenes that promote autophagy or 
necroptosis for example could achieve a similar result.   
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1.5.6 The role of the innate immune system in mediating the antitumour effects of 
VV immunotherapy 
 
Innate immunity plays a well-established and pivotal role in helping to prime and direct 
subsequent antigen specific adaptive immunity, but its cellular and soluble players may 
also contribute to tumour clearance via more direct mechanisms of action. 
 
1.5.6.1 Antigen presentation 
 
Following ubiquitinisation, cytosolic proteins in nearly all nucleated cells undergo 
proteasome mediated degradation into peptides of up to 25 amino acids in length. These 
are transported to the endoplasmic reticulum (ER) lumen via transporter associated with 
antigen processing (TAP)-1 or 2 proteins, trimmed further into 8-10 αα peptides and 
loaded via chaperone molecules into an MHCI molecule, before being translocated to 
the cell surface ready to engage CD8+ restricted T cells (187). Different components of 
this antigen processing machinery in tumour cells are often defective or absent (159, 
188, 189).  
 
The classic MHCII antigen presenting pathway is generally restricted to professional 
APCs and involves the degradation of proteins in lysosomes that have either been 
generated from the endocytosis of extracellular antigens or through autophagy (and thus 
carry intracellular antigens). MHCII molecules carrying invariant chains in their peptide 
binding groove (Class II-associated invariant chain peptide (CLIP)) are subsequently 
channelled to these endosomes where CLIP is exchanged for the epitope peptide.  
Peptide bound MHCII molecules are then transported to the cell surface ready to engage 
CD4+ restricted T-helper cells.   
 
In general, antigens are channelled separately via these pathways, with endocytosed 
lysosomal antigens ultimately being presented in MHCII complexes, in contrast to 
proteasome degraded intra cytoplasmic epitopes that are presented in MHCI complexes. 
APCs are the only cells in vivo that retain the capacity to “cross” present antigens (190, 
191) i.e. they can process and channel antigens of extracellular origin (self or non-self) 
through an (non-infectious) endocytic route into MHCI complexes. In this scenario, 
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peptides from such antigens could engage both CD4+Th cells and CD8+ CTLs to obtain 
maximal “help” and amplification of an effector CTL response.  
 
TCR engagement is one of the three major signals required to prime naïve T cells into 
effector and memory cells, the other two being cell-cell and cytokine (paracrine) 
mediated co-stimulation. Key co-stimulatory pairs of molecules found on APCs and T 
cells respectively include CD80/86 with CD28; CD40 with CD40L and 4-1BBL with 4-
1BB. Class I and II MHCs in intra-tumour DCs obtained from tumour models and 
patients are often down regulated along with their co-stimulatory molecules (188, 189, 
192). Such APCs may also express inhibitory molecules like PD-L1 (193).  
 
Many OVs that are currently under investigation are capable of reversing the pre-
dampened state of intra-tumour APCs (159). APCs that have been isolated from the 
spleens of murine tumour models display lower expression of co-stimulatory molecules 
than their naïve counterparts, but this expression is reversed or even enhanced in some 
cases after OV injection into the tumour (194, 195). In the presence of OVs, APCs 
receive additional activation signals through engagement of their pattern recognition 
receptors (see section 1.5.1), which drives the production of key innate effector 
molecules, particularly the type-1 IFNs (159, 196, 197). Type-1 IFNs up-regulate MHC 
pathways in APCs and cancer cells, as well as co-stimulatory molecules like CD40, 
CD80 and CD86 on APCs.  
Some OVs have the capacity to enhance cross presentation of viral and TAAs. Thus 
uninfected DCs were able to prime a CD8+ T cell response against viral and non-viral 
TAA  following exposure to tumour cells infected with Modified vaccinia Ankara 
(MVA) (an attenuated strain of VV) (198, 199), reovirus (194) and measles virus (200). 
 
1.5.6.2 Cellular innate immune effector cells 
 
As previously described (section 1.4), the replicating VVL recombinant GLV-1h68 
selectively colonized a range of human xenografts in nude mice following IV 
administration. In these models, gene expression profiling consistently revealed a 
positive correlation between tumour eradication and host expression signatures 
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representative of “innate defence” activation (79). These included IFN regulatory  genes 
(e.g., signal transducers and activator of transcription(STAT)-1 and interferon 
regulatory factor (IRF)-7; certain chemokines and their receptors (e.g. regulated on 
activation, normal T cell expressed and secreted (RANTES), IFNγ induced protein-10 
(IP10), monocyte chemotactic protein (MCP)-1); and cytokines:  type-1 IFNs, IL1s, 
IL6, IL15, and IL18. 
 
Peritumoural infiltrates of mononuclear and granulocytic cells are also a feature of 
virally treated tumours. In a syngeneic colorectal tumour model treated with WRDD, 
massive tumour necrosis occurred consequent to the influx of neutrophils interrupting 
tumour vascularity (157).  
 
NK cells are directly cytotoxic to tumour cells, and infiltrating NK cells appear to be a 
positive prognostic factor in some tumours (201-204). Indeed in some tumour models 
treated with OVTs, NK cell depletion abrogated tumour clearance (153). OVs may 
therefore be an ideal candidate to focus an NK cell infiltrate into the TME (153, 205). 
Given their potential importance in the context of the current project, the next section 
provides a detailed description of the role of NK cells in limiting viral and tumour 
growth (section 1.5.6.3).  
 
In other tumour models however, the direct antitumour contribution by innate immunity 
may be more modest, instead appearing to primarily limit viral replication and 
oncolysis. For example, cyclophosphamide depletion of leukocytes prior to the 
administration of GLV-1h68 into a human breast tumour xenograft model actually 
enhanced tumour eradication (206). We have also demonstrated enhanced uptake of IV 
administered VVL15 in syngeneic tumour bearing immune-competent mice following 
selective and temporary monocyte depletion (Ferguson, unpublished data).  
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1.5.6.3 The role of NK cells in controlling local tumour growth and metastasis  
 
1.5.6.3.1 Activation of NK cells 
 
NK cells are a key cellular component of the innate immune system and play significant 
roles in immune surveillance against cancer cells as well as host defence against 
pathogens, particularly viruses. They are of lymphoid origin but lack clonal specificity. 
This enables them to be activated in response to a range of non-specific stimulants. In 
the steady state, NK cells comprise 5-20% of peripheral blood mononuclear cells and 
may also be found in spleen, lymph nodes and visceral organs (207). 
 
Traditionally, NK cells were thought to be activated solely by cells missing MHCI 
molecules (e.g. in tumour transformed or virally infected cells), which in healthy normal 
cells  bind to inhibitory NK receptors and prevent the damaging consequences of their 
stimulation (208). However activation is now known to occur as a consequence of a 
complex balance of inhibitory and activating ligands. The latter include host cellular 
ligands that are not constitutively present, but which may be induced by cellular stress 
(207).  
 
Important families of NK receptors include the murine Ly49 lectin like receptors (in 
mice), killer immunoglobulin like receptors (KIRs), the natural cytotoxicity receptors 
(NCRs) and the NKG2 family of receptors.  
 
KIRs and the murine Ly49 receptors bind to the MHCI or components thereof and are 
generally inhibitory in nature (209, 210). However some members of their families are 
stimulatory, and are often activated by viral particles e.g. KIR2DS1 activates NK cells 
upon recognition of an Epstein-Barr virus (EBV) peptide loaded MHCI (211) and 
likewise Ly49H following recognition of the m157 ORF of murine cytomegalovirus 
(CMV) (212).  
 
NCR and NKG2 receptors are generally activating in nature and important in tumour 
cell lysis. The NCR, NKp46 (on mice and humans) is particularly important in this 
context (213). NKp46 is also activated by viral derived ligands (214); for example the 
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vaccinia haemagluttinin protein A56 activates it, triggering NK cell mediated cellular 
cytotoxicity (215). NKG2D binds to stress induced ligands such as MIC-A or MIC-B, 
often present in tumour transformed cells and appears to be critical to the control of 
infection with VV (216). NKG2D ligands may also be induced on cells involved in 
antigen presentation (DCs, macrophages and CTLs).   
 
Finally CD16, a receptor for the Fc portion of immunoglobulin molecules, is 
responsible for the antibody dependent cellular cytotoxicity (ADCC) mediated by NK 
cells upon binding antibody coated tumour cells. This appears to be a primary 
mechanism by which antibody based immunotherapy (e.g.  monoclonal antibodies like 
trastuzumab (anti-human epidermal growth factor receptor (HER)-2) and cetuximab 
(anti-EGFR)) eradicates tumours (217).  
 
1.5.6.3.2 The role of NK cells in curbing tumour growth and metastasis 
 
NK cells employ three main strategies to kill their activating cell: the secretion of 
cytolytic granules, death receptor mediated apoptosis and the production of cytokines 
particularly IFNγ (218). 
 
NK cells may kill through release of preformed granules containing perforin and 
granzymes, akin to CTLs (218-220). This is the fastest mode of cell death. Many studies 
have shown that perforin plays an important role in the immune surveillance of several 
malignancies (221).  
 
A slower mode of death (hours) may occur through the extrinsic apoptotic pathway in 
target cells, following engagement of the cell death surface receptor Fas by TNF family 
ligands (Fas ligand (FasL) or TNF-related apoptosis-inducing ligand (TRAIL)) 
expressed on NK cells (222). Cancer cells are often resistant to this mode of death. 
 
Activated NK cells secrete many cytokines including IFNγ. This cytokine may 
eliminate tumour cells by directly inhibiting their proliferation and/ or by the induction 
of antiangiogenic factors e.g. IP10 (223, 224). It can also enhance the sensitivity of 
neighbouring tumour cells to perforin/ granzyme or death ligand mediated cell death 
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(225). IFNγ may also induce DCs to produce IL12, which aids the development of 
antitumour cytotoxic T cells (226).  
 
Numerous experimental studies have demonstrated that NK cells can eliminate tumour 
cells that either express activating ligands or lack inhibitory ligands on their surface 
(207, 227). Mice deficient in NK cells have higher rates of spontaneous tumour 
generation and accelerated growth of induced tumours (228-230). Low NK cell activity 
is also associated with increased cancer risk in humans and there is evidence of NK cell 
dysfunction in advanced cancer patients (231).  
 
NK cells appear to play a role in the prevention of metastatic disease. Certainly in 
animal studies, expansion and activation of NK cells using CpG motifs (TLR agonists) 
or IFNγ is sufficient to prevent pulmonary and metastatic dissemination (232, 233).  
These and other studies have promoted the development of therapeutic protocols 
designed to enhance the activity of NK cells in the context of tumour.  
 
1.5.6.3.3 NK cells and viral infection 
 
Cancer therapeutics that utilise a tumour selective virus platform, may exploit their 
additional capacity to rapidly recruit and activate NK cells within the TME. Little is 
known about the migration of NK cells in untreated tumours (although selectins may 
play a role (234)), but migration towards virally infected cells is mediated 
predominantly via the chemokine receptors CCR2, CCR5 and CXCR3 (235). 
 
Virally infected cells activate NK cells through many of the same receptors used by the 
tumour cells, described above. In addition NK cells may also be activated by cytokines 
released upon viral infection (236). The major activators include type-1 IFNs, IL12, 
IL15 and IL18. They all enhance NK cell mediated cytotoxicity (237). Stimulation of 
TLRs on NK cells is another activation mechanism utilised by viruses and other 
infectious organisms (238-240). TLR2 stimulation on murine NK cells appear critical 
for the control of VV in vivo (216).  
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Intriguingly, viral mediated NK cell activation could lead to the generation of 
“memory” NK cells, a feature hitherto recognised as a hallmark of the adaptive immune 
response (227). For example, a murine CMV model of infection, gave rise to long lived 
memory like NK cells, with enhanced sensitivity to ligands that signal through 
unstimulated activating receptors (241-245). Thus NK cells that had been initially 
driven by a powerful non-tumour stimulant, may up regulate receptors important in 
tumour eradication e.g. NKp46 and NKG2D, and have demonstrated enhanced cross 
reactivity to tumour (227). This may be an important mechanism of OVT mediated 
antitumour efficacy.  
 
1.5.6.4 Effective harnessing of innate immunity 
 
OVs have adapted various strategies to ensure survival, replication and propagation in 
their hosts. These are mediated by different virulence gene products that may be 
classified as follows: those acting intracellularly e.g. to block apoptosis; those acting on 
the cell surface to enhance or supress cellular signalling cascades and those that act 
extracellularly to block secreted components of the antiviral immune response e.g. 
decoy molecules that sequester cytokines and chemokines.  Vaccinia codes genes that 
fall into all these categories, and features genes designed to counter innate antiviral 
defences; namely apoptosis, IFN and TNF responses (9, 68). One way of enhancing the 
innate immune response against a virus in a bid to provide a backdrop for efficient 
antigen presentation would be by arming it with transgenes encoding innate 
immunomodulators like IFNs, TNFs or chemokines. For example, the IFNβ transgene 
was cloned into the B18R locus (which codes for an anti-interferon protein) of a WR 
VV recombinant (246). Antitumour efficacy was enhanced despite the anticipated 
enhanced clearance of virus.  
 
An alternative way to achieve the same aim would be to disrupt one or more of the viral 
genes that curb antiviral immunity such as the VV N1L gene (247). 
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1.5.7 The VV N1L gene 
 
The VV N1L gene (called L025 in the VVL strain) is a major virulence gene, that when 
disrupted, was shown to significantly reduce pulmonary toxicity following various 
routes of administration into animal models (248, 249). Replication of mutant virus in 
cultured cell lines were not however attenuated in these studies.  
 
The WR VV was originally developed following multiple passages through murine 
central nervous systems (CNSs) (71). N1L gene disruption led to a significant reduction 
in the neurovirulence of WRDD; with reduced viral titres in the brains of mice that had 
been directly inoculated (250). In contrast, moderate intranasal doses of the wild type 
strain led to high viral loads within the CNS (251). 
 
The improvement in neurotoxicity following N1L gene disruption may simply have 
reflected viral attenuation in vivo i.e. a diminished ability to survive and disseminate in 
tissues within an immune competent host. Indeed disruption of the homologue of this 
gene in the pox virus, ectromelia, for which mice are the natural hosts, abrogated the 
ability of intranasally delivered virus to travel beyond the lung into peripheral tissue 
(249). However the N1L gene product, a dimeric 14 kDa cytosolic protein, may 
specifically confer tropism of pox viruses for neural tissue. In a study designed to search 
for human intracellular proteins that might interact with the N1L protein, human brain 
originated cellular basement membrane-associated chondroitin sulfate proteoglycan 
(BAMACAN) (252) co-immunoprecipitated with the N1L protein and confocal 
microscopic analysis confirmed their co-localisation. BAMACAN is expressed at 
higher levels in neural versus non-neural tissue and its enhanced expression and 
interaction with the VV N1L protein in a neural cell line appeared to positively support 
its viral growth within that cell line. Mechanistic detail regarding the role of the N1L 
protein in the neurovirulence of VVs is currently limited, but it is of potential 
importance, as neurotoxicity, although an extremely rare complication when 
administered in vaccine doses might become more prominent with anticipated higher, 
prolonged dosage regimes in cancer therapy.  
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The N1L gene product is therefore a vitally important non redundant in vivo virulence 
protein that must enable viral survival via modulation of host innate and or adaptive 
antiviral immunity. Although disruption of the N1L gene did not impair VV’s 
propensity to generate robust long term humoral or cellular antiviral immune responses 
in comparison to the wild type virus (247, 253, 254), it did not conclusively enhance 
adaptive antiviral immunity either (254). Nevertheless, in one study at least, splenocytes 
harvested from mice inoculated intranasally with  N1L gene disrupted VV (WR in this 
case), demonstrated superior cytotoxicity against virally infected murine lymphoma 
(RMA) cells (253). Furthermore, in a similar murine model using ectromelia, the loss of 
virulence that occurred following disruption of the N1L gene homologue, was regained 
in recombination activation gene (RAG)-1 knockout mice (which lack both mature B 
and T cells), as well as by simultaneous depletion of  CD4+ and CD8+ T cells (249).   
 
Whilst the role of the N1L gene product as an immunomodulator of adaptive immunity 
remains to be further defined, more studies have focussed on its role in modulating 
innate antiviral immunity (247). 
 
As with other viruses, VV induces the accumulation, activation and proliferation of NK 
cells at the site of infection (220, 236) and possesses numerous virulence genes that may 
counter their activation, often indirectly, by modulating the production of certain 
chemokines and cytokines (247). The N1L gene product may be one such candidate. 
Intranasal administration of N1L gene disrupted VV, led to an enhanced NK cell 
infiltrate into murine lungs in comparison to the wild type (WR) virus during the first 
six days post infection. Furthermore, these NK cells also demonstrated superior 
cytotoxicity, confirmed by their ability to lyse Yac-1 lymphoma cells. In keeping with 
the enhanced cellular immune response, there was a corresponding drop in lung titres of 
the N1L disrupted recombinant virus from day seven onwards (254).  
 
The N1L protein is expressed within three hours after cellular infection (255). Like 
some other VV proteins involved in immunomodulation, part of its structure resembles 
a Bcl-2 like structural fold. However, unlike most other VV encoded proteins in this 
category, which inhibit either apoptosis or the activation of pro-inflammatory 
transcription factors, the N1L protein appears to inhibit both (256-258).  
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1.5.7.1 The VV N1L protein inhibits intracellular inflammatory pathways 
 
The major inflammatory signalling pathways thought to be modulated by the N1L 
protein are the IFN and NF-κB pathways (247). 
 
 
 
 
Figure 1.2 IFN signalling and its regulation by VV (247) 
ISRE:  IFN-stimulated response elements; ISGF3: IFN-stimulated gene factor 3 complex (see main text 
for other abbreviations). The positions at which viral protein products may inhibit the production or 
subsequent action of IFN are illustrated by the red stars. 
 
 
The IFN response commences upon sensing of viral PAMPs by host cellular PRRs 
(figure 1.2). Upon their engagement, signalling cascades are induced leading to the 
activation of transcription factors such as IRF3, IRF7, NF-κB and activator protein 
(AP)1, that ultimately translocate into the nucleus to induce the transcription of genes 
encoding type-1 IFNs (notably IFNβ) and numerous other cytokines and chemokines. 
Secreted IFNs, through autocrine or paracrine activation of their cognate receptor, 
activate the Janus kinase (JAK)/ STAT signalling pathways which culminate in the co-
ordinated transcription of hundreds of IFN-stimulated genes (ISGs) (259). Many of 
these, such as protein kinase R (PKR), 2’-5’-oligoadenylate synthase (OAS) and Mx 
inhibit aspects of the viral life cycle and confer an antiviral state (247). The N1L protein 
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has been shown to inhibit signalling through NF-κB and IRF3, possibly via inhibition of 
the inhibitor of κB (IκB) kinase (IKK) and TANK-binding kinase 1, upstream regulators 
of these pathways (258), although this mechanism is currently disputed (260).   
 
 
 
 
Figure 1.3 Signalling through the NFκB complex (247) 
The N1L protein is thought to inhibit signalling through the NFκB cascade at the level of the IKK 
complex. The blue and purple boxes or ovals respectively represent adapter proteins and intermediate 
signalling enzymes that form complexes upon binding of PAMPs or inflammatory cytokines to their 
cognate receptors (beige boxes or ovals). See main text for further details.  
 
 
The NF-κB complex consists of a family of transcription factors that are retained in the 
cytoplasm of resting cells by association with inhibitory IκB proteins (261). Signalling 
through this complex may be initiated by PAMPs binding to PRRs (e.g. TLRs, RIG-1) 
or cytokines such as IL1 or TNFα binding to their cognate receptors (IL1-R, TNFR 
respectively); each of which subsequently associates with specific adaptor proteins 
(figure 1.3). Ultimately, signalling cascades converge onto the activation of the IKK 
complex, which phosphorylates IκB causing its ubiquitination and degradation by the 
proteasome. This then frees the NF-κB subunits, p50 and p65 which translocate into the 
nucleus and induce the transcription of NF-κB dependent genes.  
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Many antiviral effector cytokines are produced by professional APCs and monocytes, in 
response to infectious microorganisms. N1L gene disrupted VV WR infection of 
peripheral human blood monocytes led to an enhancement in the secretion of the pro-
inflammatory cytokines IFNα/β, TNFα and IL8 (262).  
 
1.5.7.2 The VV N1L protein inhibits apoptosis 
 
Apoptosis is an irreversible sequence of biochemical events that converge on the 
activation of caspase proteases to effect cell death. It represents an important defence 
mechanism against viral infection. The Bcl-2 family of proteins regulate the activation 
of the intrinsic pathway of apoptosis through a complex interaction of pro apoptotic and 
anti-apoptotic proteins (figure 1.4) (247, 263). 
 
 
 
 
Figure 1.4 The N1L protein inhibits apoptosis (247) 
The N1L protein may directly inhibit pro-apoptotic proteins as shown. See main text for further details 
and abbreviations.  
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Under steady state conditions, antiapoptotic proteins like Bcl-2 and Bcl-xl inhibit 
effector pro-apoptotic proteins (Bax and Bak) on the mitochondrial outer membrane. 
Various intrinsic death triggers, including DNA damage or viral components trigger 
other cytosolic pro-apoptotic proteins to bind and inhibit the anti-apoptotic Bcl-2 
proteins or directly bind to and activate pro-apoptotic effector proteins (figure 1.4). 
Either way, these events cause the oligomerisation of Bak and Bax which permeabilises 
the outer mitochondrial membrane leading to the cytoplasmic release of cytochrome c 
and subsequent formation of the apoptosome (264). The apoptosome initiates the 
activation of the caspase protease cascade. The N1L protein has a groove that is 
structurally similar to the cellular anti-apoptotic Bcl-2 protein and may similarly bind to 
and inhibit pro-apoptotic intermediate proteins (57, 257).  
 
In summary, the N1L protein product is multifunctional and appears to be able to 
modulate three important innate antiviral mechanisms: apoptosis, IFN and NF-κB 
signalling. It is therefore an ideal candidate for disruption in order to enhance and focus 
host innate (and possibly adaptive) anti-viral immunity to within the confines of a TME.  
    
1.5.8 Vaccinia induced enhancement of the adaptive immune response 
 
Optimal central thymic selection should theoretically have eliminated T cells that 
strongly react to self-antigens and it is therefore possible that a host organism may not 
possess any T cell clones that are capable of mounting an antitumour response. The 
heterogeneous nature of tumour cells and by implication, their TAAs makes this 
scenario unlikely. Certainly autoimmune disorders represent a breakdown in tolerance 
to autoantigens and are often characterised by strongly self-reacting T-cell clones. 
Furthermore, the expansion of multiple potentially weak immunogenic T cell clones 
could prove efficacious as demonstrated by experiments using  adoptively transferred ex 
vivo expanded tumour infiltrating lymphocytes (TILs) (265). 
 
In an attempt to enhance their ability to cross-prime antitumour immunity, VV and 
other OVs have been armed with transgenes coding for single or multiple (single-digit) 
tumour antigens (266). Their monotherapeutic use in either prophylactic or therapeutic 
tumour vaccination has yet to demonstrate reversal of tolerance to TAAs (266, 267). 
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Theoretically, single (or few) self-antigens would face stiff competition from the 
immunodominant antiviral response, even if they are over-expressed. Epitope spreading 
may not be successful for the same reason. Furthermore, even if tolerance to the target 
antigen(s) were to be reversed, there is a real danger of selecting out tumour cells that 
do not carry the antigen.  
  
The ideal scenario would be to simultaneously vaccinate against similar frequencies of 
multiple tumour antigens, individualised to a specific host and tumour. This could be 
achieved by whole cell viral lysates either generated ex vivo or in situ, although the 
frequency of individual TAAs would be expected to be relatively low. In a group of 
pioneering experiments, Vile and colleagues recently demonstrated that systemic 
treatment with a pool of highly immunogenic vesicular stomatitis viruses (VSVs) 
engineered to express a cDNA library of xenoantigenic human cancer tissue could reject 
established murine tumours of a similar histological type. In their studies, which utilised 
prostate (268) and melanoma (269) models, there were no detectable autoimmune side 
effects. This demonstrated that the simultaneous presentation of a broad range of 
individually weak tumour antigens derived from a particular histological subtype, does 
indeed have the capacity to reject a histologically similar tumour. Although extremely 
promising, there may be logistic and quality control barriers to the translation of this 
highly heterogeneous biologic into the clinic. In situ vaccination strategies with one (or 
two) fully sequenced biologics should be more amenable in this regard. 
  
Preclinical and indeed clinical data exploring the use of OVs as cancer therapeutics 
suggests that efficacy is significantly improved by arming viruses with 
immunomodulatory gene(s) designed to boost either or both of the afferent (antigen 
presentation) or efferent arms (effector response) of a developing adaptive antitumour 
immune response. Indeed two of the most clinically advanced viruses, a recombinant 
HSV and a Wyeth strain recombinant VV, carry the GMCSF cytokine transgene (146). 
   
One way to enhance antigen uptake and presentation is by providing a localized boost to 
this phase. GMCSF has been used in multiple platforms including VV and other OVs 
(20, 270, 271) for cancer therapy ever since Dranoff first demonstrated its capacity to 
successfully generate tumour specific CTLs (272). GMCSF enhances the infiltration 
and differentiation of naïve APCs to mature activated ones. In similar vein, the 
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chemokines RANTES  and FMS-like tyrosine kinase (FLT)-3 ligand, when delivered on 
viral vector platforms enhanced intratumoural infiltration of DCs, T and NK cells and 
were associated with  tumour regression in the context of a tumour specific CTL 
response (273, 274).  
 
A wide variety of VV recombinants incorporating various other immunomodulatory 
transgenes have been used in an attempt to boost the effector response and the 
generation of antitumour memory T cells, with variable success. These include 
transgenes coding for T cell co-stimulatory ligands e.g. B7.1 (275) and CD40L (276); 
IL-2 (53, 277, 278) and IL-12 (53, 278, 279). In the main, the goal of these therapeutic 
strategies were to nurture a Th-1 cytotoxic antitumour response (152). 
 
IL12 which is mainly produced by activated APCs is a particularly important cytokine 
in bridging the gap between innate and adaptive immunity, skewing it in favour of a Th-
1 phenotype (141, 226). It primes and activates both NK and CD8+ T cells to produce 
IFNγ, modulates angiogenesis and may additionally upregulate the cellular expression 
of both class I and II MHCs (141, 226). IL12 administered in a variety of different 
forms has consistently demonstrated efficacy in animal models of cancer but human 
trials, with predominantly systemic IL12 have been limited by toxicity (142, 226). 
Highly localised delivery into the TME on an OV platform could alleviate this problem.   
 
With regards the Lister strain of VV, Chen et al. engineered a group of recombinant 
VVLs armed with transgenes encoding IL-2, IL-12, or both (53). Recombinants 
expressed high levels of cytokines in vitro and in vivo in a SC xenograft rat glioma (C6) 
model. Antitumour efficacy was significantly better with all constructs in comparison to 
the unarmed control virus following low-dose IT injection. Because nude mice were 
utilized, this surplus effect was likely to have been mediated by tumour-focused 
activation of innate immunity, evidenced by localized increases in IFN-γ and NK cells 
in all experimental arms. 
 
The sequence of events in a developing immune response has been well characterised 
and typically takes about seven days after initial antigen exposure. Antigen loading, 
migration and presentation in draining lymph nodes occurs during the first half of this 
period, leading to the expansion of effector CTLs thereafter. Optimal enhancement of 
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these phases could be expected if OVs carrying transgenes designed to act primarily in 
one or other phase were administered in the appropriate order. For example, a virus 
armed with the GMCSF transgene could be administered during the first few days of 
treatment, followed by virus armed with IL12 in the days thereafter.  
 
Obviously, strategies that enhance the immunogenicity of the virus are likely to enhance 
viral clearance in immune-competent hosts. This indeed has been observed in vivo with 
VVs armed with some of the aforementioned immunomodulatory genes (56, 280, 281). 
This could prove to be problematic, as secondary “booster” doses of virus are likely to 
be necessary in any vaccination protocol. However, only a small quantity of virus needs 
to be delivered into residual tumour tissue to effect killing of some, but not all, tumour 
cells; just enough to release enough TAAs required for boosting tumour-specific 
memory T cells. When administered in relatively high doses, VV colonization, 
replication, and transgene expression in solid tumour has been demonstrated following 
systemic administration in both animal models and patients, even in the face of pre-
existing neutralizing antibodies (20, 282). 
 
As previously mentioned, another potential problem with OVT is that upon 
administration of booster doses, the secondary immune response against viral antigens 
may swamp that against the much weaker tumour antigens. An alternative strategy 
might be to use an antigenically different OV for the secondary boost. Release and 
presentation of tumour antigens following administration of a second virus (to which 
the host is naive) should stimulate a secondary antitumour immune response that 
dominates the primary response to the new virus (283, 284). Bridle et al. used such a 
heterologous prime-boost strategy to treat an aggressive intracranial syngeneic B16-F10 
murine melanoma model (266). They demonstrated that intramuscular administration of 
a recombinant adenovirus armed with a transgene encoding a melanoma antigen (DCT), 
followed later by an IV dose of recombinant VSV armed with the same gene, led to a 
significant increase in median survival compared to therapy with either virus alone or 
indeed with the same combination but with viruses lacking the DCT transgene. The 
heterologous regime was associated with a significantly enhanced percentage of anti-
DCT CD8+ T cells. Importantly, there was a corresponding reduction in the anti-VSV 
CD8+ T cell response compared to that within naive mice infected with the VSV 
recombinant. In a similar experiment, Zhang et al. (285) used sequentially presented 
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Semliki Forest and vaccinia viruses to enhance antitumour efficacy against a 
disseminated ovarian cancer model. Again, the best results were observed when viruses 
were armed with a transgene encoding a common tumour antigen. 
 
Whilst such regimes may ultimately be the future of OVT, there is evidence that single 
viral therapy can indeed induce a clinically significant antitumour response. A VV 
armed with GMCSF was used to treat a small cohort of patients with advanced 
disseminated malignant melanoma. Intralesional administration of virus into the 
primary lesion in a multidose regime led to the regression of tumour deposits at distant 
sites as well as the primary in four of seven patients (286). The lesions were associated 
with lymphocyte infiltration. Even more impressively, a HSV mutant armed with 
GMCSF (Talimogene laherparepvec (T-Vec)) led to complete long term cure of 8 of 50 
patients with similarly advanced malignant melanoma (287).  
 
Perhaps the success of these and other similar studies reflected a pre-existing weak level 
of antitumour immunity, resembling a primary response, that may have been triggered 
spontaneously or following prior conventional therapies. This pre-existing antitumour 
immunity may not have been strong enough to effect tumour eradication at first, but 
could have been “secondarily” boosted by presentation of tumour antigens released by 
initial doses of OVT. In effect, a scenario akin to the aforementioned heterologous 
prime boost regime.  
 
1.5.9 Innate v adaptive immunity in OVT  
 
The role of both innate and adaptive immunity in OV mediated antitumour clearance is 
therefore important but complex and is likely to vary with virus, strain, tumour type, 
and host. As an example, Wang et al. (246) demonstrated equivalent antitumour 
responses following IT administration of a VV WR recombinant into two different 
syngeneic SC murine lung cancer models. Viral recovery from one of the tumours (TC-
1) was high. In this model, viral oncolysis played the dominant antitumour role because 
alteration of the immune competence of the host made little difference to antitumour 
efficacy. In contrast, viral recovery from the other model (LKRM2) was poor; and 
depletion of CD8+ T cells reversed tumour eradication. 
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 Oncolytic viruses as a neoadjuvant treatment to surgery 1.6
 
The most effective means of curing a solid tumour remains surgical excision. However 
evidence from clinical and experimental data suggests that in many cases surgical 
excision with curative intent may actually promote tumour  metastasis and 
metachronous recurrence (288-292).  A major source of recurrence is from minimal 
residual disease (MRD) i.e. microscopic primary deposits left behind near clearance 
margins  or micrometastases that were either pre-exisitant or potentially encouraged by 
surgical manipulation (288). Indeed recurrant tumour, either  locoregional or 
disseminated is a major cause of mortality following oncologic surgery.  
 
The growth dynamics of residual disease does appear to be altered following surgical 
manipulation. For example, sub-total excision of primary tumours in various 
experimental models causes an acceleration in the growth of residual primary tumour as 
well as in metastatic deposits (288, 293, 294). This phenomenon has also been observed 
in clinical series of cytoreduction operations and metastectomy. In one clincal study for 
example, novel metastasis at distant sites appeared much sooner than anticipated 
following lung metastectomies, and grew at much faster rates than their excised 
counterparts (295). Presumably therefore, they represented accelerated growth of 
previously dormant metastases (295, 296).  
 
The extent of surgical manipulation can have a profound influence on subsequent 
tumour dissemination, as demonstrated for example by the enhanced likelihood of intra 
and extra peritoneal tumour dissemination following laparotomy versus laparoscopy 
(297-299). Direct seeding of tumour cells into the circulation or lymphatics following 
tissue handling is unlikely to fully explain the enhanced metastatic rates. Patients with 
early stage primaries often have circulating tumour cells (CTCs), but most do not 
develop recurrence (300). Furthermore, post operative CTC levels do not conlusively 
correlate with survival. Indeed only  0.01% of CTCs actually aquire the capacity to 
become clinically overt metastases (288).  
 
Following surgery, there appear to be perturbations of the molecular oncology of 
residual cancer cells, as well as in the biological behaviour of residual and metastatic 
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tissue; for example, enhanced DNA sysnthesis and cellular resistance to apoptosis in 
addition to enhanced microvessel density (288, 301). Surgical trauma leads to elevated 
levels of circulating inflammatory factors such as acute phase proteins (TNFα, IL1, IL6, 
IL8) and VEGF, all of which may potentiate tumour growth via multiple mechanisms. 
VEGF for example, may promote resistance to apoptosis (by upregulating Bcl-2) as 
well as being proangiogenic (302). Furthermore, primary tumours may secrete soluble 
factors into the circulation that actively inhibit the growth of disseminated tumour (303, 
304). These include inhibitors of angiogenesis e.g. angiostatin, endostatin and 
thrombospondin (301, 304, 305). The disinhibition of angiogenesis following excision 
of the primay, coupled with elevation of proangiogenic factors may kick start previously 
dormant metastatic deposits.   
 
An important feature of perioperative stress is immunosuppression, which is 
exacerbated by anaesthesia and blood transfusions (306-309). Innate immune 
surveillance mechanisms, particularly NK cells, are often impaired in patients with 
malignancy. Numbers and function of these drop even further postoperatively (309-
312); related adversely to extent and length of the operation (298, 299). Animal studies 
have demonstrated a correlation between post operative NK cell suppression and 
enhanced metastases in models of spontaneous and inoculated metastases (310-313).  
 
Other prominent immunological changes that occur perioperatively include a reduction 
in DC numbers (314) and a cytokine pattern that promotes Th-2 immunological priming 
(288, 315, 316). Immunosupression appears to peak by post operative day three, but the 
restoration in the host’s ability to mount an antigenic cellular response could take up to 
three weeks (288). These changes generate a window of opportinity for tumour to 
escape host immune surveillance.  
 
At present, there are no stardard perioperative therapeutic approaches aimed at 
preventing post operative recurrence or metastasis from MRD and it therefore remains a 
signficant area of unmet clincal need. Traditional chemotherapeutic agents are too toxic 
to administer to patients either just prior to major surgery or in the early post operative 
recovery period and are likely to impair wound healing.  
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Cytokine therapy has been investigated in a bid to globally reverse perioperative   
immunosuppression. For example IL-2 (317, 318) and IFNα (319, 320) administration 
demonstrated early promise and reversed post-operative NK suppression; however such 
therapies have been hampered by substantial dose-limiting toxicities (321).  
 
Other perioperative candidates including inhibitors of inflammation (e.g. 
cyclooxygenase (COX)-2 inhibitors, anti TNFα antibodies) and angiogenesis (e.g. anti 
VEGF antibodies), are currently being used in the context of clinical trials, but have yet 
to demonstrate a survival benefit (307).   
 
OVT might be an attractive option to use in the context of neoadjuvant therapy. 
Intravenously active tumour selective OVs such as vaccinia may be able to directly 
target preexisitng, potentially dormant micrometastatic deposits (282). They are 
powerful stimulants of innate immunity and NK cells in particular (322). Furthermore, 
their ability to break down the immune suppressive TME and promote anti-tumour 
adaptive immunity may also aid long term immunosurveillance (44). This may be aided 
by utilising the ability of some OVs to locally deliver immunomodulatory proteins. 
IL12 for example may be an ideal candidate in the current context. It is a potent 
activator of both NK and CTLs and inhibits angiogenesis in an IFNγ dependent manner 
(141, 226). 
   
Tai et al have recently demonstrated that a single IV dose of replicating pox virus (VV 
or orf virus) administered hours prior to surgery could reverese surgical stress induced 
NK cell suppression and enhanced metastases in experimental models of metastatic 
breast cancer and melanoma (310). A similar result was also obtained when  inactivated 
influenza vaccine was used in the perioperative period; an affect that was dependent on 
a TNFα surge (323). These studies are certainly encouraging, but as yet lack long term 
survival data. In addition, a question mark remains regarding the optimum time of 
administration to enable adaptive antitumour priming and thus longer term immune 
surveillance.  
 
An important aim of the current project is to explore the role of recombinant VVLs in 
the context of presurgical neoadjuvant therapy.  
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 Safety 1.7
 
VV is relatively contraindicated in patients with severe immune deficiency, those who 
are pregnant, infants, and patients with widespread chronic dermatological conditions. 
Serious adverse effects are well documented and include post-vaccinial encephalitis (2–
1200/106), eczema vaccinatum (8–80/106), and fulminant vaccinia (1–70/106) (324). 
The risk of death with naive vaccinations is estimated to be approximately 1/106, 
although it may be strain dependent (325). A meta-analysis based on retrospective data 
estimated the death rates from NYCBOH, Lister, and CPN strain-derived vaccines to be 
1.5, 8, and 25 deaths per million, respectively (326). In contrast, a second-generation 
NYCBOH strain derivative, ACAM2000, used recently to vaccinate healthy 
individuals, caused an unexpectedly high incidence (5730/106) of cardiac complications 
(arrhythmias, pericarditis, myocarditis, and dilated cardiomyopathy) (327).  Mild side 
effects of VVs include painful injection sites, skin reactions, and constitutional 
symptoms (e.g., headache, malaise, and fever). 
 
Side effects attributed to VV recombinants in clinical cancer trials conducted thus far 
have generally been mild. It has been safely administered via SC, IV, IT, and 
intravesical routes. However, the combined total numbers of patients in these trials 
amass to only hundreds. Given the rarity of some of the more serious side effects, they 
would not be expected to be detected in this relatively small cohort. Furthermore, 
patients with advanced cancer are generally at a higher risk of suffering a severe 
complication due to relative immune suppression and/or comorbid conditions (328, 
329); a problem that is compounded by the fact that optimum dosing regimens, which 
are anticipated to be much higher than that used for vaccination, have yet to be 
established. 
 
To reduce the risk of serious complications, traditional vaccine strains have been 
attenuated. MVA (Ankara strain), NYVAC (Copenhagen strain), ACAM200 
(NYCBOH), and LC16m8 (Lister) are highly attenuated VV derivatives that (aside 
from LC16m8) have minimal or no replication competence (330). Although they retain 
their immunogenicity and may be used to vaccinate against pox viruses, their use in 
cancer therapy is likely to be limited. As previously described, replication competence 
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appears to be an important characteristic for the generation of a favourable antitumour 
response and is necessary to mediate tumour cell oncolysis.  
 
Toxicity may be reduced by targeted disruption of virulence genes that are not required 
for virus replication in tumours and/or through genetic manipulations designed to 
improve tumour selectivity. The tumour selectivity of the attenuated but still 
replication-competent VVL mutant, GLV1h68, was enhanced compared to that of its 
parental strain, with a significant reduction in viral toxicity (54). Upon sequencing, 
ORFs coding for certain non-targeted virulence genes (e.g., one encoding a TNF 
receptor homologue (L195) and another encoding a viral golgi-associated anti-apoptotic 
protein) were found to be inadvertently disrupted (55). In general, however, the extent 
of genetic disruption is likely to proportionately reduce the replication efficiency of VV, 
as indeed will the transcriptional and translational burdens imposed by multiple 
transgene inserts, particularly if driven by strong promoters (58).  
 
Disruption of the VV N1L gene in the current project was a bid to enhance the safety of 
the virus as well its immunogenicity.  
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 Aims 1.8
 
1. To engineer a set of Lister strain vaccinia viruses with deletions of the VTK and 
N1L gene regions, armed with either GMCSF or IL12 cytokine transgenes 
2. To validate these constructs in tumour models in vitro 
3. To explore whether these mutants are capable of cross stimulating immunity against 
tumour cells and  tumour associated antigens  
4. To develop and optimise viral treatment strategies that are capable of treating in vivo 
models of primary and metastatic cancer 
5. To develop a neoadjuvant tumour vaccination strategy to prevent postoperative 
metastasis and long term recurrence 
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Chapter 2 Materials and methods 
 Cell lines  2.1
Immortalised tumour cells lines were derived from either murine, Syrian hamster or 
human hosts. They were chosen to represent a broad spectrum of solid carcinomas. All 
cell lines with the exception of DT6606-Ova, were maintained in stock culture medium 
(sCM) comprised of Dulbecco’s modified Eagle’s medium (DMEM) (Sigma Aldrich, 
Dorset, UK) supplemented with 5% heat inactivated foetal calf serum (FCS) and 1% 
penicillin streptomycin (Sigma Aldrich) and incubated at 37oC  in air with 5% carbon 
dioxide (CO2).  DT6606-Ova cells were maintained under similar incubation conditions 
in sCM which additionally contained 2 mg/ ml of the antibiotic G418 (Gibco®, Life 
Technologies, Paisley, UK). All human cell lines had been authenticated by short 
tandem repeat (STR) analysis. All cell lines were negative for mycoplasma (tested using 
the MycoAlertTM mycoplasma detection kit, Lonza Biologics PLC, Slough, UK). Table 
2.1 lists the cell lines used in this project. 
 
Table 2.1 A list of tumour cell lines used in the current project 
Cell line Organ of origin Histology Host: strain 
CT26 Metastatic colon Adenocarcinoma Mouse: BALB/c 
CMT93 Rectal Adenocarcinoma Mouse: C57BL/6 
LLC Metastatic lung cancer Squamous cell carcinoma Mouse: C57BL/6 
B16-F10 Metastatic melanoma Melanoma Mouse: C57BL/6 
SCCVII Oral cavity Squamous cell carcinoma Mouse: C3/HeN 
DT6606 Pancreatic Ductal adenocarcinoma Mouse: C57BL/6 
(transgenic – see text) 
HPD-1NR Pancreatic Ductal adenocarcinoma Syrian Hamster 
HCPC-1 Oral cavity Squamous cell carcinoma Syrian Hamster 
SUIT-2 Metastatic pancreatic  Ductal adenocarcinoma Human 
A549 Lung  Adenocarcinoma Human 
HCT-116 Colonic Adenocarcinoma Human 
FaDu Oral cavity Squamous cell carcinoma Human 
A-172 Brain  Glioblastoma Human 
UW-228 Brain Medulloblastoma Human 
CV1 Kidney (non-tumour 
immortalised) 
Fibroblast African green monkey 
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2.1.1 Murine derived carcinoma cell lines 
 
The metastatic colon adenocarcinoma cell line CT26 originated from the BALB/c 
murine strain, whilst CMT93 (rectal adenocarcinoma), Lewis lung carcinoma (LLC, 
metastatic lung squamous cell carcinoma) and B16-F10 (metastatic melanoma) cell 
lines were derived from the C57BL/6 strain. These were all obtained from the Cancer 
Research UK central cell bank (CRUK, Clare Hall, Herts, UK) 
  
SCCVII is a spontaneously arisen murine oral cavity squamous carcinoma cell line 
(C3H/HeN strain) and was a kind gift of Dr Osam Mazda (Department of Microbiology, 
Kyoto Prefectural University of Medicine, Kyoto City, Japan).  
 
DT6606 (pancreatic ductal adenocarcinoma) originated from a C57BL/6 strain 
transgenic mouse with mutations in K-RAS and TP53 genes that were engineered to be 
conditionally expressed in the pancreas (331, 332). This was a kind gift of Professor 
David Tuveson (CRUK, Cambridge Research Institute, Cambridge, UK). DT6606-Ova 
was previously made by our group, whereby the plasmid, pCL-neo-cOVA (Addgene, 
Middlesex, UK) was stably transfected into DT6606 cells. The plasmid contains 
neomycin and ampicillin resistance cassettes in addition to the chicken ovalbumin 
transgene.   
 
2.1.2 Syrian Hamster derived carcinoma cell lines 
 
HPD-1NR is a pancreatic ductal adenocarcinoma cell line obtained from the German 
Collection of Microorganisms and Cell cultures (DSMZ; Braunschweig, Germany). 
HCPC-1 is a chemically induced squamous cell carcinoma of buccal pouch mucosa that 
was a kind gift of Professor Joel Schwartz (Department of Oral Medicine and 
Pathology, University of Illinois at Chicago, USA). 
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2.1.3 Human carcinoma cell lines 
 
SUIT-2 (metastatic pancreatic carcinoma) and A549 (lung adenocarcinoma) were 
obtained from the CRUK central cell bank; whereas HCT-116 (colonic 
adenocarcinoma) and FaDu (buccal squamous carcinoma) were obtained from the 
American Type Culture Collection (ATCC; VA, USA).  
 
The following cell lines: A-172 (adult brain glioblastoma) and UW-228 (adult 
medulloblastoma) were kind gifts respectively of Dr Sarah Martin at the Barts Cancer 
Institute and Professor Silvia Moreno at the The Blizzard Institute, Barts and The 
London School of Medicine and Dentistry, London, UK.   
 
2.1.4 Non-tumour cell lines 
 
CV1 is an African Green Monkey immortalised kidney fibroblast cell line obtained 
from the ATCC. 
 
 
 Previously constructed viruses 2.2
 
VVL15-LacZ (84) is a Lister strain vaccinia virus in which the VTK gene was disrupted 
by the insertion of firefly luciferase and E coli lacZ reporter transgenes, placed under 
the control of the VV P7.5 promoter and a synthetic early-late promoter respectively 
(figure 2.1). This was used as the backbone for all viral constructs in this project.  
 
 
 
Figure 2.1 The transgene cassette in place of the VTK gene in VVL15-LacZ 
The back to back promoters are shown in blue. P7.5: VV early-late promoter; EL: synthetic early-late 
promoter 
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VVL15-RFP was constructed by Dr Louisa Chard from our group. It is equivalent to 
VVL15 but contains a red fluorescent protein (RFP) transgene in place of lacZ (figure 
2.2). This virus was used as the control in all experiments involving VVL15∆N1L. 
 
Figure 2.2 The transgene cassette in place of the VTK gene in VVL15-RFP 
The back to back promoters are shown in blue. P7.5: VV early-late promoter; EL: synthetic early-late 
promoter 
 
 
 General DNA techniques used in the construction and testing of recombinant 2.3
viruses 
 
2.3.1 Agarose gel electrophoresis 
 
Agarose gels (1%) were made using 1 g of electrophoresis grade agarose powder 
(Invitrogen, Life Technologies, Paisley, UK) in 100 ml of 1x Tris, acetate, EDTA 
(TAE) electrophoresis buffer.  Ethidium bromide (EtBr) (Sigma Aldrich) was added to 
the molten agarose to obtain a final concentration of approximately 0.5 µg/ ml prior to 
casting the gel. Analytic samples were added to 5 μl of 6x blue/ orange loading dye 
(Promega; Southampton, UK) in distilled water (dH2O) (made up to a total volume of 
30 µl) before being loaded into the wells.  For reference, a 1 kb DNA ladder (5 µl) 
(Promega) was also ran alongside.  Electrophoresis was performed in 1x TAE buffer 
and bands visualised in an ultraviolet (UV) light trans-illuminator. 
 
A 50x TAE buffer solution was made up from 242 g tris base, 57 ml of glacial acetic 
acid and 0.5M EDTA (pH 8.0), made up to a total volume of one litre with dH2O. 
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2.3.2 Low melting point gel electrophoresis 
 
Low melting point (LMP) agarose gels were used for purification of DNA.  LMP 
agarose gels (1%) were made using 1 g of electrophoresis grade LMP agarose powder 
(Invitrogen) in 100 ml 1x TAE buffer.  EtBr was added to the molten agarose to obtain 
a final concentration of 0.5 µg/ ml prior to casting the gel. Electrophoresis was 
performed in 1x TAE buffer.  The DNA bands were observed under low intensity UV 
light and appropriate gel bands excised with a knife.  The DNA was purified from the 
gel using the GFXTM PCR DNA and Gel Band purification kit, according to the 
manufacturer’s protocol (GE Healthcare Life Sciences, Buckinghamshire, UK).  DNA 
was eluted in 50 µl dH2O and quantified using a NanoDrop® 1000 spectrophotometer 
(Thermo Scientific, DE, USA). 
 
2.3.3 Restriction digests 
 
5 µg of the plasmid DNA and appropriate amount of restriction enzyme(s) (all from 
New England Biolabs® Inc. (NEB) MA, USA), bovine serum albumin (BSA) and 
digestion buffer (supplied by NEB) were made up to a 50 µl volume digest with dH2O. 
Digests were incubated for two hours at either 25 or 37oC (depending on the optimum 
working temperature of the enzyme). 5 µl of the digest solution was analysed via 
agarose gel electrophoresis (section 2.3.1) to confirm that the desired division(s) had 
occurred. The simultaneous digestion of a plasmid with two different enzymes could 
only occur if their optimal working temperatures and buffers were identical. Where this 
was not the case, digests were performed in sequence, whereby DNA was extracted 
from buffer solution after the first digest (using the GFXTM PCR DNA and Gel Band 
purification kit) and digested with the second restriction enzyme in a different buffer 
solution. 
 
2.3.4 T4 DNA polymerase 
 
T4 DNA polymerase was used for blunt end repair of DNA. 1 µl of T4 DNA 
polymerase (5 U/ µl) (NEB) was added directly to 50 µl of the restriction digest 
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(approximately 1U/ µg digested DNA), along with 2-3 µl of 10 mM 
deoxyribonucleotide triphosphates (dNTPs) (NEB). The reaction was incubated at 12oC 
for 15 minutes and subsequently stopped by heat inactivation (75oC for 20 minutes). 
 
2.3.5 Antarctic phosphatase treatment 
 
To remove 5’ phosphate groups, 50 µl of the restriction digest was incubated for 30 
minutes at 37oC with 0.5 µl Antarctic phosphatase (AP)  (1 U/ µl) (NEB) in 5.5 µl 10x 
dephosphorylation buffer (NEB). 
 
2.3.6 Ligations 
 
Ligations were carried out using 25-30 ng of vector with a quantified amount of purified 
insert at a ratio of 1:3 respectively.  To this, 10 µl of 2x rapid DNA ligation buffer 
(Promega) and 1 µl of T4 high fidelity DNA ligase (3 U/ µl) (Promega) were added and 
the reaction made up to 20 µl with dH2O.  The mixture was incubated at 23oC for a 
minimum of 30 minutes and then transformed into chemically competent E. coli cells 
(One Shot® TOP10, Invitrogen) (section 2.3.7). Linearised, dephosphorylated “no 
insert” controls were similarly processed. 
 
2.3.7 Transformation of competent E. coli cells  
 
5 µl of each ligation reaction (from section 2.3.6) was added to 50 μl thawed competent 
E. coli cells and the mixture incubated on ice for 10 minutes.  Each reaction was heat 
shocked at 42oC for 30 seconds, cooled for two minutes on ice, before adding 300 μl of 
standard Luria Bertani (LB) broth.   
 
50 μl of transformed bacteria (per plate) was streaked out on LB agar plates containing 
100 μg/ ml ampicillin (Sigma Aldrich) and incubated overnight at 37oC. 
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For midi preparations, 50 μl of transformed bacteria was added to 50 ml LB media 
containing ampicillin (100 μg/ ml) and incubated overnight (12-16 hours) at 37oC in a 
flask shaker.  Preparations were then pelleted by centrifugation at 5000 rpm for 15 
minutes in a Beckman Coulter (High Wycombe, UK) refrigerated centrifuge. Pellets 
were stored at -20oC prior to purification. 
 
2.3.8 Mini-preparation of plasmid DNA 
 
Single colonies were picked from the LB agar plates and grown up overnight at 37oC in 
5-10 ml LB broth containing ampicillin (100 μg/ ml). The culture was divided, 
centrifuged for three minutes at 12,000 rpm and supernatant discarded to create pellets 
(two pellets per 5 ml of overnight culture). Plasmid DNA was purified from the pelleted 
bacterial cells using the QIAprep© mini-prep kit (Qiagen, Manchester, UK) according 
to the manufacturer’s protocol.  DNA was eluted in 50 µl dH2O and 5 µl of the sample 
was analysed by restriction digestion and subsequent agarose gel electrophoresis. 
 
2.3.9 Midi-preparation of plasmid DNA 
 
Midi-prepped DNA was obtained using the Hi-Speed Plasmid Midi Prep Kit (Qiagen) 
according to the manufacturer’s protocol and the DNA eluted in 1 ml of dH2O.  The 
DNA was then precipitated for one hour at -80ºC in a solution made up by the addition 
of a 2x volume of 100% ethanol (EtOH) (i.e. 2 ml) and 1/10th the original volume (100 
μl) of 3M sodium hydroxyl acetate. After thawing, the DNA was pelleted following 
maximal speed centrifugation and washed once in 70% EtOH.  The purified DNA was 
quantified using a NanoDrop® 1000 spectrophotometer. 
 
2.3.10 Transfection of plasmid DNA 
 
For the purposes of homologous recombination, CV1 cells were plated in 6-well plates 
(WPs) and incubated overnight to achieve 90% confluence. Each well was subsequently 
infected with 0.1 PFU/ cell of VVL15 in 1.5 ml of fresh sCM and incubated for a 
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further two hours. At this time, 0.4 μg of plasmid DNA per well was complexed with 
the Effectene® Transfection Reagent (Qiagen), according to the manufacturer’s 
protocol. The transfection-complex mix (approximately 700 μl) was added drop-wise to 
a virally infected well. Forty eight hours later, cell lysate and supernatant were scrape-
harvested and stored at -80ºC prior to plaque purification.    
 
2.3.11 Viral DNA extraction 
 
For the purposes of analytical polymerase chain reaction (PCR) or sequencing, viral 
DNA was extracted from cellular lysates or concentrated viral preparations using the 
QIAamp® DNA Blood Mini Kit (Qiagen), a column based extraction system, in 
accordance with the manufacturer’s instructions. DNA was eluted in dH2O and 
quantified using the Nanodrop® 1000 spectrophotometer.  
 
2.3.12 PCR 
 
PCR reactions were performed using primers listed in the appropriate results 
subsections. The following cycling conditions were applied to 25 μl reaction mixes.  
 
Table 2.2 PCR cycle conditions 
Step Temperature Time 
1   Initial denaturation 94 oC 2 minutes 
2   Denaturation 94 oC 30 seconds 
3   Annealing* 52-54 oC 1 minute 
4   Elongation 72 oC 1 minute  
Go to 2, repeat 31 times 
5   Final elongation 72 oC 5 minutes 
6   Hold  4 oC Infinity 
 
*The annealing temperature was adjusted according to the lowest melting temperature of each primer 
pair.     
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Each 25 μl reaction contained at least 10 ng of template DNA, 10 pmol of each primer 
(forward and reverse, manufactured on demand by Sigma Aldrich), 2.5 µl of 10x PCR 
reaction buffer (Roche, West Sussex, UK), 1 µl 10mM PCR nucleotide mix (NEB) and 
0.5 µl High Fidelity PCR System (a mix of Taq DNA polymerase and a DNA 
polymerase with proof reading capacity) (3.5 U/ µl, Roche), with the rest made up by 
dH2O. PCR cycles were performed following the program in table 2.2.  PCR products 
were analysed via electrophoresis on a 1% agarose gel as described in section 2.3.1. 
 
2.3.13 Homologous recombination and plaque purification 
 
Each pUC19 (NEB) based VV super-shuttle vector was transfected, using an 
Effectene® based protocol (section 2.3.10), into near confluent monolayers of CV1 
cells (in 6-WPs) that had been pre-infected with VVL15. Forty eight hours later, the 
presence of red fluorescence under green light confirmed expression of the relevant 
transgene cassette, either from free intracellular plasmid or from the relatively few 
vaccinia virions in which homologous recombination had been successful. 
  
Cells and supernatant were harvested by scraping and freeze-thawed twice. 1 μl of this 
lysate was used to infect all six wells of a 6-WP containing CV1 cells grown to 
approximately 90% confluence. A further 48 hours later, each well was carefully 
scrutinized under green light, searching for those viral PFUs that fluoresced red. The 
colony was carefully picked by touching it with a 20 μl pipette tip after aspirating the 
media from the well. The tip was then submerged into a cryotube containing 250 μl of 
sCM. Following further freeze-thaw cycles, 5-20 μl of this virus solution was added to 
each well of a new 6-WP containing CV1 cells as before. This process was repeated 
until every PFU in a well fluoresced red; i.e. all viral colonies stemmed from novel 
recombinant virus. The viral lysate was then harvested and the purity of viral colonies 
confirmed by PCR analysis of extracted DNA.  
 
50 μl of purified viral lysate was added to a T175 flask containing a near confluent CV1 
cell monolayer. Following a further two days of incubation, cells and supernatant were 
scrape harvested, collected into 50 ml tubes and stored at -80ºC as a primary viral 
passage (PVP). 
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2.3.14 Mass viral production  
 
Each PVP was rapidly freeze-thawed twice and used to infect between 36 to 40 T175 
flasks containing near confluent monolayers of CV1 cells. Forty eight hours later, the 
infected CV1 cells were scrape harvested and through repeated rounds of centrifugation 
at 2000 rpm (at 4°C), collected into a single pellet. The pellet was washed in phosphate 
buffered saline (PBS), re-suspended in 12 ml of 10 mM Tris-HCl (pH 9.0) and stored at 
-80°C.  
 
2.3.15 Viral purification 
 
Each concentrated viral lysate suspension was freeze-thawed twice, transferred to a 40 
ml Dounce homogeniser (Fisher Scientific, Loughborough, UK) and homogenised via 
60 strokes. Solutions were then ultrasonicated for 30 seconds. Following centrifugation 
at 2000 rpm at 4°C for 5 minutes, the supernatant (containing released virion particles) 
was collected and diluted to a total volume of 30 ml with 10 mM Tris-HCl. The solution 
was divided into four; each layered gently onto 17 ml of 36% sucrose (w/v) in 10 mM 
Tris-HCl within a 36 ml Beckman ultracentrifuge tube (Beckman Coulter); and 
centrifuged at 13500 rpm at 4°C for 80 minutes. The pellets were re-suspended in 1-4 
mls of viral re-suspension buffer (10% glycerol (w/v) in PBS containing 138 mM NaCl, 
pH 7.4). Each sample of purified virus was titrated via a TCID50 assay (see section 
2.6).  
 
 
 The MTS cytotoxicity assay as a measure of in vitro oncolysis 2.4
 
Between 1000 and 2000 tumour cells in 90 μl of sCM were plated into individual wells 
of a 96-WP and incubated overnight. A starting quantity of 100 PFU/ cell in 10 μl sCM 
was added to the first column of wells; eight further 10-fold serial dilutions of virus 
were added across the plate. Wells containing sCM only, acted as positive controls i.e. 
100% cell lysis, whereas wells containing uninfected cells were negative controls i.e. 
0% cell lysis. The plate was incubated at 37°C in air with 5% CO2. After six days, 20 μl 
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of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) (Promega) and phenazine methosulfate (PMS) (Promega) in a ratio 
of 20:1 respectively, was added to each well and further incubated for two to four hours. 
The absorbance of light at 490 nm wavelength for each well was obtained using an 
Opsys MR 96-WP reader (Dynex, VA, USA). Optical density (OD) comparisons with 
positive and negative controls enabled a viral dose-response (percentage tumour cell 
death) curve to be created on Prism 6 (GraphPad, CA, USA). The EC50 value was 
calculated as the number of PFU/ cell required to kill 50% of cells. Each virus-tumour 
cell experimental condition was performed in triplicate. 
 
 
 Viral replication  2.5
 
2x105 tumour cells were seeded into each well of a 6-WP (12 wells in total), in 2 ml of 
sCM per well. Twenty four hours later, an average live cell count/ well was calculated 
from harvesting and counting cells from three of the wells. Media was aspirated from 
the remaining wells and replaced with 2 ml of sCM containing 1 PFU/ cell of virus. 
Cells and supernatant were harvested from a triplicate set of wells at 24, 48 and 72 
hours post infection and subjected to two freeze-thaw cycles prior to being stored at -
80°C, ready to be titrated via TCID50 assays (section 2.6).   
 
 
 The TCID50 assay to quantify viral concentration 2.6
 
96-WPs were seeded with 8000 CV1 cells/ per well in 200 μl sCM and incubated 
overnight.  A sample from each viral replicate was diluted 1000 fold in sCM and 20 μl/ 
well of this was mixed into the top row of the 96-WP. Ten fold serial dilutions were 
carried down to the penultimate row leaving the final row uninfected to act as a negative 
control. Plates were incubated for seven days, after which the number of infected wells 
per row was recorded. These values were used to calculate a viral titre in PFU/cell, 
using the Reed Muench method (333).  
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This protocol was also used to establish the concentration (PFU/ ml) of a batch of 
purified virus (following an initial 1x106 fold dilution) and also to determine the amount 
of viral PFUs per gram of organ tissue following the systemic delivery of virus in bio-
distribution experiments. In the latter case, each tissue homogenate was initially diluted 
five fold with DMEM. 
 
 
 Enzyme linked immunosorbent assay for the detection of viral induced 2.7
chemokines     and cytokines 
 
The concentration of a cytokine/ chemokine in supernatant samples from virally 
infected cells or ex vivo cultured splenocytes was measured by enzyme linked 
immunosorbent assays (ELISAs), in accordance with the manufacturer’s instructions. 
All reagents unless otherwise stated were provided by the manufacturer.  
 
In brief, ELISAs consisted of a number of steps, between which plates were washed 
four times by submerging them in a large beaker of wash buffer (0.05% Tween 20® 
(Sigma Aldrich) in PBS). Ninety six well, flat bottomed ELISA plates were coated with 
100 μl of capture antibody diluted in coat buffer, sealed and refrigerated at 4ºC 
overnight. Plates were washed and blocked with 200 μl per well of assay diluent (AD) 
(1% BSA in PBS) for one hour at room temperature (RT). Plates were washed; 100 μl 
of diluted (in AD) test samples/ antigen standards were added to each well and left at 
RT for two hours. Plates were washed; 100 μl of diluted biotinylated detection antibody 
was added to each well and left at RT for one hour. Plates were washed; 100 μl of 
diluted streptavidin horse radish peroxidase (S-HRP) was added to each well and left in 
the dark at RT for 30 minutes. After a final wash step, 100 μl/ well of a 
tetramethylbenzidine substrate solution was added and left in the dark for 15 minutes 
prior to the addition of 50 μl/ well of stop solution (2N H2SO4). Finally the absorbance 
of light at 450 nm wavelength for each well was obtained from an Opsys MR plate 
reader. Each concentration of standard or sample was performed in duplicate. Mean OD 
values for antigen standards were used to create curves from which sample 
concentrations were extrapolated. Table 2.3 lists the ELISA kits that were used during 
the course of this project 
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Table 2.3 A list of the single analyte ELISA kits used in the project 
Cytokine/ Chemokine Species Company 
GMCSF Mouse Biolegend® 
GMCSF Human Biolegend® 
GCSF Mouse R&D Systems™ 
IL1α Mouse Biolegend® 
IL1β Mouse Biolegend® 
IL4 Mouse Biolegend® 
IL12 Mouse Biolegend® 
IL12 Human Biolegend® 
IL10 Mouse Biolegend® 
IL15 Mouse R&D Systems™ 
IL18 Mouse R&D Systems™ 
KC (CXCL1) Mouse R&D Systems™ 
MIP-1α Mouse eBioscience® 
IFNγ Mouse Biolegend® 
 
Biolegend®, London, UK; R&D Systems™, Abingdon, UK; eBioscience®, Hatfield, UK 
 
 
 Ex-vivo stimulation of tumour-antigen specific T cells 2.8
 
2.8.1 Preparation of a single cell suspension of splenocytes from harvested spleens 
 
Spleens from euthanized tumour bearing mice were harvested under sterile conditions 
via a midline laparotomy; mashed through 70 μm Becton Dickinson Falcon™ cell 
strainers (Beckton Dickinson biosciences, Oxford, UK) and flushed through with T cell 
culture media (tCM) (Roswell Park Memorial Institute (RPMI)-medium 1640 (Sigma 
Aldrich), 10% FCS, 1% streptomycin/ penicillin, 1% sodium pyruvate and 1% non-
essential amino acids (Gibco®)) into 50 ml conical flasks. Splenocytes were re-
suspended in 2 ml of red blood cell (RBC) lysis buffer (see below for recipe) following 
centrifugation at 1200 rpm and left at RT for five minutes. Following a wash, they were 
re-suspended with tCM to a final concentration of 5x106 cells/ ml.  
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RBC lysis buffer was prepared as follows: 8.29 g of ammonium chloride (NH4Cl) (0.15 
M), 1 g of potassium bicarbonate (KHCO3) (10 mM) and 37.2 mg of disodium 
ethylenediaminetetraacetate (Na2EDTA) (0.1 mM) was dissolved dH20 to a total 
volume of one litre and sterile filtered through a 0.2 μm mesh filter. 
 
2.8.2 Preparation of growth arrested stimulator cells 
 
Single cell suspensions of 5x106 cells/ ml of stimulator tumour cells (target or control) 
were prepared in 50 ml conical tubes. A 1 mg/ ml solution of Mitomycin C (MMC) 
(Roche) was added to this suspension to achieve a final concentration of 100 μg/ ml and 
incubated in a humidified incubator at 37°C in air with 5% CO2 for one hour. Cells were 
subsequently washed twice with 40 ml of PBS, re-suspended in 40 ml sCM and placed 
in the incubator until ready to seed (within 30-60 minutes). Live stimulator cells were 
finally re-suspended in tCM to achieve a final concentration of 5x105 cells/ ml. 
 
2.8.3 Assessment of T cell activation by measurement of IFNγ release 
 
2.8.3.1 T cell activation by whole tumour cells 
 
100 μl of splenocyte suspension was co-cultured with 100 μl of target stimulator cell 
suspension in duplicate wells of round bottomed 96-WPs (i.e. 5x105 splenocytes with 
5x104 growth arrested tumour cells). Splenocyte only control wells contained 5x105 
splenocytes in 200 μl of tCM.  To demonstrate tumour specificity, splenocytes were 
also co-cultured with 100 μl of tCM containing 5x104 MHC compatible growth arrested 
control cells. 
 
Plates were incubated at 37°C in air with 5% CO2 for three days, after which they were 
centrifuged at 1200 rpm for five minutes. The concentration of IFNγ in supernatants 
taken from each of the wells was established by ELISA (Biolegend®). The final 
“stimulated” concentration of IFNγ per sample, averaged across duplicate wells, was 
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determined after deducting values from corresponding wells containing splenocytes 
alone. 
 
2.8.3.2 T cell activation by peptides 
 
Where indicated, 100 μl of splenocyte suspension was co-cultured with 100 μl of the 
working solution of individual peptides restricted to the H-2Kb or H-2Db Class I MHC 
(to which T cells from C57BL/6 mice can bind). Table 2.4 lists the peptides used in this 
project, all of which were obtained from Proimmune, Oxford, UK.  
 
Table 2.4 A list of the peptides used to stimulate epitope specific T cells clones 
Peptide epitope Amino acid sequence MHCI restriction 
Chicken Ovalbumin SIINFEKL H-2Kb 
Vaccinia WR B8R TSYKFESV H-2Kb 
K-RAS GADGVGKSA H-2Kb 
Mesothelin GQKMNAQAI H-2Db 
 
 
Peptides were dissolved in dimethyl sulfoxide (DMSO) (Sigma Aldrich) to achieve a 
stock concentration of 5 μg/ ml. They were diluted a further 500 fold in tCM to achieve 
the working concentration. IFNγ concentrations following a three day incubation period 
were obtained by ELISA as detailed in section 2.8.3.1. 
 
2.8.4 A non-radioactive LDH based cytotoxic T lymphocyte assay 
 
Splenocyte suspensions were prepared from mice bearing SC tumours treated with virus 
or PBS (section 2.8.1) and were resuspended to 5x106 cells/ ml. 1 ml aliquots of 
splenocytes from each experimental condition were co-cultured with 1 ml of 5x105 
cells/ ml of growth arrested stimulator cells (either LLC or DT6606 depending on the 
primary tumour model used) in each well of a 12-WP. Plates were incubated at 37°C in 
air with 5% CO2 for five days.  
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Non adherent cells and media were carefully collected and samples from each 
experimental condition pooled. Cells were resuspended to a concentration of 3x106 live 
cells/ ml in tCM. 100 μl of this suspension was added to 100 μl of live tumour cells 
(5x104 cells/ ml in tCM) in wells of 96 well V bottomed plates; thus establishing a top 
ratio of 60:1 effector (splenocyte) to tumour cell respectively.  
 
Splenocyte cell suspensions were serially diluted by two fold and added to tumour cells 
in order to obtain effector: target ratios of 30:1 and 15:1. tCM containing splenocyte or 
tumour cells alone were similarly plated in order to calculate background signals. All 
samples were plated in quadruplicate. The plates were incubated at 37°C in air with 5% 
CO2 for four hours. Plates were subsequently centrifuged at 250 g for one minute. 50 μl 
of supernatant from each well was transferred to a flat 96-WP. A non-radioactive 
colorimetric cytotoxicity assay kit (CytoTox 96®, Promega) was used (in accordance 
with the manufacturer’s instructions) to measure lactate dehydrogenase (LDH) released 
from lysed cells. This relies on the conversion of a tetrazolium salt (INT) into a red 
formazon product. The mean absorbance of light at 490 nm wavelength for each well 
was quantified using an Opsys MR 96-WP reader. 
 
Mean ODs (after deduction of background) from each experimental condition were 
divided by that derived from wells containing maximally lysed target/ control tumour 
cells to estimate the percentage of total lysis.  
 
      
 Preparation of harvested tissue for flow cytometry 2.9
 
1. Single cell splenocyte suspensions (section 2.8.1) 
 
2. Single cell suspensions of blood leucocytes (section 2.9.1) 
 
3. Single tumour cell suspensions from SC LLC or DT6606 tumours (section 2.9.2) 
 
4. Single cell suspensions of murine bone marrow derived DCs/ monocytes (section 
2.9.3) 
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2.9.1 Single cell suspensions of blood leucocytes  
 
Following sacrifice of a mouse via CO2 inhalation, a laparotomy was promptly 
performed; bowel and omentum were gently moved aside and blood was extracted via 
hepatic vein cannulation with a 23 gauge blue needle connected to a 1 ml syringe. 
Blood samples were added to 200 μl of heparin (50 μg/ ml) (Sigma Aldrich) in 1.5 ml 
microcentrifuge tubes to prevent coagulation. 0.5 to 1 ml of RBC lysis buffer (section 
2.8.1) was added to each sample and left to stand for five minutes at RT. After 
centrifugation at 200 rpm, pellets were resuspended in 1 ml of RBC lysis buffer and left 
again for a similar time. Large clots or clumps of dead cells were removed by filtration 
of the solution through 70 μm cell strainers into 50 ml tubes. Leucocytes were 
resuspended to a final concentration of 1x106 cells/ ml in flow cytometry buffer (FB) 
(1% FCS in PBS); ready to be stained by fluorophore labelled antibodies.  
 
2.9.2 Single tumour cell suspensions from SC LLC or DT6606 tumours 
 
A SC tumour from a sacrificed mouse was carefully dissected out, in a disinfected 
environment, and placed in one well of a 6-WP, in 2 ml of collagenase D (1 mg/ ml) 
(Roche) and DNAse I (0.1 mg/ ml) (Roche) in PBS. Debris (skin, hair, fat) was 
carefully removed and the remaining tumour tissue cut into fine 1-3 mm cubes. The 
plate was incubated at 37ºC in a shaker for up to two hours, until tissue disaggregation 
was complete. Homogenates were repeatedly pipetted through a 1 ml tip and then 
filtered through 70 μm cell strainers into 50 ml tubes. Following a PBS wash, tumour 
cell pellets were re-suspended to a final concentration of 1x106 cells /ml in FB, ready to 
be stained by fluorophore labelled antibodies.  
 
2.9.3 Single cell suspensions of murine bone marrow derived DCs/ monocytes 
 
Murine monocyte-colony stimulating factor (M-CSF) or GMCSF (Roche) was added to 
bone marrow culture medium (mCM; RPMI-1640, 1% sodium pyruvate, 1% non-
essential amino acids, 1% penicillin streptomycin and 0.1% β-mercaptoethanol) to 
obtain a stock concentration of 30 ng/ ml.  
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Six to seven week old C57BL/6 mice were sacrificed via CO2 inhalation.  Subsequent 
dissection took place in a disinfected environment. The femur and tibia of both hind 
legs were denuded of skin and muscle tissue, dissected out of the mouse and placed in a 
petri dish containing mCM. The ends of the bones were amputated to expose the red 
marrow which was then flushed with mCM into a mini dish using a 23G needle attached 
to a 3 ml syringe. The cells were homogenised further with the needle and syringe to 
create a uniform suspension and filtered through 70 μm cell strainers into 50 ml 
centrifugation tubes (one per mouse). Cells were centrifuged at 1300 rpm, resuspended 
in 2 mls of RBC lysis buffer and left for five minutes at RT. Following a wash cycle 
with RPMI-1640, cell suspensions from each mouse were split into two and each 
resuspended to a total volume of 50 mls with mCM containing either M-CSF (monocyte 
sample) or GMCSF (DC sample).  
 
The monocyte sample was divided into five sterile, “non-culture” 10 cm petri dishes 
(approximately 10 ml per dish). They were incubated at 37°C in air with 5% CO2. The 
media was topped up by 2.5 to 5 ml of M-CSF containing mCM every two to three days 
(M-CSF was added to the media to maintain an approximate concentration of 30 ng/ ml 
in the plate). At day seven or eight, adherent monocytes were washed with PBS, gently 
scraped from the plates and re-suspended in growth factor free mCM.  
 
A similar protocol was followed for the DC sample using GMCSF containing mCM. 
This was divided and plated into five, 10 cm diameter sterile “culture” dishes. On day 
three, the supernatant and loose cells in each plate were discarded. Adherent cells were 
washed with PBS and replenished with mCM containing GMCSF. By day seven or 
eight, the non/ loosely adherent DCs were ready to use.  
 
To confirm the purity of this enrichment process, cells were stained with fluorophore 
labelled antibodies that specified DCs (CD11c+MHCII+) and monocyte 
(CD11b+F4/80+) populations (section 2.10).  
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 Flow cytometric analysis of cellular suspensions  2.10
 
Approximately 1x106 cells from each suspension were plated into each well of a V 
bottomed 96-WP. Control samples were derived from a pool of all the different 
treatment conditions and were stained with fluorescence minus one (FMO) 
combinations of target antibodies. For the purposes of compensating for light spill over 
from neighbouring channels in the flow cytometer, control samples were also singly 
stained with antibodies attached to each of the different fluorophores used.  
 
Plated cells were washed twice with 150 μl FB; each plate was centrifuged at 1500 rpm 
at 4°C for three to five minutes per wash cycle. All antibodies were acquired from 
eBioscience® and were diluted 200 fold in FB. After discarding the supernatant, cells 
were re-suspended in 100 μl Fc block (anti-CD16/32) and incubated for 15 minutes at 
4°C in the dark. After a wash cycle with FB, each pellet from experimental wells was 
resuspended in 100 μl of the diluted antibody master mix solution. The plate was left on 
ice for 45 minutes in the dark. Antibody stained cells were washed a further three times 
with FB,  re-suspended  in 200 μl 2% formaldehyde (in PBS) and transferred into 1.2 ml 
cluster tubes (Qiagen). These were stored at 4°C in the dark for less than 24 hours and 
analysed in an LSRFortessa™ multichannel flow cytometer (Becton Dickinson). The 
raw data was analysed using FloJo v10 (FloJo, LLC. Or, USA). 
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Table 2.5 Fluorophore labelled antibodies used for flow cytometry  
 
Antibody  
(anti-mouse)  
Species Clone Labelled 
fluorophore 
Dilution  
(from X mg/ml) 
Fc Block 
CD16/32 Rat 93 Unlabelled 1:200 (0.5mg/ml) 
 The common leukocyte antigen 
CD45 Rat 30-F11 eFluor® 450 1:200 (0.2mg/ml) 
CD45 Rat 30-F11 FITC 1:200 (0.5mg/ml) 
CD45 Rat 30-F11 APC-eFluor® 780 1:200 (0.2mg/ml) 
Lymphocyte markers 
CD3e Rat 145-2C11 PerCP-Cy5.5 1:200 (0.2mg/ml) 
CD3 Rat 17A2 FITC 1:200 (0.5mg/ml) 
CD8a Rat 53-6.7 FITC 1:200 (0.5mg/ml) 
CD8a Rat 53-6.7 APC 1:200 (0.2mg/ml) 
CD44 Rat IM7 APC 1:200 (0.2mg/ml) 
CD44 Rat IM7 eFluor® 450 1:200 (0.2mg/ml) 
CD62L Rat MEL-14 PE-Cy7 1:200 (0.2mg/ml) 
CD49b Rat DX5 PE 1:200 (0.2mg/ml) 
Myeloid cell markers 
CD11b Rat M1/70 PerCP-Cy5.5 1:200 (0.2mg/ml) 
Gr1 (Ly-6G) Rat RB6-8C5 Alexa Fluor® 700 1:200 (0.2mg/ml) 
F4/80 Rat BM8 PE-Cy7 1:200 (0.2mg/ml) 
Antigen presenting cells (APCs) 
CD11c Armenian 
Hamster 
N418 PE 1:200 (0.2mg/ml) 
CD11c Armenian 
Hamster 
N418 Alexa Fluor® 700 1:200 (0.2mg/ml) 
MHCII Rat M5/114.15.2 FITC 1:200 (0.5mg/ml) 
CD80 (B7-1) Armenian 
Hamster 
16-10A1 PE 1:200 (0.2mg/ml) 
CD86 (B7-2) Rat GL1 APC 1:200 (0.2mg/ml) 
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2.10.1 Pentamer staining of mesothelin epitope specific CD8+ T cell clones.  
 
A custom built pentamer consisting of phycoerythrin (PE) labelled Pro5® H-2Db class I 
MHC complexed to the mesothelin epitope, GQKMNAQAI (Proimmune©) was used to 
identify its complementary clone of CD8+ T cells. The staining protocol was identical 
to that with the fluorophore labelled antibodies outlined above, with an additional step. 
5 μl of pentamer, made up to 100 μl in FB, was used to resuspend the relevant pellet of 
splenocytes after the initial wash and was left at RT for 10 minutes. Cells were 
subsequently treated as described in section 2.10 with Fc block and stained with the 
other antibodies.   
 
 
 Measurement of activation of virus infected bone marrow derived monocytes 2.11
and DCs. 
 
Monocytes/ DCs were stained with fluorophore labelled antibodies against class II 
MHC and/ or CD80 and CD86 cell surface co stimulator molecules, at various times 
post viral infection (see the relevant results sections for details).  
 
1x106 cells of monocytes or DCs in 2 ml mCM/ well were plated in triplicate wells of a 
6-WP. Following a two hour incubation period 1 PFU/ cell of virus in 500 μl of mCM 
was added to each well. At each time point, cells were gently scrape-harvested, washed 
in FB, stained with the relevant antibody cocktail and analysed as described in section 
2.10. 
 
 
 A screen of chemokines/ cytokines secreted within viral treated LLC tumours 2.12
 
A stock solution of tissue extraction buffer (TEB) containing a proteinase inhibitor 
cocktail solution and EDTA (inhibits metalloproteinases) was prepared by dissolving 
one cOmplete ULTRA mini tablet (Roche) into 10 mls of 50 mM Tris-HCl at pH 7.4.  
Tumours from euthanized mice were carefully harvested from flanks, leaving behind as 
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much skin as possible and placed into 2 ml cryotubes. Following the addition of a small 
volume of TEB they were homogenised with an Ultra-Turrax® (IKA®, Staufen, 
Germany) homogeniser (at 12000 rpm) for 30 seconds, diluted 10 fold w/v in 15 ml 
centrifuge tubes and finally centrifuged at high speed (6000 rpm) for 5 minutes. 
Supernatants were carefully removed without disturbing the pellet and their total protein 
concentration (g/ ml) was obtained using the NanoDrop® 1000 Spectrophotometer. 
 
Each sample was diluted in 1% BSA in PBS and simultaneously screened for a panel of 
12 chemokines or cytokines using Qiagen® Multi-analyte ELISArray kits: 
inflammatory cytokines or common chemokines. These consisted of 96 well plates, 
comprised of eight, 12-well strips that were pre-coated with 12 different capture 
antibodies against the different chemokines or cytokines. All reagents including 
standards and wash buffer were provided by the manufacturer. Each experimental 
sample was plated in triplicate. A standard protocol for a sandwich ELISA was 
performed as per the manufacturer’s instructions.  
 
The absorbance of light at 450 nm wavelength for each well was obtained from an 
Opsys MR plate reader; an arbitrary OD value per gram of tumour protein was 
calculated and subsequently normalised to the corresponding mean value of the VVL15 
treatment group.  
 
If  there were any consistent differences between the levels of a particular cytokine or 
chemokine across time, then further quantitative analyses were performed on 
supernatants taken from in vitro infected tumour cells or APCs (see below) using the 
relevant single analyte ELISA kit.  
 
 
 Cytokine release from monocytes, DCs and tumour cells following infection 2.13
with recombinant virus 
 
1x105 bone marrow derived monocytes or DCs and murine tumour cell lines (LLC or 
DT6606) were plated (in 200 μl of tCM or sCM per well respectively) in triplicate, into 
flat bottomed 96-WPs and incubated at 37ºC in air with 5% CO2. Two hours later, 1 
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PFU/ cell of virus in 50 μl of the appropriate CM or CM alone was added to each well. 
At 24 and 48 hours post infection, single analyte ELISAs were performed on the 
supernatant to determine the concentration of the specific cytokines as indicated in the 
results subsections (see also section 2.7). 
 
 
 Histological analysis of virally infected tumours 2.14
 
All histology including immunohistochemistry was performed by George Elliah 
(Pathology department, BCI, QMUL). This included the processing of formaldehyde 
fixed and snap frozen samples and the optimisation of all primary antibodies used for 
immunohistochemistry (IHC). All slides were subsequently reviewed by Jahangir 
Ahmed (JA) or Yaohe Wang (YW).  
 
Specimens that had been fixed with 4% formaldehyde (for at least 24 hours) were 
washed with 70% EtOH, paraffin embedded and cut into 4 μm sections with a Leica 
EG1160 microtome (Leica Microsystems UK Ltd, Milton Keynes, UK). Cut sections 
were stained with haematoxylin and eosin (H&E) in accordance with standard protocols 
on a Leica autostainer XL. 
 
Snap frozen specimens were cut to widths of 6 μm, air dried at RT and fixed in neutral 
buffered formalin. IHC staining was performed using the Ventana® Discovery staining 
system (Ventana Medical Systems Inc. Az, USA). All primary antibodies were rat 
antimouse antibodies and had been previously optimised using frozen sections of mouse 
spleen. They are listed in table 2.6. The staining layer comprised of secondary 
biotinylated rabbit anti rat antibody (AI 4001, Vector laboratories UK, Peterborough, 
UK) to which S-HRP (Omnimap, Roche) could  conjugate. The latter catalyses the 
oxidation of the chromogenic substrate, 3, 3’ diaminobenzidine tetrahydrochloride 
(DAB) (Roche) by hydrogen peroxide to produce a dark brown stain, visible on light 
microscopy.    
 
Light microscopy was performed using an Olympus BX-51 microscope (Olympus, 
Southend on Sea, UK) in conjunction with a digital camera (Pixera, Bourne End, UK). 
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Images were acquired under a 20x objective (200x overall magnification) and visualised 
on a PC through the Pixera viewfinder. Quantification of cells positive for a particular 
surface antigen was performed by averaging independent manual cell counts from 10 to 
15 randomly selected high power fields (HPFs) depending on the size of the histological 
section.  
      
Table 2.6 Antibodies used for purposes of immunohistochemistry 
Antibody against Species clone Optimised dilution 
(from 0.5mg/ml) 
Company 
CD4 Rat GK 1.5 1:200 Biolegend® 
CD8a Rat 53-6.7 1:300 Biolegend® 
NK1.1 Rat PK 136 1:50 Biolegend® 
F4/80 Rat CI:A3-1 1:2000 AbD Serotec® 
 
 
 
 Establishment of in vivo models 2.15
 
Unless otherwise specified, studies with live animals were conducted at the biological 
services unit (BSU), BCI by JA.  All other experiments were conducted at the Sino-
British Research Centre for Molecular Oncology (SBRCMO), Zhengzhou University, 
Henan Province, China, according to protocols designed by JA. All animals were 
treated in accordance with UK home office regulations (334). Tumour volumes were 
calculated as w2 x l x π/6, where w is the maximal width at 90 degrees to the maximal 
length l. 
 
The following syngeneic murine models were used: 
CT26 (colon cancer) cells in BALB/c mice 
SCCVII (head and neck squamous cancer) cells in C3/HeN mice 
4T1 (metastatic breast cancer) cells in BALB/c mice (performed at the SBRCMO) 
DT6606/ DT6606-Ova (pancreatic cancer), CMT93 (rectal cancer) and LLC (lung 
cancer) cells in C57BL/6 mice 
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2.15.1 Establishment and IT treatment of subcutaneous syngeneic tumour models 
 
The relevant number of tumour cells (see table 2.7 and table 2.8) in 100 μl of serum free 
DMEM were injected subcutaneously into the shaved right flanks of six to seven week 
old BALB/c, C3/HeN or C57BL/6 mice. When tumours were approximately 100 mm3 
in volume, mice were randomized into treatment groups. Doses of 1x108 PFU of virus 
in 50 μl of PBS were injected IT using a 1 ml insulin syringe attached to a 29 gauge 
needle (dosing schedules varied depending on the experiment). The needle was passed a 
number of times in different directions throughout the tumour prior to virus deployment 
for broad dissemination. Control groups were injected with the equivalent volume of 
vehicle buffer i.e. 50 μl of PBS.  
 
Tumour volumes were monitored via twice weekly calliper measurement when mice 
were also weighed. Animal models were euthanized via CO2 inhalation at appropriate 
time points post-infection (see specific experiments) or when the tumour volume 
exceeded that stipulated by UK home office guidance.  
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Table 2.7 Biological time-point experiments  
See text for details, n=3-4 mice per treatment group per time-point. 
 
No. Model Mouse Cell no./route Definition of  
day 0 
One dose Schedule   
(day/ route) 
Additional 
procedures 
Time-point (s) (day) 
1 LLC C57BL/6 1x106 SC Tumour 100 mm3 1x108 PFU Virus/ 
50μl PBS 
0/ IT  1, 3, 5, 7, 14 (depending 
on experiment) 
2 DT6606 C57BL/6 3x106 SC Tumour 100 mm3 1x108 PFU Virus/ 
50μl PBS 
0/ IT  7, 14, 21 (depending on 
experiment) 
3 DT6606-Ova C57BL/6 3x106 SC Tumour 100 mm3 1x108 PFU Virus/ 
50μl PBS 
0/ IT  14 
4 DT6606 C57BL/6 3x106 SC Tumour 100 mm3 1x108 PFU Virus/ 
50μl PBS 
0,1,2,3,4/ IT  14 
 
5 LLC C57BL/6 1x106 SC IV virus injection 1x108 PFU Virus/ 
50μl PBS 
0/ IV  1, 3, 5, 8, 11 
6 CT26 BALB/c 2x106 SC IV virus injection 1x108 PFU Virus/ 
50μl PBS Virus/ 
0/ IV  1, 3, 7, 10 
7 LLC C57BL/6 1x106 SC Tumour 100 mm3 1x108 PFU Virus/ 
50μl PBS 
0,1,2,3,4/ IT  Sacrificial endpoint 
8 LLC C57BL/6 1x106 SC Tumour 100 mm3 1x108 PFU Virus/ 
50μl PBS 
0,1,2,3,4/ IT 
 
Day 11: Tumour 
excision 
18 
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Table 2.8 Intratumourally treated syngeneic flank tumour models to demonstrate efficacy 
See text for details, n=5-7 mice per treatment group 
 
No.  
 
Model Mouse Cell no./ route Definition of  
day 0 
One dose Schedule   
(day/ route)  
Additional 
procedures 
End-point  
1 LLC C57BL/6 1x106 SC Tumour  100 mm3 1x108 PFU Virus/ 
50μl PBS 
0,1,2,3,4/ IT Thoracotomy Tumour  >1200 mm3 
2 SCCVII C3/HeN 2x106 SC Tumour  100 mm3 1x108 PFU Virus/ 
50μl PBS 
0,1,2,3,4/ IT  Tumour  >1200 mm3 
3 CMT93 C57BL/6 5x106 SC Tumour  100 mm3 1x108 PFU Virus/ 
50μl PBS 
0,1,2,3,4/ IT  Tumour  >1200 mm3 
4 CT26 BALB/c 2x106 SC Tumour  100 mm3 1x108 PFU Virus/ 
50μl PBS 
0,1,2,3,4/ IT  Tumour  >1200 mm3 
5 DT6606 C57BL/6 3x106 SC Tumour  100 mm3 1x108 PFU Virus/ 
50μl PBS 
0,1,2,3,4/ IT  Tumour  >1200 mm3 
6 DT6606 
(Sequential 
virus) 
C57BL/6 3x106 SC Tumour  100 mm3 1x108 PFU Virus/ 
50μl PBS 
Virus A: 0,1,2/ IT 
Virus B: 4,5,6/ IT 
(see text) 
 Tumour  >1200 mm3 
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2.15.2 Assessment of viral biological distribution following IV virus into tumour 
bearing mice 
 
Following the establishment of SC CT26 or LLC syngeneic flank tumours, 1x108 PFU 
(in 50 μl PBS) of either VVL15 or VVL15∆N1L was injected via tail vein. At various 
times post virus injection (table 2.7, experiments 5 and 6), three mice from each group 
were sacrificed via CO2 inhalation. The following organs were harvested:  tumour, 
brain, lung, liver, spleen, kidneys and ovaries. They were immediately snap-frozen in 
precooled (to -80°C) isopentane. Samples were subsequently thawed, weighed and 
homogenised using an Ultra-Turrax® homogeniser (at 12000 rpm) in a small volume of 
serum-free DMEM. Samples were diluted five fold w/v (i.e. 5 μl DMEM per mg). After 
a further freeze-thaw cycle, tissue homogenates were titrated for live viral PFUs using 
the TCID50 assay described in section 2.6.  
 
2.15.3 Efficacy of VVL recombinants against an orthotopic lung cancer model 
 
5x105 LLC cells in 100 μl PBS were injected into the tail veins of seven week old 
C57BL/6 mice. Repeated, non-contrast CT scans of the lungs were used to assess lung 
volumes of individual mice over a period of 21 days and any reduction used to 
extrapolate tumour burden. When tumour was initially present on CT, the first of three 
IV doses of virus/ PBS was administered as outlined in table 2.9, experiment 3. Mice 
were weighed twice weekly and were sacrificed if they showed signs of distress or if 
weight loss exceeded 20% of their maximal weight.  
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Table 2.9 Viral treatment of syngeneic orthotopic and surgical models of cancer. See text for details, n=7-10 mice per treatment group. 
.No. 
 
Model Mouse Cell no./ route Definition 
of day 0 
One dose Schedule  
(day/ route) 
Additional procedures End-point 
1 LLC 
(IT neoadjuvant) 
C57BL/6 1x106 SC Tumour  
100 mm3 
1x108 PFU Virus/ 
50μl PBS 
0,1,2,3,4/ IT Day 11: Tumour 
excision 
Thoracotomy 
Weight loss >20% 
Tumour regrowth 
Signs of distress 
2 4T1 
(Orthotopic breast) 
BALB/c 1x105 SC  (into 
mammary fat pad) 
Tumour  
50 mm3 
1x108 PFU Virus/ 
50μl PBS 
0, 2, 4/  IT Day 9:  Tumour 
excision 
Thoracotomy 
Weight loss >20% 
Tumour regrowth 
3 LLC 
(Orthotopic lung) 
C57BL/6 5x105 IV LLC cell 
injection 
1x108 PFU Virus/ 
50μl PBS 
5, 7, 9/ IV CT lungs 
Thoracotomy 
Weight loss >20% 
Signs of distress 
 
Table 2.10 Schedule of treatment of tumour models with immune cell subset depletion. See text for details, n=7-10 per treatment group. IP: intraperitoneal. 
No. Model Mouse Cell no./ 
route 
Definition 
of day 0 
Treatment Schedule  
(day/ route)  
Additional procedures End-point  
1 DT6606 C57BL/6 3x106 SC Tumour   
100 mm3 
1x108 PFU 
VVL15∆N1L 
0,1,2,3,4/ IT IP 200 μg cell depleting antibody or control 
IgG: Day: -1, 3, 7, 11...end of experiment  
Tumour  >1200 mm3 
2 LLC C57BL/6 1x106 SC Tumour   
100 mm3 
1x108 PFU 
VVL15∆N1L 
0,1,2,3,4/ IT IP 200 μg cell depleting antibody or control 
IgG: Day: -1, 3, 7, 11...end of experiment  
Day 11: Tumour excision 
Thoracotomy 
Weight loss >20% 
Tumour regrowth 
Signs of distress 
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2.15.4 Efficacy of VVL recombinants against a spontaneously metastatic lung 
cancer model 
 
Syngeneic flank LLC tumours were established and randomised into the appropriate 
number of treatment groups (section 2.15.1).  Injections of recombinant virus/ PBS were 
administered IT as per the treatment schedule in table 2.7, experiment 7. Tumours were 
monitored via calliper until a group reached the sacrificial end point. All animals were 
euthanized at the same time; their lungs were harvested and any gross tumour deposits 
noted. Lung lobes were separated and fixed in 4% formaldehyde. They were 
subsequently embedded in paraffin, sectioned through the largest cross sectional 
dimension and stained with H&E (performed by George Elliah in the BCI pathology 
unit). For each lobe, slices were also performed above and below the largest cross 
section. All three sections were scrutinized for tumour deposits by an experienced 
pathologist (YW) who was blinded to the treatment schedule.  
 
2.15.5 Efficacy of pre-surgical neoadjuvant recombinant VVL treatment against 
spontaneously metastatic tumour models 
 
Syngeneic LLC lung or 4T1 breast tumour models were established in the flanks or 
mammary glands of seven week old female mice respectively (table 2.9, experiments 1 
and 2). The latter experiment was performed at the SBRCMO, China. Following 
randomisation into treatment groups, the tumour bearing mice were treated with IT 
virus/ PBS (see table 2.9).  
 
Five or seven days after the final dose of virus as indicated (table 2.9), tumours were 
carefully excised under general anaesthetic (continuous isofluorane and nitrous oxide 
via nose cone) and wounds were closed primarily with interrupted 4-0 monocryl 
absorbable sutures (Ethicon, Livingston, UK). Mice that suffered from surgical 
complications e.g. wound infection/ dehiscence were excluded. To capture regrowth 
from minimal microscopic residual disease, any tumour that clinically regrew within a 
week of the operation were also excluded. Mice were followed up via twice weekly 
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weight measurements and assessment of general well-being. All sacrificed mice had 
thoracotomies to confirm whether their likely cause of demise was due to overt lung 
metastases.  
 
At the end point of the experiment with LLC tumours (day 60 post op), surviving 
animals were re-challenged with a subcutaneous injection of 2x106 LLC cells in 100 μl 
serum free DMEM and assessed for tumour regrowth. A further 14 days later all mice 
were sacrificed and harvested splenocytes were tested for the presence of antitumour 
memory T cells using the IFNγ immunoassay described in section 2.8.3.1.  
 
In a separate biological time-point experiment, syngeneic LLC tumour bearing mice 
were established and treated as above with similar criteria for exclusion. Mice were 
sacrificed seven days after resection (approximately 14 days following the final dose of 
IT virus) (table 2.7, experiment 8). Harvested splenocytes were tested for the presence 
of antitumour T cells using the IFNγ immunoassay described in section 2.8.3.1.  
 
2.15.6 Immune cell subset depletion protocol 
 
These experiments were conducted at the SBRCMO, China. The VVL15∆N1L 
treatment arms of experiment 5 in table 2.8 (IT therapy of DT6606 flank tumours) and 
experiment 1 in table 2.9 (IT neoadjuvant therapy prior to surgical resection of LLC 
flank tumours) were repeated under the following conditions: depletion of NK, CD4+ or 
CD8+ cells. Table 2.11 lists the IgG clones of antibodies used. All antibodies were 
derived from in-house cultured hybridomas.  
 
A single 200 μg intraperitoneal dose of cell depleting antibody caused a reduction of 
over 90% of the relevant splenic cell population (measured 48 hours later), when 
compared to mice treated with IgG control antibody (data not shown). 
 
Intraperitoneal antibody was commenced when tumour growth approached 100 mm3, a 
day prior to the initial dose of VVL15∆N1L. Control rat IgG and PBS treatment (no 
antibody) groups were also included (see table 2.10 for treatment schedules).        
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Table 2.11 Antibodies used for in vivo immune cell subset depletion 
Antibody against cell Species IgG clone Volume per dose (1 mg/ ml) 
CD4  Rat GK 1.5 200 μl 
CD8  Rat TIB210 200 μl 
NK  Rat PK 136 200 μl 
 
 
 
 Statistical Analysis  2.16
 
GraphPad Prism 6 was used for comparative statistical analysis. Dual condition 
comparisons were made using the unpaired student t-test. For more than one condition 
or for an additional variable such as time, one or two-way ANOVAs respectively were 
performed. A post hoc Tukey test compared pairs of conditions. For the purpose of 
comparing specific treatment pairs when data was categorical, the Fisher’s exact test 
was used following sub-classification into multiple 2x2 tables. Survival data was 
represented as a Kaplan-Meier plot with log rank analyses to delineate whether any 
differences between specific treatment pairs were statistically significant. 
 
Key to significance level characters used in the thesis:   
*   P ≤ 0.05 
** P ≤ 0.01 
*** P ≤ 0.001 
**** P ≤ 0.0001 
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Chapter 3 Results 
 
 Construction and in vitro validation of N1L(L025) deleted and cytokine-armed 3.1
VVL15 recombinant viruses 
 
3.1.1 Creation of pUC19 based VV super-shuttle vectors -summary  
 
Murine and human cytokine transgenes were incorporated into the VVL15 (luciferase) 
backbone via homologous recombination. This process involved creating plasmid 
super-shuttle vectors containing the relevant transgene(s), straddled on either side by 
short sequences homologous to those flanking the insert position within the virus. 
Recombination with virus would effectively delete the intervening viral DNA between 
these “left” and “right” arm sequences, replacing it with the transgene(s). 
 
Specifically, transgene cassettes designed to replace the L025 (N1L) coding region were 
constructed via standard cloning techniques (see below) and incorporated into VV 
specific super-shuttle vectors, based on the pUC19 plasmid vector (NEB, figure 3.2). 
RFP plus/ minus cytokine transgenes were designed to be individually driven by the 
constitutively stimulated VV H5 transcription factor promoter (335). Each transgene 
cassette was straddled on either side by sequences homologous to that on the extreme 
left and right of the L025 gene and included code belonging to the L024 and L026 
ORFs respectively.  
The following murine transgene super-shuttle vectors had already been constructed by 
Dr Ming Yuan in our group: 
pUC19-LA-H5-mGMCSF-H5-RFP-H5-RA 
pUC19-LA-H5-H5-RFP-H5-mIL12-RA  
 
Three further super-shuttle vectors were constructed as part of the current project by JA: 
pUC19- LA-H5-H5-RFP-H5- RA 
pUC19- LA-H5-H5-RFP-H5-hGMCSF- RA 
pUC19- LA-H5-H5-RFP-H5-hIL12- RA 
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Key: 
LA: left arm sequence of L025 
RA: right arm sequence of L025 
RFP: ORF sequence of DSRed Express 2 (Clontech labs Inc. CA, USA)  
H5: the VV H5 transcription factor promoter 
mGMCSF/ hGMCSF: murine or human GMCSF transgenes respectively 
mIL12/ hIL12: murine or human IL12 transgenes respectively 
 
3.1.2 Detailed steps in the construction of VVL15∆N1L and the human cytokine 
transgene armed N1L gene deleted viruses 
 
The following shuttle vectors had previously been constructed by Dr Ming Yuan: 
pGEM-T-H5-RFP- H5 (figure 3.1) 
pGEM-T-LA-H5 (figure 3.1) 
pUC19-RA (figure 3.2) 
 
See figure 3.1 and figure 3.2 for maps of the parent pGEM-T Easy (Promega) and 
pUC19 cloning vectors respectively. 
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Figure 3.1 pGEM®-T Easy based shuttle vectors 
The left arm sequence of the L025 gene (L Arm) and the RFP coding sequence had previously been 
cloned into the pGEM®-T Easy platform. Note relevant restriction sites on either side of the transgene 
insert. See text for further details and abbreviations.  
 
Figure 3.2 Right arm sequence of the L025 gene within the pUC19 (NEB®) vector  
Note the relevant restriction enzymes used to clone the transgene into the multiple cloning site (MCS) of 
the plasmid. See text for details. 
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Further plasmids were purchased from the companies indicated: 
pORF-hGMCSF (InvivoGen, Toulouse, France) 
pORF-hIL12 (InvivoGen) 
pCMV-DsRed-Express 2 (Clontech labs Inc.)  
 
3.1.2.1 Step 1. Construction of the shuttle vector: pGEM-T-H5-RFP-H5-hGMCSF  
 
The following plasmid vectors were amplified and purified as described in the methods 
(sections 2.3.7, 2.3.8 and 2.3.9): 
1. pGEM-T (SacII)-H5-RFP-H5-(HindIII SmaI MluI) 
2. pORF-(HindIII)-hGMCSF-(SwaI)  
 
Note the relevant restriction sites used for cloning in brackets.  All restriction enzymes 
were purchased from New England Biolabs® Inc. (NEB). 
 
Vector 1 above was opened by sequential digestion with HindIII and SmaI enzymes 
(section 2.3.3, figure 3.3). SmaI digestion leaves blunt ended cuts. The final linearised 
DNA was 5’ de-phosphorylated (with Antarctic phosphatase) to prevent re-annealing. 
Following electrophoresis in a LMW agarose gel, the DNA was cut out, extracted from 
the gel and quantified (section 2.3.2). 
 
The hGMCSF insert fragment was similarly extracted from its parent plasmid (vector 2, 
above and figure 3.3) by sequential digestion with HindIII and SwaI enzymes. The latter 
enzyme also leaves blunt ends. It was subsequently ligated to the open vector 1, in a 
ratio of 3:1 (insert: vector), using T4 high fidelity ligase. 
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Figure 3.3 Creation of the pGEM-T based hGMCSF shuttle vector 
See text for abbreviations and details. 
 
The newly constructed pGEM-T based hGMCSF shuttle vector was then transformed 
into competent E. coli cells and plated on ampicillin containing agar plates (as was the 
linearised vector 1 as a control). Only the circularized hGMCSF shuttle vectors 
produced colonies and these were picked, amplified and purified as described in 
sections 2.3.7 and 2.3.8.    
 
3.1.2.2 Step 2. Creation of super-shuttle vectors: pUC19-LA-H5-H5-RFP-H5-RA 
and pUC19-LA-H5-H5-RFP-H5-hGMCSF-RA 
 
The shuttle vectors below were initially singly digested with SacII and the resulting 
“stepped” ends were blunted with T4 polymerase (see figure 3.4): 
1. pGEM-T-(SacII)-H5-RFP-H5-hGMCSF-(MluI) (from step 1) 
2. pGEM-T-(SacII)-H5-RFP-H5-(MluI) 
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Following DNA extraction after gel electrophoretic separation, the linearized vectors 
were subsequently digested with MluI freeing up the insert fragments: 
3. (blunt end)- H5-RFP-H5-hGMCSF-(MluI) 
4. (blunt end)- H5-RFP-H5-(MluI) 
 
 
Figure 3.4 Blunting and release of the RFP and RFP-hGMCSF transgene fragments from their 
respective pGEM-T shuttle vectors  
See text for abbreviations and details. 
 
 
pGEM-T-(HindIII)-LA-H5 (SalI) was digested initially with SalI and the free ends were 
blunted with T4 polymerase. A HindIII digest released the LA-H5 insert fragment from 
the linearised pGEM-T-(HindIII)- LA-H5-(blunt end) plasmid (figure 3.5). 
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Figure 3.5 Blunting and release of the left arm transgene fragment from its pGEM-T shuttle vector. 
See text for abbreviations and details. 
The shuttle vector pUC19-(HindIII MluI)-RA was simultaneously digested with HindIII 
and MluI to linearise the vector (figure 3.5). It was then 5’ phosphorylated. The open 
vector was ligated to the insert fragment, (HindIII)-LA-H5-(blunt end) in tandem with 
either fragment 3. or 4. above, to produce the following VV “super-shuttle” vectors 
(figure 3.6): 
pUC19-(HindIII)-LA-H5-(blunt ligation)- H5-RFP-H5-hGMCSF-(MluI) RA 
pUC19-(HindIII)-LA-H5-(blunt ligation)- H5-RFP-H5-(MluI) RA  
 
 
Figure 3.6 Final steps in the creation of the pUC19 based RFP and RFP-hGMCSF VV super shuttle 
vectors. See text for abbreviations and details.   
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These VV super-shuttle vectors were transformed into competent E. coli cells, amplified 
and column purified (sections 2.3.7, 2.3.8 and 2.3.9). For ease of constructing other 
similar transgene cassettes, numerous single-digestion sites were retained from the 
parental pORF plasmid on either side of the hGMCSF sequence. 
 
3.1.2.3  Step 3. Using the super-shuttle vector: pUC19-LA-H5-H5-RFP-H5-
hGMCSF-RA to create the equivalent human IL12 cytokine transgene vector 
 
The hGMCSF fragment was digested out from its super shuttle vector, pUC19- LA-H5-
H5-RFP-H5-(AfeI)- hGMCSF-(NheI)-RA, using the enzymes indicated in brackets and 
replaced with an insert from a similarly digested sequence (hIL12) from the pORF-
(AfeI)-hIL12-(NheI) plasmid (figure 3.7). This was followed by the same amplification 
and column purification steps previously described. 
 
 
 
 
Figure 3.7 Creation of the pUC19 based hIL12 VV super-shuttle vector. See text for abbreviations 
and details. 
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We had now collectively created the following five pUC19 based VV super-shuttle 
vector plasmids: 
1. pUC19- LA-H5- mGMCSF -H5- RFP –H5 RA 
2. pUC19-LA-H5-H5-RFP-H5-mIL12- RA  
 
3. pUC19- LA-H5-H5-RFP-H5- RA 
4. pUC19- LA-H5-H5-RFP-H5-hGMCSF- RA 
5. pUC19- LA-H5-H5-RFP-H5-hIL12-RA 
They were fully sequenced (The Genome Centre, BCI) (see Appendix). 
 
3.1.2.4 Each VV pUC19 based super-shuttle vector expressed its relevant cytokine 
transgene product   
 
To validate the production of functional VV super-shuttle vectors, each vector was 
transfected into VVL15 infected CV1 cells. Forty eight hours later, microscopic 
inspection revealed scattered red fluorescent dots (figure 3.8).  
 
 
Figure 3.8 Confirmation of the successful transfection of VV super-shuttle vectors into VVL15 
infected CV1 cells  
The red dots under fluorescent microscopy indicated expression of RFP driven by the VV H5 promoter 
(400x magnification).  
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This indicated viral activation of the H5 promoter, which drove the RFP portion of the 
super-shuttle cassettes. ELISA assays were subsequently performed on supernatant 
samples taken from the wells at this time to confirm that the relevant cytokine transgene 
was also expressed (figure 3.9).  
 
 
Figure 3.9 Cytokine transgene containing super-shuttle vectors successfully expressed their 
cytokine insert  
Supernatant samples at 48 hours post infection were taken from wells containing VVL15 infected CV1 
cells that had been transfected with super-shuttle vectors, or mock infected. These were analysed by the 
relevant ELISAs (corresponding to the title of each graph). X axis: mGMCSF/ hGMCSF: super-shuttle 
vectors containing mouse/ human GMCSF transgenes respectively; mIL12/ hIL12: super-shuttle vectors 
containing mouse/ human IL12 transgenes respectively; ∆N1L: super-shuttle vector containing RFP only; 
Y axis. OD (450nm): optical density for light at 450 nm wavelength. 
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3.1.2.5 Confirmation of the deletion of the N1L gene in novel VVL15 recombinant 
viruses 
 
To replace the N1L region of VV with our cytokines, VVL15 (in which the VTK gene 
deletion had previously been confirmed by our lab) infected cells were transfected with 
each super-shuttle vector separately and the recombinant virus plaque purified as 
detailed in section 2.3.13). For each novel virus, visual inspection, under green 
fluorescent light, of the final round of plaque purification confirmed that all colonies 
within a well expressed RFP (figure 3.10).  
 
Figure 3.10 An example of colonies formed by an RFP expressing recombinant virus 
A near confluent monolayer of CV1 cells was infected with a viral MOI of 0.1 PFU/ cell and analysed 48 
hours later by fluorescence microscopy under green fluorescent light (400x magnification).  
 
Viral DNA was subsequently extracted from infected CV1 cells (section 2.3.11) and the 
L025 (N1L) primer pairs listed in table 3.1 (sequences 1 and 2) used to PCR amplify 
any virions containing the N1L gene. The N1L gene was expected to be absent if 
homologous recombination had been successful. As a positive control, the VV A52R 
gene was also PCR amplified using the primer pairs listed in table 3.1 (sequences 5 and 
6). All novel constructs were negative for L025 (N1L) (figure 3.11) and positive for 
A52R (figure 3.12). Sequencing of the junctions between L024/25 and L025/26 (using 
primers 3 and 4 respectively in table 3.1) confirmed that the ORFs of the neighbouring 
L024 and 26 genes remained intact. 
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Table 3.1 Primer sequences used for PCR and sequencing  
See text for details 
 
 Lies in Gene/ORF Sense/Antisense Primer Sequence 5’ 3’ 
1 L025 (N1L) Sense CAATCTATCTAGCAATGGACC 
2 L026 (N2L) Antisense CCGAAGGTAGTAGCATGGA 
3 L024 (C1L) Sense CATCCGGATATTCTTCTACGA 
4 L026 (N2L) Antisense GTTACGTCCTGTACGAGAACG 
5 L170 (A52R) Sense ATGATGCGGAAGAACAAT 
6 L172 (A56R) Antisense TTGCGGTATATGTATGAGGTG 
 
 
 
 
 
 
Figure 3.11 The N1L gene was deleted in all novel VVL recombinants  
Sense and anti-sense N1L gene primers were used to amplify this locus via PCR, from viral DNA that had 
been extracted from infected CV1 cells. Each lane is representative of a recombinant virus, plaque 
purified from a single PFU following homologous recombination. The VVL15 DNA samples were 
extracted from VVL15-LacZ (left) and VVL15-RFP (right) infected CV1 cells (see figures 2.1 and 2.2).  
The parent platform, VVL15 contained the gene. The gene segment spanning the primer pair was 
expected to be approximately 750 bp.  
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Figure 3.12 The A52R gene was present in all VVL recombinants  
Sense and anti-sense A52R gene primers were used to PCR amplify this locus from viral DNA extracted 
from virally infected CV1 cells. Each lane is representative of a recombinant virus, plaque purified from a 
single PFU following homologous recombination. The VVL15 DNA sample was extracted from VVL15-
RFP infected CV1 cells (see figure 2.2). The A52R gene segment spanning the primer pair was expected 
to be approximately 880 bp.  
 
 
3.1.3 Validation of the cytotoxic ability of novel recombinant VVL viruses against 
tumour cells in vitro  
 
Using the MTS cytotoxicity assay outlined in section 2.4, the cytotoxic capacity of 
VVL15∆N1L was compared with the parental virus VVL15 against a range of murine 
cancer cell lines in vitro. Based on the EC50 values, i.e. the PFU required to kill 50% of 
cells, there was no significant difference in cytotoxicity between the two viruses against 
CT26 (colon) or DT6606 (pancreatic ductal) cells. In contrast VVL15∆N1L was 
significantly more potent at killing CMT93 (rectal), LLC (lung), SCCVII (head and 
neck) and B16-F10 (metastatic melanoma) cells (figure 3.13). 
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Figure 3.13 The oncolytic potency of VVL15∆N1L against murine tumour cell lines  
MTS based assays were performed to measure the cytotoxicity of viruses against the indicated tumour 
cell lines. The line graphs represent typical viral dose-response curves with percentage cell death (Y axis) 
plotted against increasing viral concentration (X axis). From these, the corresponding EC50 values (i.e. 
the number of PFUs/cell required to kill 50% of cells) were calculated and plotted on a bar chart. 
Unpaired t-tests were used to compare means of EC50s. 
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In anticipation of testing our recombinant viruses in immune competent Syrian hamster 
in vivo models, cytotoxicity was assessed against two Syrian hamster cell lines: HCPC-
1 (cheek pouch) and HPD-1NR (pancreatic). The cytotoxicity of VVL15∆N1L was at 
least as potent as VVL15 against these two cell lines (figure 3.14).  
 
 
 
Figure 3.14 The oncolytic potency of VVL15∆N1L against Syrian hamster tumour cell lines  
MTS based assays were performed to measure the cytotoxicity of viruses against the indicated tumour 
cell lines. The line graphs represent typical viral dose-response curves with percentage cell death (Y axis) 
plotted against increasing viral concentration (X axis). From these, the corresponding EC50 values (i.e. 
the number of PFUs/cell required to kill 50% of cells) were calculated and plotted on a bar chart. 
Unpaired t-tests were used to compare means of EC50s. 
 
To assess the cytotoxic potency of VVL15∆N1L against human tumour cells, a panel of 
human tumour cell lines were also infected and analysed using MTS assays. All human 
cell lines were exquisitely sensitive to the cytotoxic effects of both viruses, and 
exhibited very low EC50 values. In contrast to the rodent cell lines, VVL15 was 
however significantly more cytotoxic than VVL15∆N1L against three of the six human 
cell lines tested: SUIT-2 (pancreatic), FaDu (buccal) and HCT-116 (colon) (figure 
3.15).    
 
 
115 
 
 
          
Figure 3.15 The oncolytic potency of VVL15∆N1L against human tumour cell lines  
MTS based assays were performed to measure the cytotoxicity of viruses against the indicated tumour 
cell lines. The line graphs represent typical viral dose-response curves with percentage cell death (Y axis) 
plotted against increasing viral concentration (X axis). From these, the corresponding EC50 values (i.e. 
the number of PFUs/cell required to kill 50% of cells) were calculated and plotted on a bar chart. 
Unpaired t-tests were used to compare means of EC50s. 
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Following confirmation that deletion of the N1L gene had not ablated the cytotoxicity 
of VVL15, the cytotoxic potency of murine transgene (mIL12 and mGMCSF) armed 
viruses against murine tumour cell lines were compared to VVL15∆N1L. In general, the 
EC50 values following infection with transgene-armed viruses were significantly higher 
than VVL15∆N1L, i.e. they were worse than VVL15∆N1L at killing the relevant cell 
line (except against LLC and CMT93 cells). The VVL15∆N1L-mIL12 recombinant 
appeared to be more potent at cell killing than VVL15∆N1L-mGMCSF (figure 3.16).  
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Figure 3.16 The oncolytic potency of murine cytokine transgene armed viruses against murine 
tumour cell lines  
MTS based assays were performed to measure the cytotoxicity of viruses against the indicated tumour 
cell lines. The line graphs represent typical viral dose-response curves with percentage cell death (Y axis) 
plotted against increasing viral concentration (X axis). From these, the corresponding EC50 values (i.e. 
the number of PFUs/cell required to kill 50% of cells) were calculated and plotted on a bar chart. One 
way ANOVAs with post hoc Tukey tests were used to compare means of EC50s. 
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The cytotoxic potencies of human transgene-armed viruses were also compared to 
VVL15∆N1L against both Syrian hamster (figure 3.17) and human (figure 3.18) cell 
lines. In general, the results reflected a similar pattern to that observed against murine 
cells i.e. VVL15∆N1L was a more potent cytotoxic agent than the transgene-armed 
recombinants, although VVL15-hIL12 demonstrated the best cytotoxic potency against 
HPD-1NR and HCT-116 cell lines. Just like its murine counterpart, VVL15-hGMCSF 
fared the worst against all tested cell lines.  
 
 
                  
Figure 3.17 The oncolytic potency of human cytokine transgene armed viruses against Syrian 
hamster tumour cell lines  
MTS based assays were performed to measure the cytotoxicity of viruses against the indicated tumour 
cell lines. The line graphs represent typical viral dose-response curves with percentage cell death (Y axis) 
plotted against increasing viral concentration (X axis). From these, the corresponding EC50 values (i.e. 
the number of PFUs/cell required to kill 50% of cells) were calculated and plotted on a bar chart. One 
way ANOVAs with post hoc Tukey tests were used to compare means of EC50s. 
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Figure 3.18 The oncolytic potency of human cytokine transgene armed viruses against human 
tumour cell lines.  
MTS based assays were performed to measure the cytotoxicity of viruses against the indicated tumour 
cell lines. The line graphs represent typical viral dose-response curves with percentage cell death (Y axis) 
plotted against increasing viral concentration (X axis). From these, the corresponding EC50 values (i.e. 
the number of PFUs/cell required to kill 50% of cells) were calculated and plotted on a bar chart. One 
way ANOVAs with post hoc Tukey tests were used to compare means of EC50s. 
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3.1.4 Validation of novel recombinant viral replication in a panel of murine, Syrian 
hamster and human tumour cell lines.  
 
Replication assays were performed by infection of relevant cell lines with either VVL15 
or VVL15ΔN1L at a multiplicity of infection (MOI) of 1 PFU/ cell.  After 24, 48 or 72 
hours, viral titres were quantified using TCID50 assays on CV1 indicator cells (sections 
2.5 and 2.6). 
 
Viral titres plateaued by 72 hours in most cell lines. This was likely to reflect the slower 
turnover of uninfected cells in comparison to viral replication; with virions effectively 
running out of cells to infect. Toxic proteases, nucleases and acids released from lysed 
cells may have also suppressed the elevation in viral titre.  
 
In general, there appeared to be a trend for attenuated replication of VVL15ΔN1L in 
comparison to VVL15 (figure 3.19).  
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Figure 3.19 Replication of VVL15∆N1L in murine tumour cell lines  
Viral titres in PFU/ tumour cell were determined by performing TCID50 assays on viral lysates collected 
at 24, 48 and 72 hours after infection with an MOI of 1 PFU/ tumour cell (the relevant cell line indicated 
by the title). Two-way ANOVAs with post hoc Tukey tests were used to compare mean titres. 
 
 
 
 
 
122 
 
Syrian hamster and human tumour cell lines were also assessed for their ability to 
support replication of VVL15∆N1L.  All cells were permissive to infection, but both 
viruses replicated relatively poorly in SUIT-2, HCT-116 and HPD-1NR cell lines 
(figure 3.20 and figure 3.21). Again, there was a general tendency for VVL15∆N1L to 
replicate inferiorly in comparison to VVL15. This reached statistical significance in 
HCPC-1, SUIT-2 and FaDu cell lines by 72 hours post infection.  
 
 
 
 
Figure 3.20 Replication of VVL15∆N1L in Syrian hamster tumour cell lines  
Viral titres in PFU/ tumour cell were determined by performing TCID50 assays on viral lysates collected 
at 24, 48 and 72 hours after infection with an MOI of 1 PFU/ tumour cell (the relevant cell line indicated 
by the title). Two-way ANOVAs with post hoc Tukey tests were used to compare mean titres. 
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Figure 3.21 Replication of VVL15∆N1L in human tumour cell lines  
Viral titres in PFU/ tumour cell were determined by performing TCID50 assays on viral lysates collected 
at 24, 48 and 72 hours after infection with an MOI of 1 PFU/ tumour cell (the relevant cell line indicated 
by the title). Two-way ANOVAs with post hoc Tukey tests were used to compare mean titres. 
 
 
To assess whether insertion of IL12 or GMCSF transgenes into the N1L region affected 
the ability of recombinant viruses to replicate, they were compared to VVL15ΔN1L.  
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Both murine GMCSF and IL12 transgene-armed viruses were attenuated in their ability 
to replicate in all murine cell lines except CMT93 (figure 3.22). A similar trend was 
seen in experiments assessing the replication of human cytokine transgene-armed 
viruses in hamster and human cell lines (figure 3.23 and figure 3.24).  
 
 
 
Figure 3.22 Replication of murine cytokine transgene armed recombinant VVL viruses in murine 
tumour cell lines  
Viral titres in PFU/ tumour cell were determined by performing TCID50 assays on viral lysates collected 
at 24, 48 and 72 hours after infection with an MOI of 1 PFU/ tumour cell (the relevant cell line indicated 
by the title). One way ANOVAs with post hoc Tukey tests were used to compare mean titres at the 48 
hour time-point.  
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Figure 3.23 Replication of human cytokine transgene armed recombinant VVL viruses in Syrian 
hamster tumour cell lines  
Viral titres in PFU/ tumour cell were determined by performing TCID50 assays on viral lysates collected 
at 24, 48 and 72 hours after infection with an MOI of 1 PFU/ tumour cell (the relevant cell line indicated 
by the title). One way ANOVAs with post hoc Tukey tests were used to compare mean titres at the 48 
hour time-point.  
 
 
Figure 3.24 Replication of human cytokine transgene armed recombinant VVL viruses in human 
tumour cell lines  
Viral titres in PFU/ tumour cell were determined by performing TCID50 assays on viral lysates collected 
at 24, 48 and 72 hours after infection with an MOI of 1 PFU/ tumour cell (the relevant cell line indicated 
by the title). One way ANOVAs with post hoc Tukey tests were used to compare mean titres at the 48 
hour time-point.  
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3.1.5 Cytokine transgene expression in tumour cell lines following infection with 
novel recombinant VVL viruses 
 
The expression of transgenes from VVL15-IL12 (murine and human) and VVL15-
GMSCF (murine and human) was confirmed over a 72 hour time course in the same cell 
lines used to assess their replication (figure 3.25). 
 
 
Figure 3.25 Expression of human and murine cytokine transgenes in tumour cell lines  
Supernatant samples from wells containing murine, Syrian hamster or human tumour cells (as indicated 
on the X axes) infected with recombinant cytokine transgene-armed virus (murine or human as indicated) 
or VVL15∆N1L, were taken at 24, 48 and 72 hours following infection with an MOI of 1 PFU/ tumour 
cell. Concentrations (in pg/ml) of the relevant cytokines in supernatant samples were determined by 
ELISAs (corresponding to the title of each graph). mGMCSF/ hGMCSF refers to mouse/ human GMCSF 
respectively; mIL12/ hIL12 refers to mouse/ human IL12 respectively. 
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Of note, certain murine cell lines, namely SCCVII, CMT93 and in particular DT6606, 
appeared to secrete a background level of murine GMCSF. Figure 3.26 illustrates the 
variation of mGMCSF concentration in supernatant samples with time from both mock 
and VVL15∆N1L infected tumour cell lines. The levels were lower following 
VVL15∆N1L infection, presumably due to viral cell destruction; this also excluded the 
possibility that viral infection per se. led to the up regulation of cellular mGMCSF.  
 
 
Figure 3.26 Some tumour cell lines endogenously secrete GMCSF  
Supernatant was collected from wells containing murine tumour cells (as indicated on the X axis) infected 
with VVL15∆N1L or mock infected at 24, 48 and 72 hours following infection with an MOI of 1 PFU/ 
tumour cell. The concentration (in pg/ml) of murine GMCSF [mGMCSF] in the supernatant was 
determined by ELISA. 
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3.1.6 Summary of results chapter 3.1 
 
We have successfully cloned a set of recombinant N1L deleted VVL15 viruses, armed 
with either murine or human versions of transgenes encoding the cytokines GMCSF or 
IL12. Viral genes down and upstream of the N1L ORF were intact upon sequencing. 
The novel recombinant viruses were all able to infect cell panels of hamster, human 
and/ or murine cancer cell lines and express detectable quantities of their cytokine 
transgene. 
There are multiple mechanisms by which a tumour cell may be killed by VVs. These 
include the triggering of apoptosis, death from virus mediated cellular burst and host 
immunological defence mechanisms. If a virus is excessively cytotoxic to a cell, it may 
not generate enough progeny to self-propagate throughout a tumour. Furthermore its 
ability to replicate might also be hampered if it has been subject to significant genetic 
manipulation.  
 
In general, the replication of VVL15∆N1L was moderately attenuated across most 
tested cell lines. However, its ability to kill cells, particularly murine cell lines appeared 
to be enhanced. This may have reflected the anti-apoptotic function of the N1L gene 
product, which upon deletion may have enhanced viral induced cellular apoptosis 
(section 1.5.7.2).  
 
As might have been expected, the replication and cytotoxic potency of the cytokine 
transgene armed viruses appeared to be further attenuated in comparison to 
VVL15∆N1L; but despite this they were all able to express detectable levels of their 
transgene following infection of all tested cell lines. GMCSF armed recombinants (both 
murine and human) appeared to be less cytotoxic to cell lines in comparison to their 
IL12 armed counterparts. A partial explanation for this could relate to that fact that 
some murine cell lines appear to naturally secrete GMCSF and for those cells this 
GMCSF may have acted as a growth factor.  
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 VVL15∆N1L is capable of enhancing adaptive antitumour immunity 3.2
 
The major rational for deleting the VV N1L gene was to create an oncolytic viral 
backbone with enhanced antitumour immunogenic potential. Syngeneic immune 
competent animal models would thus be required to explore whether this was indeed the 
case. 
 
In this section, three syngeneic in vivo models were used: 
DT6606 (pancreatic) or DT6606-Ova tumours in C57BL/6 strain mice 
LLC (lung) tumours in C57BL/6 strain mice 
 
3.2.1 VVL15∆N1L enhanced adaptive antitumour immunity against LLC (lung) 
and DT6606 (pancreatic) cancer models 
 
Subcutaneous syngeneic LLC and DT6606 tumours were established and treated with a 
single dose of virus or PBS (table 2.7, experiments 1 and 2).  Upon co-culture with 
growth arrested LLC or DT6606 cells respectively, splenocytes from VVL15∆N1L 
treated groups produced higher levels of IFNγ than those from VVL15 or PBS groups 
(figure 3.27). IFNγ levels from VVL15∆N1L treated mice were higher at day seven in 
comparison to day 14 in both models.  
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Figure 3.27 Intratumoural VVL15∆N1L enhanced tumour specific IFNγ release from ex vivo 
cultured splenocytes  
LLC (Exp. A) or DT6606 (Exp. B) flank tumours in C57BL/6 strain mice were treated with 1x108 PFUs 
of IT virus or the equivalent volume of PBS (n= 3-4/ group). Seven, 14 or 21 days later, splenocyte 
suspensions were co-cultured with either growth arrested target (LLC or DT6606) or control (B16-F10 or 
LLC in respective experiments) cells or VV B8R peptide as indicated. IFNγ concentrations (in pg/ ml, Y 
axes) of supernatants were measured by ELISA. Two-way ANOVAs with post hoc Tukey tests were used 
to compare means.  
 
 
Interestingly, in the LLC tumour model, the antiviral (anti B8R) response appeared to 
be attenuated by deletion of the N1L gene, although this was not the case in the DT6606 
tumour model (figure 3.27). 
 
To demonstrate anti-tumour specificity, splenocytes from both experiments were also 
co-cultured with an MHC haplotype compatible control tumour cell line: B16-F10 cells 
for the LLC tumour model and LLC cells for the DT6606 tumour model.  
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For LLC tumour bearing mice, splenocytes from the VVL15∆N1L treatment group, that 
were co-cultured with B16-F10 cells also released significant levels of IFNγ (figure 
3.27 Exp.A). It is certainly likely that a number of tumour epitopes are shared between 
these and other solid tumour cell lines; CTLs generated against these could have been 
stimulated and expanded by the B16-F10 cells. In contrast, when control LLC cells 
were co-cultured with splenocytes derived from virally treated DT6606 tumour models, 
very little IFNγ was produced.  
 
For both tumour models, IFNγ levels waned with time post virus injection, with levels 
approaching the PBS group by day 21 in the DT6606 model. The highest levels in both 
experiments occurred at day seven. In addition, although inter experimental results 
cannot be statistically compared, splenocytes from mice bearing DT6606 tumours (in 
contrast to those bearing LLC tumours) consistently produced higher levels of IFNγ 
upon co-culture with their respective target cell line. The generation of an antitumour 
immune response is likely to be influenced by the suppressive nature of the TME; 
perhaps the TME of LLC tumours are more suppressive in this regard than DT6606 
tumours. It should however be noted, that the generation of a strong antiviral (anti B8R) 
immune response was not hampered in LLC tumour bearing mice. Indeed IFNγ levels 
following co-culture with the B8R antigen were comparable in the two experimental 
models.  
  
3.2.2 VVL15∆N1L enhanced immunity against a surrogate tumour antigen  
 
The TAA profile of the DT6606 cell line has yet to be fully defined. In a bid to 
demonstrate the generation of an antigen specific immune response, DT6606-Ova, 
which stably expresses the foreign antigen, chicken ovalbumin was used to create a 
syngeneic subcutaneous flank model (table 2.7, experiment 3). At 14 days post IT 
injection of virus, IFNγ levels following splenocyte co-culture with growth arrested 
DT6606-Ova cells or Ova peptide were highest in the VVL15∆N1L injected group 
(figure 3.28).  
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Figure 3.28 Intratumoural VVL15∆N1L enhanced the adaptive immune response against an 
artificial TAA   
DT6606-Ova flank tumours in C57BL/6 strain mice were treated with 1x108 PFUs of IT virus or the 
equivalent volume of PBS (n=4/group). Fourteen days later, splenocyte suspensions were co-cultured 
with DT6606-Ova cells, Ova peptide or B8R peptide, as indicated. IFNγ concentrations (in pg/ ml, Y 
axes) of supernatants were measured by ELISA. One way ANOVAs with post hoc Tukey tests were used 
to compare means. 
 
 
IFNγ production in PBS groups appeared to be no different than from VVL15 treatment 
arms. This probably reflected the ability of the “foreign” chicken ovalbumin to induce a 
significant immunogenic response even in untreated tumours; a response that was 
further exacerbated by VVL15∆N1L administration but not VVL15 (figure 3.28).  
 
The antiviral (anti B8R) immune response was not significantly different between the 
two viral treatment arms.  
  
3.2.3 VVL15∆N1L enhanced immunity against a natural tumour-antigen  
 
Mesothelin is a 40 kDa protein present in normal mesothelial cells and overexpressed in 
several human tumours, including mesothelioma, ovarian and pancreatic 
adenocarcinoma (336). Following on from the DT6606-Ova experiment above, our 
group established by Western blot that DT6606 cells also express a murine mesothelin 
homologue. We therefore explored the possibility that this might be a candidate protein 
against which a natural TAA specific immune response may be generated. A nonamer 
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peptide was created by Proimmune™ (section 2.8.3.2). This nonamer was predicted to 
be the best fit into the H-2Db MHCI binding groove, and thereby potentially the most 
immunogenic. Splenocytes from VVL15∆N1L injected DT6606 tumour bearing mice 
produced the highest levels of IFNγ upon co-culture with this mesothelin peptide. As 
might be expected, the response generated against this solitary peptide antigen was less 
than that generated against whole tumour cells carrying multiple TAAs.  
 
 
 
Figure 3.29 Intratumoural VVL15∆N1L enhanced the adaptive immune response against a natural 
TAA   
Syngeneic DT6606 flank tumours were treated with 1x108 PFUs of IT virus or the equivalent volume of 
PBS (n=3-4/group). Fourteen days later, splenocyte suspensions were co-cultured with murine mesothelin 
peptide or B8R peptide as indicated. IFNγ concentrations (in pg/ ml, Y axes) of supernatants were 
measured by ELISA. Two way ANOVAs with post hoc Tukey tests were used to compare means. The 
B8R+ stimulated graph is identical to that from figure 3.27 (Exp. B) 
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3.2.4 VVL15∆N1L administration enhanced the generation of an effector CD8+ T 
cell population 
 
The ultimate goal of any antitumour immunotherapeutic is to enhance the pool of 
tumour specific CTLs. Although debate exists as to which type of CTL memory pool 
(central or effector) is relatively important (section 4.1), clearance of tumour in the 
periphery at any time will necessarily rely on a significant proportion of effector CTLs. 
We therefore explored by fluorescence cytometry, whether VVL15∆N1L treatment 
could alter the immunological profile of CD8+ T cells in this regard. The CD62L 
surface antigen (a central lymphoid homing integrin) is lost in both primary effector and 
effector memory T cells, allowing them to circulate into the periphery in order to 
mediate their cytotoxic effects (section 4.1). Activated memory T cells also upregulate 
CD44, a cell adhesion molecule. Thus CD8+ effector memory T cells were defined as 
CD44hiCD62Llo. Splenocytes from experimental groups were stained with the 
following combinations of fluorophore labelled antibodies (for gating strategy see 
figure 3.30): anti CD45-eFluor® 450, anti CD3e-PerCP-Cy5.5, anti CD8a-FITC and 
anti CD62L-PE-Cy7. 
 
Figure 3.31 depicts the percentage of CD8+ T cells that were CD44hiCD62Llo amongst 
splenocytes taken from treated LLC or DT6606 tumour bearing mice. In both tumour 
models, there was an enhancement of this population following treatment with 
VVL15∆N1L. This enhancement declined with time, dropping to levels comparable to 
the PBS group by day 21 in DT6606 tumour bearing mice. Given the absence of any 
significant enhancement of antiviral (anti B8R) immunity following IT VVL15∆N1L 
(figure 3.27), any differences in the overall percentage of effector memory CD8+ T 
cells may have reflected differences within the tumour specific CTL subset.   
 
Note the relatively higher percentages of effector memory CD8+ T cells in mice bearing 
DT6606 tumours in comparison to those bearing LLC tumours. Coupled with the 
previous IFNγ immunoassays, these results further strengthened the impression that 
DT6606 tumours in comparison to LLC tumours were more likely to be sensitive to 
immunotherapy with oncolytic VV.  
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Figure 3.30 Gating the effector memory (CD44hiCD62Llo) percentage of CD8+ T cells 
Following the selection of CD3+CD8+ cells (C), an experimental sample from the PBS group was used to 
set the CD62L lo/hi and CD44 lo/hi boundaries as shown (D). Dot plots from samples stained with all 
except anti CD62L (E) or anti CD44 (F) (fluorescence minus one (FMO) samples, section 2.10) 
confirmed the appropriateness of these gaits.  
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Figure 3.31 Intratumoural VVL15∆N1L enhanced the generation of an effector memory CD8+ T cell population  
Syngeneic LLC (Exp. A) or DT6606 (Exp. B) flank tumours were treated with 1x108 PFUs of IT virus or the equivalent volume of PBS (n=3- 4/group). Seven, 14 or 21 
days later as indicated, splenocyte suspensions were stained with fluorophore labelled antibodies against CD45, CD3, CD8, CD44 and CD62L surface antigens and 
analysed in a multichannel flow cytometer. The bar charts depict the effector memory (CD44hiCD62Llo) percentage of CD8+ T cells. Two-way ANOVAs with post 
hoc Tukey tests were used to compare means. 
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3.2.5 IT VVL15∆N1L viral treatment invoked a higher intratumoural infiltrate of 
CD8+ cells in comparison to VVL15  
 
LLC and DT6606 flank tumours were harvested at 14 days following a single IT dose of 
virus/ PBS. Tumours were snap frozen in precooled isopentane, sectioned and stained 
with anti CD4 and CD8 antibodies. Slides were scrutinised for the presence of the 
relevant marker as described in section 2.14. Although VVL15∆N1L administration (in 
comparison to VVL15 or PBS) appeared to enhance the number of CD8+ cells that 
infiltrated LLC tumours, absolute counts per high power field (HPF) were relative low; 
certainly when compared to CD8+ T cell infiltration within similarly treated DT6606 
tumours (see figure 3.32 and figure 3.33).  
 
Note all IHC slides in this project were also stained with anti NK1.1 and F4/80 
antibodies. However, positively stained NK cells were too sparse to count, whereas the 
numbers of anti F4/80 stained macrophages were contrastingly too substantial to 
quantify by manual counting (see figure 4.1); hence these data are not presented. 
 
IHC cell counts in this project were performed by JA who was not blinded to group 
allocation. To minimise inadvertant error, 10-15 randomly selected HPFs were counted 
and averaged per sample. To verify JA’s mean counts, randomly selected slides were 
independently counted by YW who was blinded to treatment arms. 
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Figure 3.32 Intratumoural VVL15∆N1L enhanced the infiltration of CD8+ cells into LLC tumours  
Syngeneic LLC flank tumours were treated with 1x108 PFUs of IT virus or the equivalent volume of PBS 
(n=3- 4/group). Fourteen days later, frozen sections of harvested tumour were immunostained with either 
anti CD4, CD8, NK1.1 or F4/80 antibodies. The bar chart depicts the mean manual cell count per HPF 
from 10-15 HPFs (x200 magnification). One way ANOVAs with post hoc Tukey tests were used to 
compare means.  
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Figure 3.33 Intratumoural VVL15∆N1L enhanced the infiltration of CD8+ cells into DT6606 
tumours  
Syngeneic DT6606 flank tumours were treated with 1x108 PFUs of IT virus or the equivalent volume of 
PBS (n=3- 4/group). Fourteen days later, frozen sections of harvested tumour were immunostained with 
either anti CD4, CD8, NK1.1 or F4/80 antibodies. The bar chart depicts the mean manual cell count per 
HPF from 10-15 HPFs (x200 magnification). One way ANOVAs with post hoc Tukey tests were used to 
compare means. 
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3.2.6 VVL15∆N1L treated LLC and DT6606 tumours produced higher levels of 
tumour-specific cytotoxic lymphocytes 
 
IFNγ production from splenocytes in response to tumour cell or antigen challenge is an 
indirect measure of a CTL response (the major IFNγ producing adaptive immune cell), 
with the magnitude of response likely to be proportional to the number of CTLs 
generated. ELISPOT assays measuring secreted IFNγ or granzyme B for example could 
quantify the numbers of potential CTLs, nevertheless such assays will not be able to 
demonstrate the ability of antigen specific CTLs to actually lyse their target containing 
cells. To demonstrate this, we performed a non-radioactive CTL assay, based on the 
release of the enzyme LDH from lysed cells (section 2.8.4).  
 
As illustrated in figure 3.34, at the effector to target ratio of 60:1, splenocytes from 
VVL15∆N1L treated groups from both models were able to lyse a higher percentage of 
target tumour cells in comparison to those harvested from the other treatment arms. The 
specificity of response was demonstrated by the inability of these effector splenocytes 
to lyse MHC compatible control tumour cells. Splenocytes from all mice within each 
treatment group were pooled to produce a solitary mean value per time point and was 
therefore not amenable to statistical analysis.  
 
In keeping with the previous experiments in this section, VVL15∆N1L treatment 
induced a more potent cytolytic response against DT6606 (in comparison to LLC) 
tumour cells. 
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Figure 3.34 VVL15∆N1L enhanced the generation of tumour specific cytolytic splenocytes  
Syngeneic LLC (Exp. A) or DT6606 (Exp. B) flank tumours were treated with 1x108 PFUs of IT virus or 
the equivalent volume of PBS (n=3- 4/group). Fourteen days later splenocyte suspensions were co-
cultured with growth arrested target (LLC or DT6606) tumour cells. Five days later splenocytes from 
each treatment group were pooled and further co-cultured with 5000 target or control (B16-F10 or LLC) 
tumour cells in ratios of 15:1, 30:1, and 60:1. A non-radioactive lymphocyte cytotoxicity assay based on 
LDH release from lysed cells, was used to estimate percentage tumour cell lysis (Y axes).  
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3.2.7 Summary of results chapter 3.2 
 
IT VVL15∆N1L led to significantly higher levels of IFNγ from tumour cell/ TAA 
stimulated splenocytes in comparison to VVL15. Interestingly there was no such 
enhancement in the antiviral response (as measured by the anti B8R antigen response).  
 
Flow cytometric profiling of CD8+ T cells within splenocytes, suggested the generation 
of a higher proportion of effector memory CD8+ T cells in response to IT 
VVL15∆N1L, which in parallel to the IFNγ assays peaked at around day seven post 
infection then waned to control levels by day 21.  
 
The magnitude of adaptive antitumour immunity evoked by VVL15∆N1L appeared to 
be much higher in DT6606 tumour bearing mice in comparison to their LLC 
counterparts. Evoked anti-tumour IFNγ levels, percentage effector memory CD8+ T 
cells and counts of intratumoural CD8+ cells were all higher in the former group. 
Indeed splenocyte mediated tumour cell lysis in a CTL assay was also superior. The 
DT6606 tumour model appears to be more immunogenic than the LLC model and 
thereby potentially more responsive to immunotherapeutic strategies with VV.  
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  In vivo efficacy of VVL15∆N1L  3.3
 
3.3.1 VVL15∆N1L was more efficacious than VVL15 against a model of pancreatic 
cancer.   
 
In order to establish the broad antitumour utility of VVL15∆N1L, SCCVII, LLC, CT26, 
CMT93 and DT6606 syngeneic subcutaneous flank models were established (table 2.8) 
and treated with  five daily IT doses of virus or PBS. For SCCVII, LLC and CMT93 
models, there were no statistically significant differences in tumour growth rates 
between the two viral treatment groups (figure 3.35). VVL15∆N1L did however 
significantly slow the growth of CT26 and DT6606 tumours (figure 3.35).  
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Figure 3.35 Intratumoural VVL15∆N1L slowed tumour growth in models of pancreatic and 
colorectal cancer  
Syngeneic DT6606, CMT93, LLC, SCCVII and CT26  flank models (as indicated) were treated with five, 
daily IT doses of 1x108 PFUs of virus or the equivalent volume of PBS (n=5-7 per group). The first dose 
was injected at day 0. Tumour growth was followed up via twice weekly calliper measurement. Two way 
ANOVAs with post hoc Tukey tests were used to compare mean tumour volumes. The arrow depicts the 
time point to which the comparative statistical figures on each graph relate to. 
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3.3.2 CD8+ T cells play a pivotal role in the efficacy demonstrated by VVL15∆N1L 
treated DT6606 subcutaneous tumours 
 
The DT6606 flank tumour model was the most sensitive to treatment with VVL15∆N1L 
as might have been predicted by the results from chapter 3.2. In order to explore this 
further, the VVL15∆N1L arm of the experiment was repeated in mice that had been 
depleted of key immune effector cells (section 2.15.6 and table 2.10, experiment 1). 
Figure 3.36 demonstrates that the efficacy of IT VVL15∆N1L was abrogated when 
CD8+ cells were depleted for the duration of the experiment; similar depletion of NK or 
CD4+ cells made no difference.  
 
 
 
 
Figure 3.36 CD8+ cells play a pivotal role in mediating the efficacy of VVL15∆N1L against 
subcutaneously implanted DT6606 tumours  
Cell depleting or IgG control antibodies were commenced intraperitoneally in mice bearing syngeneic 
DT6606 flank tumours, a day prior to the initial dose of IT treatment with VVL15∆N1L (n=8-10 per 
group) (see table 2.10, experiment 1). Tumour growth was followed up via twice weekly calliper 
measurement. Two way ANOVAs with post hoc Tukey tests were used to compare mean tumour 
volumes. The arrow depicts the time point to which the comparative statistical figures on each graph 
relate to. 
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3.3.3 Confirmation of antitumour immunogenicity following a multidose regime of 
IT VVL15∆N1L in DT6606 tumours 
 
Immunoassays were repeated after DT6606 tumour bearing mice were treated with 
multiple doses of IT virus (section 2.15.1 and table 2.7, experiment 4). This served a) to 
confirm the reproducibility of the previous immunoassay experiments, and b) to 
enhance the likelihood of detecting the presence of in vivo generated mesothelin specific 
CD8+ T cells.  
 
Another way of demonstrating an enhancement in tumour specific immunity is to 
confirm the elevation of tumour epitope specific clones of CD8+ T cells. A pentamer of 
H-2Db MHCI complexed to a murine mesothelin epitope (section 2.10.1) had recently 
been created by Proimmune© and could be utilised for this purpose. Unlike the IFNγ 
and CTL assays, where splenocytes were selectively expanded ex vivo, for up to five 
days, antigen specific T cells were measured at the point of animal sacrifice. Therefore 
in order to maximise the chances of detecting this likely small pool of cells, the 
experiment was conducted following multiple doses of virus.  
 
IFNγ assays were set up as previously described, using splenocytes harvested at day 14 
after the initial dose of virus. The level of IFNγ produced from splenocytes co-cultured 
with growth arrested DT6606 cells was highest following treatment with VVL15∆N1L. 
Splenocytes were also co-cultured with a mesothelin peptide, a peptide derived from a 
mutated K-RAS proto-oncogene (an activating mutation of K-RAS may be a critical 
step in the initiation of pancreatic and other cancers (331)) or an artificial ovalbumin 
peptide (Ova) as a control (table 2.4). The mesothelin and K-RAS peptides evoked IFNγ 
production from splenocytes harvested from VVL15∆N1L treated mice.  
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Figure 3.37 Multiple doses of intratumoural VVL15∆N1L enhanced antitumour adaptive immunity   
Syngeneic DT6606-flank tumours were treated with five daily IT doses of 1x108 PFUs or the equivalent 
volume of PBS (n=3-4/group). Fourteen days after the first dose, splenocyte suspensions were co-cultured 
with growth arrested whole tumour cells (Tumour cell+), tumour peptides (Peptide+) or the VV B8R 
peptide (B8R+). IFNγ concentrations (in pg/ ml, Y axes) of supernatants were measured by ELISA. One 
way ANOVAs with post hoc Tukey tests were used to compare means. 
 
 
Immunohistochemical staining of frozen sections of DT6606 tumour confirmed the 
previously demonstrated enhanced infiltration of both CD4+ and in particular CD8+ 
cells into the tumour.  
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Figure 3.38 Multiple doses of IT VVL15∆N1L enhanced the infiltration of CD8+ cells into DT6606 
tumours  
Syngeneic DT6606 flank tumours were treated with five daily IT doses of virus (1x108 PFUs per dose) or 
the equivalent volume of vehicle buffer (n=3-4/group). Fourteen days after the first dose, frozen sections 
of harvested tumour were immunostained with either anti CD4, CD8, NK1.1 or F4/80 antibodies. The bar 
chart depicts the mean manual cell count per HPF from 10-15 HPFs (x200 magnification). One way 
ANOVAs with post hoc Tukey tests were used to compare means. 
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Flow cytometric analysis of splenocytes harvested at day 14 post initial viral injection 
also confirmed the previously demonstrated enhancement of effector memory 
(CD44hiCD62Llo) CD8+ T cells in the VVL15∆N1L treated group (figure 3.39). The 
following fluorophore labelled antibodies were used to stain splenocytes, with a similar 
gating strategy to that shown in figure 3.30: anti CD45-FITC, anti CD3e-PerCP-Cy5.5, 
anti CD8a-APC, anti CD62L-PE-cy7 and anti CD44-eFluor® 450. 
 
 
Figure 3.39 Multiple doses of IT VVL15∆N1L enhanced the generation of an effector memory 
CD8+ T cell population  
Syngeneic DT6606 flank tumours were treated with five daily IT doses of virus (1x108 PFUs per dose) or 
the equivalent volume of vehicle buffer (n=3- 4/group). Fourteen days after the first dose, splenocyte 
suspensions were stained with fluorophore labelled antibodies against CD45, CD3, CD8, CD44 and 
CD62L cell surface antigens and analysed in a multichannel flow cytometer. The bar chart depicts the 
effector memory (CD44hiCD62Llo) percentage of CD8+ T cells. A one-way ANOVA with post hoc 
Tukey tests was used to compare mean values. 
 
Finally, the following fluorophore labelled antibodies and mesothelin pentamer 
(MesoPent) were used to stain splenocytes as described in section 2.10: anti CD3-FITC, 
anti CD8a-APC and MesoPent-PE. 
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There was a significant elevation in the mesothelin epitope specific clone of CD8+ T 
cells following VVL15∆N1L treatment (figure 3.40 and figure 3.41). Although 
statistically significant, this enhancement was relatively modest.  
 
 
Figure 3.40 Gating the mesothelin pentamer stained population of T cells  
Following the selection of CD3+CD8+ cells (B), the histogram from the MesoPent FMO sample (stained 
with all antibodies but no MesoPent) was used to set the gate for MesoPent positive clones (C). 
 
 
Figure 3.41 Multiple doses of IT VVL15∆N1L enhanced the in vivo expansion of a mesothelin 
specific clone of T cells  
Syngeneic DT6606 flank tumours were treated with five daily IT doses of virus (1x108 PFUs per dose) or 
the equivalent volume of PBS (n=3- 4/group). Fourteen days after the first dose, splenocyte suspensions 
were stained with fluorophore labelled mesothelin pentamer as well as with antibodies against CD3 and 
CD8 cell surface antigens and analysed in a multichannel flow cytometer. The bar chart depicts the 
mesothelin peptide specific clone of CD8+ T cells. A one way ANOVA with post hoc Tukey tests was 
used to compare means. 
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3.3.4 Replication of intravenous VVL15 in off-target organs was reduced by the 
deletion of its N1L gene  
 
A biological distribution experiment was performed to establish whether IV delivered 
virus could disseminate to subcutaneous tumour and importantly to determine any off 
target infection and replication. LLC and CT26 subcutaneous flank models were 
utilised, being representative of two syngeneic models from different strains of mice 
(C57BL/6 and BALB/c respectively) (section 2.15.1 and table 2.7, experiments five and 
six)  
 
Following tail vein injection, live, replication competent viruses could be recovered 
from tumour tissue until at least 10 days post injection in both models (figure 3.42). The 
peak titre appeared to lie between three and seven days. Titres in general were much 
higher with the LLC model in comparison to the CT26 model. This probably reflected 
differences in vascularity between tumours or indeed the potency of viral clearance 
between strains. Whilst there was no difference in viral recovery from tumours between 
groups with the CT26 model; with the LLC model VVL15∆N1L titres were 
significantly lower from day three onwards (figure 3.43). 
 
With the exception of lung tissue, virus was not recovered from any organ beyond 24 
hours post injection (figure 3.43). At 24 hours, VVL15∆N1L titres were significantly 
lower than VVL15 from liver and spleen in the CT26 model and liver in the LLC 
model. In the CT26 model there was no viral recovery from brain. Brain titres were 
significantly lower following IV VVL15∆N1L injection into the LLC model. Neither 
virus was recovered from ovaries. In contrast, virus persisted in the lungs until at least 
three days in the CT26 model and five days in the LLC model. In both models, 
VVL15∆N1L titres in lungs were lower than VVL15.  
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Figure 3.42 Systemic viral delivery to flank tumours  
Mice bearing syngeneic LLC or CT26 flank tumours (in C57BL/6 or BALB/c mice respectively) as 
indicated were administered tail vein injections of 1x108 PFU of either VVL15 or VVL15∆N1L. At the 
depicted time-points post virus injection (X axis), mice (n=3 per group) were euthanized and tumours 
were harvested. Viral titres in PFU/ gram weight of tumour tissue (Y axes) were estimated using TCID50 
assays on tumour homogenates. Two-way ANOVAs with post hoc Tukey tests were used to compare 
mean viral titres.  
 
Figure 3.43 N1L gene deletion reduced the off-target viral replication of VVL15  
Mice bearing syngeneic LLC or CT26 flank tumours (in C57BL/6 or BALB/c mice respectively) as 
indicated were administered tail vein injections of 1x108 PFU of either VVL15 or VVL15∆N1L. At the 
depicted time-points post virus injection (X axis), mice (n=3 per group) were euthanized and lungs and 
other organs were harvested. Viral titres in PFU/ gram weight of organ tissue (Y axes) were estimated 
using TCID50 assays on tissue homogenates. Viral titres were detectable only on day one post injection 
for non-lung organs. For lungs, two-way ANOVAs with post hoc Tukey tests were used to compare mean 
viral titres; whereas unpaired t-tests were used likewise for other organs.   
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3.3.5 Intravenous delivered virus maintained the capacity to generate antitumour 
immunity 
 
In the LLC model, viral titres within tumour tissue diminished at a faster rate following 
IV VVL15∆N1L administration in comparison to VVL15. This may have been due to 
enhanced innate as opposed to adaptive antiviral clearance mechanisms. Innate defences 
mobilise within hours to days following pathogen exposure and viral titres from 
tumours and lungs started to deviate between groups from day three in the current 
experiment. 
 
Despite the enhanced clearance of virus from tumour, could IV delivered VVL15∆N1L 
retain its ability to enhance antitumour adaptive immunity? To answer this question, 
splenocyte IFNγ assays were performed on days eight and 11 following the IV 
administration of virus or PBS into LLC tumours (table 2.7, experiment 5). IFNγ levels 
were significantly higher from splenocytes derived from VVL15∆N1L injected tumour 
bearing mice at both time points following co-culture with growth arrested LLC cells. 
As previously demonstrated, this enhancement was not paralleled by an enhanced 
antiviral (anti B8R) adaptive immune response.  
 
 
 
Figure 3.44 Intravenous VVL15∆N1L also enhanced antitumour adaptive immunity against LLC 
tumours  
Mice bearing syngeneic LLC flank tumours were treated with a single IV dose (1x108 PFU) of virus. At 
days eight and 11 post injection (X axes), splenocyte suspensions were co-cultured with either growth 
arrested LLC (target) or DT6606 (control) cells and VV B8R peptide, as indicated. IFNγ concentrations 
(in pg/ml, Y axes) of supernatants were measured by ELISA. Two-way ANOVAs with post hoc Tukey 
tests were used to compare means.  
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3.3.6 IV administered VVL15 and VVL15∆N1L prolonged survival in an 
orthotopic lung cancer model  
 
The orthotopic LLC lung tumour model is very reliable; in our experience almost all 
animals establish tumour foci within their lungs following the tail vein injection of a 
relatively low number of LLC cells. 5x105 LLC cells were injected into the tail veins of 
seven C57BL/6 mice. CT imaging was used to assess their lung volumes over time; the 
reduction of which was used as a surrogate marker for tumour volume (figure 3.45). All 
mice developed tumour, with deaths occurring between 14 to 21 days, at which time 
thoracotomy confirmed extensive lung tumour. CT detectable tumour volumes arose 
between four and seven days, thus the first dose of viral therapy in a subsequent efficacy 
study was commenced at day five post-LLC cell injection. 
 
 
Figure 3.45 The CT lung profile of an orthotopic lung cancer model  
C57BL/6 mice were injected with 5x105 LLC cells via tail vein (n=7). Their lungs were monitored by 
regular non contrast CT scans. Graph A. depicts the reduction in lung volume with time after cell 
injection and was used as a surrogate marker for lung tumour burden (B). Note the CT scans of the same 
mouse at different days following tumour cell injection. These figures and images were constructed with 
the help of Dr Mark Ferguson in our group.  
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Twenty one mice were administered tail vein injections of 5x105 LLC cells in 100 μl 
serum-free DMEM. They were randomised into three groups (table 2.9, experiment 3) 
and treatment was commenced from day five. All mice in the PBS treatment group were 
symptomatic after 10 days post LLC cell injection as evidenced by weight loss, and all 
had died or needed to be culled by 21 days (figure 3.46). The median survival was 
enhanced by 5 and 6.5 days following VVL15 and VVL15∆N1L viral treatment 
respectively (the median survival for the PBS group was 19 days). There was no 
statistically significant difference in survival between viral groups.   
 
     
 
 
Figure 3.46 Intravenous recombinant VVL15 viruses prolonged survival in an orthotopic lung 
cancer model  
C57BL/6 mice were injected with 5x105 LLC cells via tail vein (n=7). Five, seven and nine days later 
they were treated with 1x108 PFUs of virus administered via tail vein or the equivalent volume of vehicle 
buffer  (n=7 per group). The left graph demonstrates the mean weight of mice in each group as a function 
of time after LLC cell injection (X axes); the right graph is the corresponding Kaplan Meier survival 
analysis. Log rank analyses were used to compare treatment pairs.  
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3.3.7 Summary of results chapter 3.3 
 
Multiple doses of IT VVL15∆N1L reduced the tumour growth rate in some murine 
syngeneic flank tumour models. DT6606 tumours were the most responsive, whilst the 
least responsive were the aggressively growing LLC tumours. If the generation of 
adaptive antitumour immunity was indeed mechanistically important in the efficacy of 
VVL15∆N1L against primary tumour models, then this data was consistent with the 
conclusion of chapter 3.2; namely that IT VVL15∆N1L evoked a stronger tumour 
specific immune response in DT6606 tumour bearing mice, in comparison to the LLC 
counterpart. 
 
VVL15∆N1L treated DT6606 tumour bearing mice, generated elevated numbers of 
mesothelin specific CD8+ T cells in comparison to treatment with VVL15. Indeed the 
critical role of CTLs in mediating the efficacy of VVL15∆N1L in this model was 
confirmed by the complete abrogation of efficacy in tumour bearing mice that lacked 
CD8+ cells. 
 
VVL15 recombinant viruses were able to localise to syngeneic flank tumours in two 
different genetic strains of mice following a single IV dose of virus. Their presence in 
tumour tissue was maintained for at least 10 days, peaking between three and seven 
days post injection. Off-target replication of VVL15 was reduced by the deletion of its 
N1L gene, although this also appeared to enhance viral clearance from LLC tumour 
tissue. Despite this, IV VVL15∆N1L retained its ability to enhance (in comparison to 
VVL15) the generation of adaptive antitumour immunity. 
 
IV VVL recombinant viral treatment of established LLC orthotopic tumours led to 
significantly prolonged short term survival of mice in comparison to those treated with 
vehicle buffer alone. There was however, no difference in survival between viral 
treatment groups.    
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 The neoadjuvant potential of VVL15∆N1L 3.4
 
LLC is an aggressively growing murine lung carcinoma that has the propensity to 
metastasize to the lungs following primary establishment in the flank. Indeed surgical 
excision of subcutaneously grown LLC tumour has been shown to enhance the rate of 
lung metastases, perhaps via removal of an angiogenesis inhibitor secreted by the 
primary (304, 337). This would be an ideal animal model to mimic the potentially 
enhanced rate of micro-metastases secondary to surgical manipulation of relatively 
advanced solid tumours.  
 
We sought to answer two questions with this model. First, even though IT VVL15∆N1L 
had no impact on the growth of primary LLC tumours (figure 3.35), could it reduce 
seeding of metastases from the primary? Second, could IT virus administered prior to 
surgical excision of the primary tumour, prolong post-operative survival of mice?   
 
3.4.1 Intratumoural VVL15∆N1L reduced dissemination of lung metastases from 
primary flank LLC tumours 
 
Subcutaneous LLC tumours were established in female C57BL/6 mice as previously 
described. Intratumoural injections of PBS and treatment viruses (1x108 PFUs per dose) 
were commenced for a total of five daily doses (table 2.7, experiment 7). All animals 
were euthanized when the first group reached the criteria for sacrifice (mean volume 
>1200mm3) and their lungs were scrutinized macroscopically and microscopically for 
tumour metastases as described in the methods (2.15.4).   
 
There were no significant differences between groups with regards to tumour volumes 
at sacrifice. However the percentage of mice with lung metastases at the end point of the 
experiment was 14, 43 and 71% for VVL15∆N1L, VVL15 and PBS groups respectively 
(figure 3.47).  
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Figure 3.47 Intratumoural VVL15∆N1L reduced metastatic dissemination from LLC flank 
tumours  
Syngeneic LLC flank tumours were treated with five daily IT doses of virus (1x108 PFUs per dose) or the 
equivalent volume of PBS (n=14/ group). Tumour volumes were tracked via twice weekly calliper 
measurement (left). At day 15 post injection of the first dose of virus (X axis), mice were euthanized and 
lung sections were stained with H&E. The slides were scrutinized for the presence or absence of lung 
metastases by a pathologist (YW) who was blinded to the treatment groups (right hand graph). Fisher’s 
exact tests were performed on 2x2 tables comparing specific pairs of conditions.    
  
3.4.2 Pre-surgical treatment with VVL15∆N1L prolonged post-operative survival 
in models of metastatic cancer  
 
Given the possibility of reducing metastatic spread from the primary tumour, we 
explored the use of VVL15∆N1L as a neoadjuvant alongside surgical excision of 
tumour.  Many patients die post “curative” surgery as a consequence of either metastasis 
or regrowth of minimal residual local disease. The subcutaneous syngeneic LLC flank 
model would be ideal to model this scenario. First, as demonstrated it has a propensity 
to metastasise to lung from flank implants and second these tumours grow rapidly, 
infiltrating underlying tissue so even the cleanest surgical excision is likely to leave foci 
of residual disease. The model, pre-operative treatment schedule and surgical technique 
are described in detail in section 2.15.5.  
 
Of note, surgical excision took place seven days following the final dose of viral 
treatment, a) to allow the mouse to recover from the effects of a protracted course of 
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viral therapy and importantly b) to provide adequate time for the development of an 
antitumour adaptive immune response. The results are shown in figure 3.48A. 
 
 
 
Figure 3.48 Pre-surgical IT treatment with VVL15∆N1L prolonged post-operative survival in 
models of metastatic cancer  
Syngeneic 4T1 (orthotopic) or  LLC flank tumours, as indicated, were treated IT with three or five doses 
respectively of virus (1x108 PFUs per dose) or the equivalent volume of PBS (n=7-10/ group). Tumours 
were surgically resected five or seven days after the final dose of virus respectively. The X axes represent 
day’s post-surgical excision. Log rank analyses were used to delineate any significant differences 
between specific treatment pairs. 
 
 
There was no significant difference in tumour volumes between groups prior to surgical 
excision. The end points of this experiment were cure, death from lung metastasis or 
significant local regrowth from MRD. After exclusions, the numbers of mice in each 
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group were 9-10. There was a statistically significant short term survival advantage 
favouring treatment with VVL15∆N1L.  
 
In another syngeneic model of metastatic cancer, 4T1 breast cancer cells were 
orthotopically implanted into BALB/c mouse mammary glands (2.15.5). Tumours were 
treated with a similar schedule of recombinant virus or PBS prior to surgical excision. A 
significant prolongation of short term survival following treatment with VVL15∆N1L 
virus was also observed with this model (figure 3.48B). 
 
 
3.4.3 Surgery abolished the VVL15∆N1L mediated enhancement of adaptive 
antitumour immunity  
 
To assess whether general anaesthesia or operative stress per se. could impede the 
development of an adaptive immune response against either tumour or virus, 
subcutaneous LLC tumour bearing mice were treated as above with multiple doses of IT 
virus/ PBS (table 2.7, experiment 8). Seven days after tumour resection, mice were 
sacrificed and their harvested splenocytes were co-cultured with growth arrested LLC 
cells or VV B8R peptide. Splenocytes from three of four mice in each viral treatment 
group produced detectable levels of IFNγ upon co-culture with LLC cells. The mean 
values of these positive responders are shown in the graph (figure 3.49). Although the 
study contained a limited number of mice, the fact that one in four showed no evidence 
of antitumour immunity following viral treatment and that the enhancement of IFNγ 
secretion from stimulated lymphocytes (consequent to VV N1L gene deletion) was 
abolished, implied that surgical excision did indeed impair the generation of adaptive 
antitumour immunity. As further confirmation, splenocytes from LLC tumour bearing 
mice lost the ability to lyse LLC cells in a non-radioactive CTL assay (see section 2.8.4) 
(compare figure 3.49 with figure 3.34). 
 
In contrast, an anti-viral (anti B8R) IFNγ response was present in all virally treated mice 
with values comparable to previous non-surgical experiments. 
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Figure 3.49 Surgery impaired VVL15∆N1L mediated enhancement of adaptive antitumour 
immunity  
Fourteen days after the final dose of IT virus (i.e. seven days after surgical resection of tumours), 
splenocyte suspensions were co-cultured with growth arrested target (LLC) or control (DT6606) tumour 
cells or the VV B8R peptide. IFNγ concentrations (in pg/ml, Y axis) of supernatants were measured by 
ELISA three days later. One-way ANOVAs with post hoc Tukey tests were used to compare means (Exp. 
A). In a second experiment, five days following co-culture with tumour cells, the splenocytes from each 
treatment group were pooled and further co-cultured with 5000 target or control tumour cells in ratios of 
15:1, 30:1, and 60:1. A non-radioactive lymphocyte cytotoxicity assay based on LDH release from lysed 
cells, was used to estimate percentage tumour cell lysis (Exp. B).  
 
 
Finally, of the 4 of 10 mice in the VVL15∆N1L group that were apparently cured 
(figure 3.48A), two did not demonstrate tumour re-growth following re-challenge with a 
relatively high dose (2x106) of subcutaneously implanted LLC cells. The sole survivor 
of the PBS group regrew a tumour upon LLC cell implantation. IFNγ assays using 
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splenocytes isolated from surviving mice confirmed that tumour re-growth was 
associated with a low anti-LLC immune response (figure 3.50). Due to the low numbers 
of surviving mice, statistical calculations could not be performed. 
 
The VVL15∆N1L platform appeared to enhance short term survival of neoadjuvantly 
treated animal models (perhaps by enhancing innate immune surveillance – see later). It 
also had the potential to enhance long term immune surveillance. However, the latter 
certainly was not universal, as only 20% of the original number of mice treated 
developed the ability to prevent tumour regrowth. There remained significant room 
therefore to improve this therapeutic platform. 
 
 
 
Figure 3.50 Neoadjuvant IT VVL15∆N1L induced long term post-surgical antitumour immunity in 
only 20% of treated mice  
Splenocyte suspensions from mice that had reached the end point of the LLC neoadjuvant experiment 
(section 3.4.2) were co-cultured with either growth arrested LLC cells or the VV B8R peptide. The IFNγ 
concentration of supernatants was measured by ELISA. VVL15∆N1L+TG: splenocytes isolated from 
VVL15∆N1L treated mice in which tumour regrew following re-challenge with LLC cells; 
VVL15∆N1L–TG: likewise for the two mice in which tumour did not regrow.  
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3.4.4 VVL15∆N1L treated tumours attracted a disproportionate amount of 
neutrophils with a reciprocal reduction in the monocyte/ macrophage population 
 
In order to explore why pre-treatment with VVL15∆N1L led to a reduction in metastatic 
dissemination from the primary tumour in the LLC flank model, a biological time-point 
study was set up to look at  cellular players that were attracted to the TME at  relatively 
early time points following IT virus administration (table 2.7, experiment 1). We 
initially sought to establish the relative intra-tumour proportions of the main cellular 
innate (neutrophils, macrophages, NK and DCs) and adaptive (T cell) effector cells. 
 
Table 3.2 lists the fluorophore labelled antibodies used to stain single cell suspensions 
of tumour. 
   
Table 3.2 Fluorophore labelled antibodies used to stain intra-tumour leucocytes 
 
Antibodies against myeloid antigens Antibodies against lymphoid antigens 
 CD45 APC-eFluor® 780   CD45 eFluor® 450 
 CD11b PerCP-Cy5.5 CD3e PerCP-Cy5.5 
 CD11c PE CD8a FITC or APC 
 MHCII FITC or APC CD49b PE 
 Gr1 Alexa Fluor® 700  
 F4/80 Pe-Cy7  
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Figure 3.51 Selection of CD45+CD11b+ cells  
Samples that were stained with all antibodies except anti CD45 or anti CD11b antibodies (B and D) were 
used to set gates for the sequential selection of CD45+CD11b+ cells as shown.  
 
 
Figure 3.52 Gating for Neutrophils (CD11b+Gr1+) and Macrophage/monocytes (CD11b+F4/80+)  
Following the selection of CD45+CD11b+ cells (figure 3.51), FMO stained samples that excluded either 
anti Gr1 (A) or anti F4/80 (B) were used to set their respective gates as shown.  
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Figure 3.53 Intratumoural VVL15∆N1L enhanced the infiltration of neutrophils into LLC and 
DT6606 flank tumours 
Syngeneic LLC (Exp. A) and DT6606 (Exp. B) flank tumours (as indicated) were treated with 1x108 
PFUs of virus or the equivalent volume of PBS (n=3- 4/group). At one, three, five, seven and 14 days 
after virus injection, tumour cell suspensions were stained with fluorophore labelled anti CD45, CD11b, 
F4/80 and Gr-1 and analysed in a multichannel flow cytometer. The bar charts depict granulocytes or 
macrophages as a percentage of intratumoural CD45+ cells. Two-way ANOVAs with post hoc Tukey 
tests were used to compare mean values. 
 
 
Figure 3.51 and figure 3.52 depict the gating strategy used to identify neutrophils 
(defined as CD11b+Gr1+) and monocytes/macrophages (defined as CD11b+ F4/80+).  
 
Figure 3.53 shows that following a single dose of IT virus into LLC tumour bearing 
mice, there was a sustained enhancement of tumour infiltrating neutrophils with a 
reciprocal percentage decrease in the monocyte/macrophage pool. This pattern was 
exaggerated following treatment with VVL15∆N1L in comparison to VVL15. All other 
cell populations (NK, T cells) were miniscule (i.e. less than 3% of CD45+ leucocytes) 
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in comparison to CD11b+ cells, at all time-points and therefore could not be accurately 
quantified using this method. A similar experiment was conducted on DT6606 flank 
tumour models, although tumours on this occasion were analysed at only two time-
points, days seven and 14 post IT virus. Once again the granulocyte pool, as a 
percentage of CD45+ leucocytes, was markedly enhanced at both these times especially 
following IT VVL15∆N1L, with a marked decline in intra-tumour monocyte/ 
macrophages.  
 
3.4.5 IT VVL15∆N1L enhanced the systemic NK cell response 
 
As described in the introduction, NK cells are major innate antiviral and antitumour 
effectors. The systemic NK response is often elevated following viral infection, a fact 
that might have accounted for the beneficial effects of VVL15∆N1L on limiting 
dissemination from primary LLC tumours.  
 
Blood and spleen were harvested from IT injected LLC tumour bearing mice (as 
described in section 2.15.1) at days one, three, seven and 14  post treatment. They were 
processed to obtain single cell suspensions; stained with anti CD45-eFluor® 450 , 
CD3e-PerCP-Cy5.5 and CD49b-PE (a murine pan NK cell marker) and analysed in a 
multichannel flow cytometer. NK cells were defined as CD3-CD49+ and were 
expressed as a percentage of CD45+ leucocytes (see figure 3.54 and figure 3.55). There 
was a  significicant increase in circulating NK cells following VVL15∆N1L treatment 
in comparison to VVL15.  This had occurred by 24 hours of treatment and was 
sustained throughout the timecourse of the experiment. At day three, for example nearly 
50% of circulating leucocytes were NK cells. A non-significant trend for enhanced 
numbers of NK cells within spleen was also seen after day seven post infection. 
 
 
 
 
 
 
 
 
167 
 
 
 
Figure 3.54 Gating for NK cells (CD3-CD49+)  
Following the selection of CD45+ cells (B), the CD49b FMO sample (C) was used to define the CD3-
CD49+ gate as shown. 
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Figure 3.55 VVL15∆N1L enhanced systemic NK cell numbers 
Syngeneic LLC flank tumours were treated with 1x108 PFUs of virus or the equivalent volume of PBS (n=3- 4/group). At one, three, seven and 14 days post virus 
injection, blood leucocyte (Exp. A) and splenocyte (Exp. B) suspensions were stained with fluorophore labelled anti CD45, CD3 and CD49b and analysed in a 
multichannel flow cytometer. The bar charts depict NK cells (defined as CD3-CD49b+) as a percentage of CD45+ cells. Two-way ANOVAs with post hoc Tukey tests 
were used to compare mean values. 
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3.4.6 NK cell depletion abrogated the survival benefit of VVL15∆N1L in a 
neoadjuvant surgical lung cancer model 
 
It was conceivable that the systemic rise in NK cells upon IT injection of VVL15∆N1L 
was responsible for the reduction in the growth of MRD and perioperative 
dissemination of tumour metastases and thus responsible for the prolonged survival in 
the neoadjuvant surgical experiments described earlier. The VVL15∆N1L treatment arm 
was thus repeated in mice in which NK and T cells were selectively depleted (section 
2.15.6 and table 2.10, experiment 2). The efficacy of VVL15∆N1L was abrogated when 
NK cells were concurrently depleted for the duration of the experiment; whereas 
depletion of CD4+ or CD8+ cells made no difference (figure 3.56). 
 
 
 
Figure 3.56 NK cells play a pivotal role in mediating the efficacy of VVL15∆N1L in the context of 
neoadjuvant therapy prior to surgical excision 
Cell depleting or IgG control antibodies were commenced intraperitoneally in mice bearing syngeneic 
LLC flank tumours a day prior to the first dose of IT treatment with VVL15∆N1L or PBS  (n=7 per 
group). Tumours were surgically resected seven days after the final dose of virus. The X axis represents 
day’s post-surgical excision. Log rank analyses were used to delineate any significant differences 
between specific treatment pairs. 
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This result therefore revealed a different mechanistic picture to that responsible for the 
reduction in the growth of primary syngeneic DT6606 flank tumours treated with 
VVL15∆N1L in which CD8+ T cells were the apparent major player.  
 
 
3.4.7 Summary of results chapter 3.4 
 
The syngeneic LLC flank tumour model is extremely aggressive and metastasises to the 
lung if untreated. Dissemination appears to be enhanced upon surgical excision of the 
primary. It would thus serve as an effective, accelerated model of perioperative tumour 
dissemination and post-operative tumour recurrence.  
 
Although multiple IT doses of VVL15∆N1L did not slow the growth of primary LLC 
tumours, it did reduce metastatic dissemination to the lung (in comparison to treatment 
with VVL15). A similar treatment schedule administered seven days prior to surgical 
excision of tumour prolonged short term post-operative survival. The heightened 
adaptive antitumour immune response following IT VVL15∆N1L in comparison to 
VVL15 appeared to be dampened by operative or perioperative stress; confirmed by the 
fact that only 2/10 mice developed the ability to reject implanted LLC tumour cells. 
 
Contrastingly, the efficacy of VVL15∆N1L in the surgical neoadjuvant setting appeared 
to be dependent on its ability to stimulate innate immunity. Flow cytometric analysis of 
tumour infiltrating leucocytes demonstrated heightened neutrophil infiltration, with 
concurrently diminished monocyte populations. Most tellingly of all, IT VVL15∆N1L 
enhanced the numbers of circulating NK cells; an effect that was sustained for at least 
14 days post injection of a single dose of virus. The proliferation and mobilisation of 
these cells were a critical component of the efficacy of VVL15∆N1L in this 
neoadjuvant model; demonstrated by the complete abrogation of efficacy in mice 
lacking NK cells.  
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 Preliminary investigations into mechanisms responsible for VVL15∆N1L 3.5
mediated enhancement of innate and adaptive immunity   
 
3.5.1 The splenic pool of DCs was elevated following IT VVL15∆N1L injection of 
LLC tumours  
 
As has been discussed in the introduction, professional APCs play an important 
bridging role between innate and adaptive immunity. In terms of antitumour immunity, 
a rational for the deletion of the VV N1L gene was to enhance the cocktail of innate 
signals that might ultimately lead to the favourable activation of APCs.    
 
Before this hypothesis was explicitly tested, we sought to establish whether IT treatment 
with VVL15∆N1L enhanced the recruitment of DCs. Peripheral murine DCs drain 
through local lymph nodes and will also channel through the spleen. Differences in 
splenic DCs should reflect similar changes in tissue DCs, which are difficult to quantify 
within murine tumours. 
 
Splenocytes harvested at different times post IT viral injection of LLC flank tumours 
were stained with the following fluorophore labelled antibodies and analysed in a 
multichannel flow cytometer: anti CD45-eFluor® 450, anti CD11c-PE and anti MHCII-
FITC. 
 
The DC population was defined as CD11c+MHCII+ and expressed as a percentage of 
CD45+ splenocytes (figure 3.57). Although there was no statistically significant 
difference between treatment groups, there was a trend for enhanced splenic DC 
numbers following IT VVL15∆N1L, which was maintained until day seven post 
injection.  
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Figure 3.57 VVL15∆N1L enhanced DCs in the spleen 
Syngeneic LLC flank tumours were treated with 1x108 PFUs of virus or the equivalent volume of PBS 
(n=3- 4/group). At one, three, seven and 14 days post virus injection splenocyte suspensions were stained 
with fluorophore labelled antibodies against CD45, CD11c and MHCII surface antigens and analysed in a 
multichannel flow cytometer. The CD11c and MHCII FMO samples were used to set their respective 
boundaries as shown (D and E respectively). The bar chart depicts DC cells (defined as CD11c+ 
MHCII+) as a percentage of CD45+ splenocytes. Two-way ANOVAs with post hoc Tukey tests were 
used to compare mean values. 
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3.5.2 .Infection with VVL15∆N1L enhanced the activation of murine antigen 
presenting cells. 
 
In the previous section IT VVL15∆N1L appeared to enhance DCs in murine spleen. 
Could this novel virus also enhance their activation?  
 
This question was addressed in vitro. Bone marrow, containing naïve myeloid 
precursors of DCs and monocytes from C57BL/6 mice was harvested as described in 
section 2.9.3. DCs and monocytes were enriched in mCM containing GMCSF and M-
CSF respectively. Phenotypic confirmation of the desired pool of cells (i.e. DC or 
monocytes) was achieved by staining each group with the following antibodies prior to 
analysis in a multichannel flow cytometer: anti CD11b-PerCP-Cy5.5, anti F4/80-Pe-
Cy7, anti CD11c-Alexa Fluor® 700 and anti MHCII-FITC. 
 
The vast majority of GMCSF enriched cells were CD11c+MHCII+, whereas over 90% 
of cells enriched with M-CSF were CD11b+F4/80+ (figure 3.58).   
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Figure 3.58 Enrichment of mature DCs and monocytes from murine bone marrow 
Single cell suspensions of murine bone marrow were cultured for up to eight days in media containing 
GMCSF and M-CSF to selectively grow and mature DCs and monocytes respectively. For confirmation, 
at the end of the maturation period, suspensions were stained with fluorophore labelled antibodies against 
CD11b, CD11c, F4/80 and MHCII surface markers and analysed on a multichannel flow cytometer. 
Monocytes were defined as CDllb+F4/80+, whereas DCs as CD11c+MHCII+. Unpaired t tests were used 
to compare mean values 
 
 
VVL recombinants successfully infected APC populations in vitro, as demonstrated by 
the presence of the RFP marker when examined under green fluorescent light. At 
different early time points following infection, cells were harvested and stained with the 
following fluorophore labelled antibodies prior to analysis in a multichannel flow 
cytometer: anti CD11b-PerCP-Cy5.5, anti F4/80-Pe-Cy7, anti CD11c-Alexa Fluor® 
700, anti MHCII-FITC, anti CD80-PE and anti CD86-APC. 
 
CD80 and 86 are co-receptors to the MHCII-TCR “immunological synapse” and are 
upregulated upon activation of the APC. The presence of MHC class II molecules on 
the surface of monocytes enables them to take on the role of “professional” antigen 
presentation.  
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Figure 3.59 VVL15∆N1L infection of DCs and monocytes enhanced their activation 
At the time-points indicated following viral infection (MOI of 1 PFU/ cell) of enriched DCs and 
monocytes, cells were harvested and stained with fluorophore labelled antibodies against CD80, CD86 
and MHCII surface antigens. The “hi/lo” boundaries of these markers were set at the upper border of the 
densest population of mock treated cells (the bottom left dot plot in each experimental set of 
graphs/plots). Activation marker levels were normalised to the mean value for mock infected cells. Two-
way ANOVAs with post hoc Tukey tests were used to compare mean values.   
 
 
The graphs in figure 3.59 demonstrate that from 13 hours post infection and certainly by 
24 hours, surface expression of CD80 and CD86 and thereby activation of both DCs and 
monocytes were significantly higher following infection with VVL15∆N1L in 
comparison to VVL15. In addition there appeared to be an enhanced shift of the 
monocyte pool into “professional” APCs as evidenced by the significantly enhanced 
elevation in MHCII positivity following infection with VVL15∆N1L.  
 
3.5.3 The cytokine profile of VVL15∆N1L infected DCs and monocytes was 
conspicuous for enhanced IL10 expression 
 
Amongst other factors, the cytokine milieu peri-antigen presentation, plays an important 
role in the type of antigen specific adaptive immunity that develops. Many of these 
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cytokines are secreted by the APCs themselves. IL12 or IL15 for example may drive the 
development of a Th1 CTL immune response (338). In contrast IL10 production from 
APCs has traditionally been associated with local immune suppression and the 
development of Th2 CD4+ T cells (339, 340).  
 
There was no detectable murine IL4, IL12 or IL15 (measured by ELISA) in the 
supernatants from plates of virally infected DCs or monocytes. Surprisingly, there was 
an enhanced level of murine IL10 in the supernatant of wells containing VVL15∆N1L 
treated DCs and monocytes. The magnitude of response was higher following monocyte 
infection figure 3.60.  
 
 
Figure 3.60 VVL15∆N1L infection of DCs and monocytes enhanced their production of IL10 
Supernatant samples taken at 24 and 48 hours were removed from wells containing virally infected DCs 
or monocytes (MOI of 1 PFU/cell). Concentrations of murine IL4, IL12, IL15 (not shown) and IL10 were 
measured by ELISA. Two-way ANOVAs with post hoc Tukey tests were used to compare mean values. 
  
3.5.4 An analysis of the intratumoural chemokine/ cytokine milieu following 
infection with VVL15∆N1L 
 
In order to establish how VVL15∆N1L was able to effect the innate cellular changes 
demonstrated intratumourally and systemically, a further biological time-point 
experiment was set up using the syngeneic LLC flank model. Animals were euthanized 
at relatively early time points (one, three, five and seven days) following the IT 
injection of virus/ PBS and tumours were carefully harvested. These early time-points 
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were chosen in acknowledgement of the role of the early mobilisation of innate immune 
cells (NK cells, neutrophils and monocytes).  
 
Tumour tissue was processed as described in section 2.9.2 to separate the supernatant 
phase from solid cellular debris. The supernatant was screened for common 
inflammatory cytokines and chemokines via multianalyte ELISAs.  
 
The levels of cytokines/ chemokines within each tumour were normalised to the mean 
arbitrary value of VVL15 infected tumours (figure 3.61 and figure 3.62). By day seven, 
IL1α, β and GCSF cytokines were consistently and significantly elevated in 
VVL15∆N1L (as compared to VVL15) infected tumours and likewise the chemokines 
macrophage inflammatory protein(MIP)1α and keratinocyte chemoattractant (KC) (at 
later time-points).  
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Figure 3.61 Intratumoural expression of inflammatory cytokines following viral infection of LLC flank tumours  
Syngeneic LLC tumours were treated with 1x108 PFUs of virus or the equivalent volume of vehicle buffer (n=3- 4/group). At one, three, five and seven days post 
infection, harvested tumours were homogenised and centrifuged. Their supernatants were analysed for the presence of 12 common inflammatory cytokines by multi-
analyte ELISA. For comparison, arbitrary units of OD/ total gram of tumour protein were normalised to their corresponding mean values from VVL15 infected 
tumours. One-way ANOVAs with post hoc Tukey tests were used to compare means.  
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Figure 3.62 Intratumoural expression of inflammatory chemokines following viral infection of LLC flank tumours  
Syngeneic LLC tumours were treated with 1x108 PFUs of virus or the equivalent volume of vehicle buffer (n=3- 4/group). At one, three, five and seven days post 
infection, harvested tumours were homogenised and centrifuged. Their supernatants were analysed for the presence of 12 common inflammatory chemokines by multi-
analyte ELISA. For comparison, arbitrary units of OD/ total gram tumour protein were normalised to their corresponding mean values from VVL15 infected tumours. 
One way ANOVAs with post hoc Tukey tests were used to compare means.  
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3.5.4.1 Establishment of the source of the VVL15∆N1L enhanced chemokines and 
cytokines 
 
Major sources of cytokines or chemokines during the early stages in the development of 
an antigenic immune response include the professional APCs and monocytes/ 
macrophages.  To test whether they were responsible for the chemokine/ cytokine 
profile observed above, supernatants of virally infected bone marrow derived DCs and 
monocytes were analysed for the presence of IL1α/ β, GCSF, KC and MIP1α using 
single analyte ELISAs. The supernatants of similarly infected LLC and DT6606 tumour 
cells were also analysed as other potential sources.  
 
3.5.4.1.1 KC (CXCL1) 
 
The murine chemokine KC (CXCL1) is a functional homologue of human IL8 and thus 
plays an important role in the recruitment of neutrophils. Its secretion was much higher 
from virally infected tumour cells (especially DT6606) than DCs or monocytes. 
Infection with VVL15∆N1L led to higher levels of KC in comparison to infection with 
VVL15 (figure 3.63). Note uninfected tumours produced significant basal levels of KC.  
 
Figure 3.63 KC expression following VVL15∆N1L infection of DCs, monocytes, LLC and DT6606 
cells  
Supernatant samples at 24 and 48 hours post infection, were removed from wells containing viral or mock 
infected DCs, monocytes, LLC or DTT6606 cells (MOI of 1 PFU/ cell). Concentrations of KC were 
measured by ELISA. Two way ANOVAs with post hoc Tukey tests were used to compare mean values. 
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3.5.4.1.2 GCSF 
 
GCSF is a cytokine that also aids the recruitment and maturation of neutrophils as well 
as other myeloid derived cells. Its output was induced in an almost all or none fashion 
by VVL15∆N1L (in comparison to VVL15) from DCs and monocytes; with much 
higher levels from monocytes. VVL15∆N1L also induced production of this cytokine 
from DT6606 cells, but not from LLC cells (figure 3.64).  
 
Figure 3.64 GCSF expression following VVL15∆N1L infection of DCs, monocytes, LLC and 
DT6606 cells  
Supernatant samples at 24 and 48 hours post infection, were removed from wells containing viral or mock 
infected DCs, monocytes, LLC or DTT6606 cells (MOI of 1 PFU/ cell). Concentrations of GCSF were 
measured by ELISA. Two-way ANOVAs with post hoc Tukey tests were used to compare mean values. 
 
 
3.5.4.1.3 MIP1α (CCL3) 
 
MIP1α is a chemokine with multiple functions that encompass both innate and adaptive 
immune cellular recruitment. It facilitates the recruitment and activation of myeloid 
derived cells involved in antigen presentation, for example immature DCs, monocytes 
and macrophages (341). It also encourages NK cell migration and may aid the 
generation of a CD8+ CTL memory response (190, 342, 343). In the current 
experiment, MIP1α was only secreted from DCs and monocytes. VVL15∆N1L 
infection markedly increased output from both these cells (figure 3.65). 
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Figure 3.65 MIP1α expression following VVL15∆N1L infection of DCs, monocytes, LLC and 
DT6606 cells  
Supernatant samples at 24 and 48 hours post infection, were removed from wells containing viral or mock 
infected DCs, monocytes, LLC or DTT6606 cells (MOI of 1 PFU/ cell). Concentrations of MIP1α were 
measured by ELISA. Two way ANOVAs with post hoc Tukey tests were used to compare mean values. 
 
 
3.5.4.1.4 IL1α/ IL1β 
 
The classic acute phase reactant cytokines, IL1α and IL1β in the current context play a 
major role in the recruitment and activation of myeloid derived cells like macrophages 
and neutrophils as well as lymphocytes. IL1β may also drive a Th1 type antigen specific 
CTL response (344). The IL1 family of cytokines have been implicated in tumour 
progression via propagation of chronic inflammation, but may also enhance anticancer 
immunity, particularly in the context of chemotherapeutic and possibly virotherapeutic 
induced cell death (344). Both these cytokines were secreted from DCs and monocytes 
almost exclusively in response to VVL15∆N1L. Levels of IL1α were however very low. 
IL1β secretion especially from DCs, was significantly enhanced by infection with 
VVL15∆N1L (figure 3.66 and figure 3.67). Tumour cells did not secrete these cytokines 
upon viral infection.  
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Figure 3.66 IL1α expression following VVL15∆N1L infection of DCs, monocytes, LLC and DT6606 
cells  
Supernatant samples at 24 and 48 hours post infection, were removed from wells containing viral or mock 
infected DCs, monocytes, LLC or DTT6606 cells (MOI of 1 PFU/ cell). Concentrations of IL1α were 
measured by ELISA. Two-way ANOVAs with post hoc Tukey tests were used to compare mean values. 
 
 
Figure 3.67 IL1β expression following VVL15∆N1L infection of DCs, monocytes, LLC and DT6606 
cells  
Supernatant samples at 24 and 48 hours post infection, were removed from wells containing viral or mock 
infected DCs, monocytes, LLC or DTT6606 cells (MOI of 1 PFU/ cell). Concentrations of IL1β were 
measured by ELISA. Two-way ANOVAs with post hoc Tukey tests were used to compare mean values. 
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3.5.5 VVL15∆N1L also enhanced IL18 production from infected DCs and 
monocytes 
 
Transcription and post translational processing of IL1β is regulated by NF-κB and 
inflammasome signalling pathways respectively. As discussed in the introduction, the 
N1L protein is an inhibitor of NF-κB signalling, and the enhancement of IL1β may have 
been a consequence of disinhibition of this signalling pathway. However, it is possible 
that the N1L protein, indeed like the F1L protein (345) may also modulate signalling 
through inflammasome platforms. As a prelude to exploring this in detail, levels of 
IL18, another member of the IL1 family of cytokines (that is also post translationally 
activated by inflammasomes), was measured by ELISA in supernatants of virally 
infected DCs and Monocytes. IL18 is constitutively produced by certain cells and unlike 
IL1β  its further up-regulation appears  not to be regulated by NF-κB signalling (346). 
 
As can be seen in figure 3.68, IL18 levels were significantly enhanced following 
VVL15∆N1L infection of both DCs and monocytes. IL18 was not expressed by tumour 
cells. 
 
Figure 3.68 IL18 expression following VVL15∆N1L infection of DCs, monocytes, LLC and DT6606 
cells 
Supernatant samples at 24 and 48 hours post infection, were removed from wells containing viral or mock 
infected DCs, monocytes, LLC or DTT6606 cells (MOI of 1 PFU/ cell). Concentrations of IL18 were 
measured by ELISA. Two-way ANOVAs with post hoc Tukey tests were used to compare mean values. 
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3.5.6 Summary of Results Chapter 3.5 
 
Intratumoural VVL15∆N1L appeared to enhance DCs in murine spleens. In comparison 
to VVL15, VVL15∆N1L infection enhanced the activation of DCs and monocytes and 
in the latter also enhanced the up-regulation of MHCII, effectively transforming them 
into professional APCs. This may have mechanistic implications for its ability to 
enhance adaptive immunity in the LLC and DT6606 syngeneic tumour models. 
Interestingly, infection of APCs with VVL15∆N1L also led to enhanced IL10 
production from these cells. As will be further discussed in section 4.1; this may not be 
detrimental to the development of adaptive antitumour immunity. 
 
Multi-analyte ELISAs performed on LLC tumour homogenates at relatively early time-
points following IT virus administration confirmed enhanced levels of IL1α, IL1β, 
GCSF, KC and MIP1α levels within VVL15∆N1L treated tumours. These have multiple 
functions including the recruitment and activation of neutrophils (GCSF, KC, IL1β) and 
NK cells (MIP1α). The IL1 family and MIP1α may play additional roles in promoting a 
Th1 driven antigen specific CTL response. In vitro analyses confirmed the enhanced 
production of these cytokines and chemokines by VVL15∆N1L infected DCs and 
monocytes, although KC was most likely to have been produced by infected tumour 
cells. 
 
Finally, the production of IL18 (another IL1 family member) was also enhanced from 
DCs and particularly monocytes following infection with VVL15∆N1L. The apparent 
dampening of both IL1β and IL18, suggests that the N1L protein may  regulate 
signalling through inflammasome platforms, a potentially novel mechanism of action.      
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 Efficacy with the cytokine armed recombinant viruses 3.6
 
The syngeneic DT6606 flank tumour model was sensitive to IT administered 
VVL15∆N1L monotherapy; however, efficacy was either limited or modest in other 
similar models. Even in the DT6606 tumour cohort many mice were not cured. In 
addition, neoadjuvant treatment with VVL15∆N1L appeared to only enhance short term 
survival of mice following resection of LLC tumours. There thus remained significant 
scope to try and improve upon this novel VVL recombinant platform. VVL15- 
mGMCSF and VVL15- mIL12 recombinant viruses were constructed with this premise 
in mind. 
 
3.6.1 VVL15-mIL12 further enhanced the antitumour immunity induced by 
VVL15∆N1L but VVL15-mGMCSF did not 
 
Stimulated splenocyte IFNγ immunoassays were utilised as markers of antitumour and 
antiviral adaptive immunity. Splenocytes were co-cultured with growth arrested 
DT6606 cells, the murine mesothelin peptide or the VV B8R peptide (table 2.4). The 
VVL15∆N1L treatment arm was the control group in this and all subsequent 
experiments in this chapter.  
 
Figure 3.69 demonstrates that splenocytes from VVL15-mIL12 infected tumour bearing 
mice produced the highest levels of IFNγ upon co-culture with growth arrested DT6606 
cells as well as with the mesothelin peptide. Absolute levels of IFNγ diminished with 
time and any differences between groups had disappeared by day 21. 
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Figure 3.69 VVL15-mIL12 enhanced the adaptive antitumour immune response afforded by 
VVL15∆N1L 
Syngeneic DT6606 flank tumours were treated with 1x108 PFUs of IT virus or the equivalent volume of 
PBS (n=3- 4/group). Seven, 14 or 21 days later, splenocyte suspensions were co-cultured with either 
growth arrested target DT6606 cells, mesothelin peptide or VV B8R peptide. IFNγ concentrations (pg/ml, 
Y axes) of supernatants were measured by ELISA. Two-way ANOVAs with post hoc Tukey tests were 
used to compare mean values. 
 
 
 
3.6.2 Splenic CD8+ effector memory cells were further enhanced by VVL15-mIL12 
but not by VVL15-mGMCSF  
 
Splenocyte suspensions from days 14 and 21 post viral injection were stained with a 
panel of fluorophore labelled antibodies and analysed via multi-channel flow cytometry. 
The following antibodies were used: anti CD45-eFluor® 450, anti CD3e-PerCP-Cy5.5, 
anti CD8a-FITC, anti CD62L-PE Cy7 and anti CD44-APC. 
 
Previously we demonstrated that IT VVL15∆N1L enhanced the generation of effector 
memory CD8+ T cells above that stimulated by IT VVL15. A similar experiment was 
conducted to establish whether either of the two cytokine armed viruses could improve 
upon this response.  
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Figure 3.70 Intratumoural VVL15-mIL12 enhanced the generation of CD8+ effector memory T 
cells  
Syngeneic DT6606 flank tumours were treated with 1x108 PFUs of IT virus or the equivalent volume of 
PBS (n=3- 4/group). Fourteen or 21 days later, splenocyte suspensions were stained with fluorophore 
labelled antibodies against CD45, CD3, CD8, CD44 and CD62L cell surface antigens and analysed in a 
multichannel flow cytometer. The bar chart depicts the effector memory (CD44hiCD62Llo) percentage of 
CD8+ T cells. The result from a single mouse treated with PBS is also included for reference. Two-way 
ANOVAs with post hoc Tukey tests were used to compare mean values.  
 
 
Effector memory CD8+ T cells were defined as CD44hiCD62Llo. Gating was 
performed with FMO stained samples that excluded either anti CD44 or CD62L 
antibodies with a similar strategy to that illustrated in figure 3.30. At day 14 post IT 
virus, there was an enhancement of CD8+ effector memory T cells in the spleens of 
mice treated with VVL15-mIL12 (in comparison to the other two viral groups (figure 
3.70)). This enhancement had diminished by day 21. 
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3.6.3 Splenic DCs were enhanced by infection with VVL15-GMCSF but not by 
VVL15-mIL12 
GMCSF is a chemoattractant and growth factor for the mobilisation, differentiation and 
maturation of professional APCs. A number of OVTs have been armed with this 
transgene in a bid to reverse tolerance to TAAs (see section 4.1). 
 
We sought to establish whether splenic DCs could be altered by VVL15-mGMCSF 
treatment. Splenocytes were stained with the following antibodies prior to analysis in a 
multichannel flow cytometer: anti CD45-eFluor® 450, anti CD11c-PE and anti MHCII-
FITC. 
 
DCs were defined as CD11c+MHCII+ and expressed as a percentage of CD45+ cells. 
At day 14 post treatment there was a statistically significant increase in the splenic DC 
pool following IT VVL15-mGMCSF, in comparison to the other two viruses (figure 
3.71). This difference had diminished by day 21. 
 
 
Figure 3.71 Intratumoural VVL15-mGMCSF enhanced the DC pool within murine spleens  
Syngeneic DT6606 flank tumours were treated with 1x108 PFUs of IT virus or the equivalent volume of 
PBS (n=3- 4/group). Fourteen or 21 days later splenocyte suspensions were stained with fluorophore 
labelled antibodies against CD45, CD11c and MHCII cell surface antigens and analysed in a multichannel 
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flow cytometer. The bar chart depicts splenic DCs (CD11c+MHCII+) as a percentage of CD45+ 
splenocytes. The result from a single mouse treated with PBS is also included for reference. Two way 
ANOVAs with post hoc Tukey tests were used to compare mean values. 
 
 
3.6.4 Bone marrow derived DCs were highly activated by VVL15-mGMCSF in 
comparison to VVL15-mIL12 
 
Given the enhancement in numbers of in vivo DCs following treatment with VVL15-
mGMCSF, we attempted to establish if this recombinant virus was also capable of 
activating them to a greater degree. DCs were harvested from the bone marrow of naïve 
C57BL/6 mice as described in section 2.9.3, validated by flow cytometry and infected 
with the cytokine armed viruses. Cells were harvested 24 hours later and stained for the 
presence of CD80 and CD86 surface antigens. 
 
In comparison to treatment with the other viral groups, the proportion of DCs positive 
for these markers (in particular CD86) was highest following infection with VVL15-
mGMCSF (figure 3.72). 
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Figure 3.72 VVL15-mGMCSF infection of DCs enhanced their activation in comparison to VVL15∆N1L and VVL15-mIL12  
Twenty four hours after viral infection of enriched DCs (MOI of 1 PFU/cell), cells were harvested and stained with fluorophore labelled antibodies against CD80 (Exp. 
A) and CD86 (Exp. B) surface markers. The “hi/lo” boundaries of these markers were set at the upper border of the densest population of mock treated cells (left most 
dot plot). “Hi” values were normalised to the mean for mock infected cells. One way ANOVAs with post hoc Tukey tests were used to compare means.   
 
 
193 
 
We had now demonstrated that VVL15-mGMCSF could enhance splenic DCs in vivo, 
as well their activation (and by implication, their ability to present antigen); whereas 
VVL15-mIL12 greatly enhanced the tumour specific adaptive antitumour immune 
response in at least one tumour model.  
 
3.6.5 Antigen presenting cells were hijacked into expressing the relevant cytokine 
transgene following infection with VVL15∆N1L recombinant viruses 
 
Cytokine transgene armed viruses could infect, replicate and express their transgenes in 
a number of different tumour cell lines derived from murine, hamster and human hosts 
in vitro (sections 3.1.3, 3.1.4 and 3.1.5). Could they also do so in DCs and 
macrophages; in effect forcing them into expressing strong Th1 promoting cytokines? 
 
 
Figure 3.73 VVL15-mGMCSF and VVL15-mIL12 were able to express their respective cytokines 
upon infection of DCs and monocytes  
Supernatant samples at 24 and 48 hours, were removed from triplicate wells containing virally infected 
DCs or monocytes (MOI of 1 PFU/cell). Murine GMCSF and IL12 concentrations (as indicated) were 
measured by ELISA. Two-way ANOVAs with post hoc Tukey tests were used to compare means. 
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Figure 3.74 Infection with cytokine armed viruses dampened down the VVL15∆N1L induced 
production of IL10 from DCs and monocytes 
Supernatant samples at 24 and 48 hours, were removed from triplicate wells containing virally infected 
DCs or monocytes (1 PFU/cell). Murine IL10 concentrations were measured by ELISA. Two-way 
ANOVAs with post hoc Tukey tests were used to compare mean values. 
 
 
Figure 3.73 shows that the cytokine transgene armed viruses were able to infect both 
DCs and monocytes and express detectable quantities of either cytokine; mGMCSF or 
mIL12. In terms of IL10 production, this experiment replicated the ability of 
VVL15∆N1L to induce the production of this cytokine from DCs and monocytes in 
particular. Whilst not abrogating output from monocytes completely, levels of IL10 
were significantly diminished following infection with either cytokine transgene armed 
virus (figure 3.74). 
 
3.6.6 In vivo efficacy with cytokine armed viruses   
 
3.6.6.1 Early administration of VVL15-mIL12 virus led to superior efficacy against 
syngeneic flank DT6606 tumours. 
 
The data thus far illustrated that our cytokine armed recombinant VVs had the potential 
to selectively enhance different components of a developing immune response. It might 
therefore have been logical to treat a tumour with a combination of these viruses to take 
advantage of their respective functions i.e. sequential treatment with VVL15-mGMCSF 
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followed by VVL15-mIL12 virus in order to boost TAA presentation and antitumour 
effector responses respectively. 
 
To test this, DT6606 syngeneic flank models were established as described in 2.15.1 
and mice were randomised into five treatment arms (table 2.8, experiment 6). Contrary 
to expectation, initial treatment with IT VVL15-mIL12, regardless of whether it was 
followed by further doses of VVL15-mIL12 or VVL15-mGMCSF produced the most 
efficacious reduction in tumour growth (figure 3.75). Surprisingly the efficacy of the 
reverse combination of virus treatment (i.e. initial treatment with VVL15-mGMCSF), in 
this tumour model was relatively poor.  
 
 
 
 
Figure 3.75 Early IT treatment with VVL15-mIL12 led to the most efficacious reduction in tumour 
growth  
Syngeneic DT6606 flank tumour models were treated with a total of six doses (1x108 PFUs of virus per 
dose) of different combinations of recombinant viruses as shown (three single daily doses of virus A 
followed by three single daily doses of virus B (see table 2.8, experiment 6)) or the equivalent volume of 
PBS (n=7 per group). The first dose was injected at day 0 on the X axis. Two-way ANOVAs with post 
hoc Tukey tests were used to compare mean tumour volumes. The arrow depicts the time point to which 
the comparative statistical figures on the graph relate to. 
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Given the success of VVL15-mIL12 in the previous experiment, a repeat was conducted 
on syngeneic flank models of DT6606 and other solid tumours, using a monotherapeutic 
schedule. There was a dramatic reduction in the growth rate of DT6606 tumours 
following treatment with VVL15-mIL12, with long term cure of six out of seven 
tumour bearing mice (figure 3.76). Furthermore, even the more aggressive tumours, i.e. 
LLC and CT26 that were previously resistant to VVL15∆N1L, were significantly more 
responsive to treatment with VVL15-mIL12 monotherapy, although notably, there were 
no complete cures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.76 VVL15-mIL12 was the most efficacious recombinant ∆N1L virus against syngeneic 
flank tumour models  
Syngeneic DT6606, LLC and CT26  flank models were treated with five daily IT doses of 1x108 PFUs of 
virus or the equivalent volume of PBS  (n=5-7 per group). The first dose was injected at day 0. Two way 
ANOVAs with post hoc Tukey tests were used to compare mean tumour volumes. The arrows depict the 
time point to which the comparative statistical figures on each graph relate to. 
.   
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3.6.6.2 Confirmation of the enhancement of antitumour immunity after multiple 
doses of cytokine armed viruses 
 
Further splenocyte IFNγ immunoassays were conducted following the administration of 
multiple doses of virus into DT6606 tumour bearing mice. This again served dual 
purposes of confirming the reliability of the immunological data obtained following 
single dose IT virus as well has enhancing the prospect of detecting in vivo generated 
mesothelin epitope specific CD8+ T cells.  
 
 
Figure 3.77 Multiple doses of IT VVL15-mIL12 enhanced the antitumour adaptive immunity 
afforded by VVL15∆N1L  
Syngeneic DT6606-flank tumours were treated with five daily IT doses of 1x108 PFUs or the equivalent 
volume of PBS (n=3-4/group). Fourteen days after the first dose, splenocyte suspensions were co-cultured 
with growth arrested whole target (DT6606) or control (LLC) tumour cells, tumour peptides or the VV 
B8R peptide as indicated. The IFNγ concentrations (pg/ml, Y axis) of supernatants were measured by 
ELISA. One-way ANOVAs with post hoc Tukey tests were used to compare means values. 
 
 
As previously demonstrated, the highest concentrations of IFNγ were obtained 
following co culture of splenocytes from VVL15-mIL12 treated tumour bearing mice 
(figure 3.77). This pattern was also seen following co-culture with the murine 
mesothelin peptide, although not with the K-RAS peptide. The anti-B8R responses from 
all three groups were predictably high although the VVL15-mGMCSF group appeared 
to fare worse than the other two. Interestingly the antiviral immune response was not 
enhanced by the presence of mIL12.  
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The percentage of splenic CD8+ T cells was highest following treatment with VVL15-
mIl12 (figure 3.78). Of these, the effector memory (CD44hiCD62Llo) pool was also 
elevated in the VVL15-mIL12 treated group (figure 3.78).  
 
Figure 3.78 Multiple doses of IT VVL15-mIL12 enhanced the generation of effector CD8+ T cells 
afforded by VVL15∆N1L 
Syngeneic DT6606 flank tumours were treated with five daily IT doses of virus (1x108 PFUs per dose) or 
the equivalent volume of PBS (n=3- 4/group). Fourteen days after the first dose, splenocyte suspensions 
were stained with fluorophore labelled antibodies against CD45, CD3, CD8, CD44 and CD62L cell 
surface antigens and analysed in a multichannel flow cytometer. Exp. A depicts the gating strategy used 
to isolate the CD8+CD3+ population. Exp. B represents the effector memory (CD44hiCD62Llo) 
percentage of CD8+ T cells. One-way ANOVAs with post hoc Tukey tests were used to compare mean 
values. 
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Immunohistological analysis of snap frozen tumour sections, 14 days after the first dose 
of virus confirmed the enhanced intratumoural infiltration of both CD8+ and CD4+ 
cells following VVL15-mIL12 administration (figure 3.79). 
 
                        
Figure 3.79 Multiple doses of IT VVL15-mIL12 enhanced the VVL15∆N1L mediated infiltration of 
CD8+ cells into DT6606 tumours  
Syngeneic DT6606 flank tumours were treated with five daily IT doses of virus (1x108 PFUs per dose) or 
the equivalent volume of vehicle buffer (n=3-4/group). Fourteen days after the first dose, frozen sections 
of harvested tumour were immunostained with either anti CD4, CD8, NK1.1 or F4/80 antibodies. The bar 
chart depicts the mean manual cell count per HPF from 10-15 HPFs (x200 magnification). One-way 
ANOVAs with post hoc Tukey tests were used to compare pairs of means. 
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In order to control for the relatively expanded population of CD8+ splenic T cells, 
Mesothelin epitope specific CD8+ T cells were expressed as a percentage of CD3+ T 
cells (i.e. total T cells). There was no significant enhancement in this clone of anti-
tumour T cells in comparison to that obtained from the VVL15∆N1L treated group 
(figure 3.80).  
 
 
 
 
Figure 3.80 Multiple doses of IT cytokine armed recombinant viruses did not enhance the in vivo 
expansion of a mesothelin TCR specific clone of T cells  
Syngeneic DT6606 flank tumours were treated with five daily IT doses of virus (1x108 PFUs per dose) or 
the equivalent volume of PBS (n=3- 4/group). Fourteen days after the first dose, splenocyte suspensions 
were stained with PE labelled mesothelin pentamer as well as with anti CD3-FITC and anti CD8a-APC 
and analysed in a multichannel flow cytometer. The bar chart depicts the mesothelin epitope specific 
clone of CD8+ T cells, expressed as a percentage of total CD3+ T splenocytes. An FMO stained sample 
that excluded the MesoPent-PE was used to set the gate for pentamer positivity (top right graph). A one-
way ANOVA with post hoc Tukey tests was used to compare pairs of means. 
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3.6.6.3 Efficacy of cytokine armed VVL15∆N1L with neoadjuvant surgical models 
of lung cancer. 
 
Recall that: 
1. Multiple doses of IT VVL15∆N1L, appeared to significantly reduce the lung 
metastatic rate from syngeneic LLC flank tumours. There was no difference between 
viral treatment groups in terms of the growth restriction of primary tumours.   
 
2. Neoadjuvant treatment with multiple doses of IT VVL15∆N1L prior to the surgical 
excision of the primary flank LLC tumour led to significantly enhanced short term 
survival in comparison to treatment with VVL15. This appeared to be dependent on the 
enhancement of circulating NK cells. 
 
These experiments were repeated with the cytokine armed viruses 
 
1. Following the establishment of syngeneic LLC flank tumours, mice were randomly 
divided into treatment groups (section 2.15.1). Five doses of IT virus/ PBS were 
administered. 
 
Figure 3.76 demonstrated that the growth of the primary LLC tumour was slowed by IT 
administration of VVL15-mIL12 in comparison to the other viruses. All animals were 
euthanized when the first group achieved criteria for sacrifice. Their lungs were 
scrutinized macroscopically and microscopically for tumour metastases. All three N1L 
deleted recombinant viruses appeared to reduce lung metastases in comparison to 
treatment with PBS, with 0/7 positive in VVL15∆N1L and VVL15-mIL12 groups and 
1/7 in the VVL15-mGMCSF group (figure 3.81). In contrast 6/7 PBS treated mice had 
lung tumours at sacrifice.  
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Figure 3.81 Metastatic dissemination from LLC flank tumours following intratumoural cytokine 
armed recombinant viral administration 
Syngeneic LLC flank tumours were treated with five daily IT doses of virus (1x108 PFUs per dose) or the 
equivalent volume of PBS (n=7/ group). Tumour volumes were tracked via twice weekly calliper 
measurement. Mice were euthanized when the first group of tumours reached the criteria for sacrifice. 
Lung sections were stained with H&E and slides were scrutinized for the presence or absence of lung 
metastases by a pathologist (YW) who was blinded to the treatment groups. Fisher’s exact tests were 
performed on 2x2 tables comparing specific pairs of conditions.    
 
 
2. Finally, LLC flank tumour models were again established with a view to neoadjuvant 
treatment prior to surgical excision of the primary tumour (section 2.15.5). There was a 
dramatic enhancement of long-term survival following neoadjuvant treatment with 
VVL15-mIL12. Seven of eight mice were apparently cured, as dictated by long term 
health and accumulation of weight (figure 3.82). 
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Figure 3.82 Pre-surgical IT treatment with VVL15-mIL12 prolonged long term post-operative 
survival of LLC tumour bearing mice 
Syngeneic LLC flank tumours were treated with five daily IT doses of virus (1x108 PFU per dose) or the 
equivalent volume of vehicle buffer (n=8-10/group). Tumours were surgically resected seven days after 
the final dose of virus. The X axis represents days post-surgical excision. Log rank analyses were used to 
delineate any significant differences between specific treatment pairs. 
 
 
In addition to its effects on adaptive immunity IL12 is known to enhance the 
proliferation and activation of NK cells and may have simply potentiated the already 
enhanced antitumour NK response following treatment with VVL15∆N1L. It remains to 
be determined whether VVL15-mIL12 recruited additional “adaptive” immune effectors 
to mediate the long term survival benefit seen here post-operatively.  
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3.6.7 Summary of Results Chapter 3.6   
   
In a bid to improve upon the efficacy of VVL15∆N1L, mGMCSF and mIL12 cytokine 
transgenes were cloned into this platform. In vitro, these viruses were able to infect and 
express their respective transgenes in murine bone marrow derived DCs and monocytes. 
In addition, IL10 production from both cell types was reduced following infection by 
either virus.  
 
IT injection of VVL15-mIL12 into DT6606 tumour bearing mice further enhanced 
adaptive antitumour immunity in comparison to either VVL15∆N1L or VVL15-
mGMCSF. As predicted by the function of its cytokine transgene, treatment with 
VVL15-mGMCSF stimulated the highest splenic DCs in vivo as well as their activation 
in vitro.  
 
Given these results, it was initially hypothesised that sequential treatment with VVL15-
mGMCSF followed by VVL15-mIL12 might have been the most efficacious 
combination. However, monotherapy with VVL15-mIL12 produced a far superior 
growth reduction across all tested primary tumour models, especially against DT6606 
syngeneic tumours. 
  
As with VVL15∆N1L, multiple doses of IT VVL15-mIL12 or VVL15-mGMCSF also 
reduced metastatic dissemination to the lungs from LLC flank primaries. Intratumoural 
administration of VVL15-mIL12 as a neoadjuvant to surgical resection of LLC 
tumours, appeared to prolong long term survival. It remains to be determined whether 
this effect was due to the recruitment of adaptive immune effectors, as opposed to 
potentiation of an already enhanced antitumour innate immune response.     
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Chapter 4 Discussion 
 
 Analysis of results and outline of future work 4.1
 
During the past eight years, our research group has developed the Lister strain 
recombinant backbone, VVL15 for use in the therapy of solid tumours. We have been 
able to demonstrate that VVL15 has superior oncolytic potency against a large panel of 
human cancer cell lines, in comparison to more virulent platforms such as WRDD 
(Hughes et al., in press, Gene Therapy). Its antitumour efficacy in immunocompetent 
syngeneic murine cancer models was also superior. Nevertheless, monotherapy with 
VVL15 could not accomplish complete cancer cure and so there remained scope for 
further development.  
 
Appropriate activation of the innate immune system is a prerequisite to effective 
priming of adaptive immune responses against both foreign and self-antigens, including 
TAAs (347-349). Deletion of the N1L gene of VVL15 served two purposes: a) to 
locally enhance the cellular and cytokine responses consequent to viral oncolysis (i.e. 
innate immunity) and thus augment the quantity of PAMPs and DAMPs and b) to 
enhance the safety of the viral backbone. If indeed VVL15∆N1L was deemed to be 
superior to VVL15 in these regards, regardless of efficacy per se. then we could 
confidently start to explore the effects of arming it with immunomodulatory transgenes.  
 
The homologous recombination strategy used in this project was designed to replace 
almost the entirety of the coding sequence of the L025 (N1L) locus. Sequence analysis 
at the junctions of L024/25 and L025/26 (using primers 3 and 4 in table 3.1 
respectively) confirmed that the ORFs upstream and downstream of L025 remained 
intact (data not shown). In the wild type virus, there is a 14 bp overlap of the L024 ORF 
with that of L025 and this was unaltered. 
  
VVL15∆N1L was at least as potent, if not more so than VVL15 at killing murine and 
hamster derived cancer cells in vitro. The N1L gene product is a Bcl-2 structural 
homologue (57) and one of its functions is postulated to be inhibition of cellular 
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apoptosis. Infection with VVL15∆N1L could have accelerated apoptosis in these cells. 
Although, given that multiple anti-apoptotic mutations are already likely to be present in 
cancer cells, this explanation may be an over-simplification. Indeed, the cytotoxicity in 
human cell lines was more variable; VVL15∆N1L was statistically superior at killing 
only one of six human cancer cell lines tested (UW-228). Furthermore, the anti-
apoptotic function of the N1L protein has been questioned in at least one study (350). 
 
VVL15∆N1L demonstrated superior cytotoxicity against murine cancer cells lines in 
comparison to its cytokine transgene armed recombinants (VVL15-mGMCSF, VVL15-
mIL12), despite these viruses also lacking the N1L gene. A major mechanism of viral 
cell killing is by cellular burst once a threshold level of intracellular viral progeny has 
been achieved. One explanation for the observed results could be that the transcription 
machinery and indeed cellular energy resources were diverted away from the production 
of virion particles and towards cytokine expression and translation.   
 
Interestingly, the cytotoxic potencies of the IL12 transgene armed viruses were superior 
to their GMCSF armed counterparts (both murine and human). IL12, acting through its 
cognate cell surface receptor may be directly cytotoxic to certain cancer cells, of both 
haematogenous and epithelial origin (351-354). It would certainly be of translational 
significance to establish whether the cell lines used in this project constitutively express 
surface IL12 receptors. 
 
Contrary to its original premise as an anticancer immune modulator, there is an 
accumulating body of evidence that GMCSF may promote tumour growth under certain 
circumstances. A number of murine and human cancers express GMCSF as well as its 
receptor (355-357). In head and neck squamous carcinoma for example, intratumoural 
GMCSF (as well as VEGF and PDGF) expression correlated with poor prognosis in one 
cohort of patients (357). GMCSF can stimulate the growth, migration and metastases of 
tumour models both in vitro and in vivo (358-360), often indirectly via activation of 
stromal components (360-362).  
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Thus differences in cytotoxicity between the cytokine armed viruses may have reflected 
differences in the responsiveness of the tested tumour cells to the expressed cytokines.   
 
Disruption of the N1L gene in vaccinia was previously shown not to attenuate 
replication in vitro (248). Our experiments however, revealed that in comparison to 
VVL15, the replication of VVL15∆N1L was modestly but significantly attenuated in 
over half of the panel of cell lines tested, with an inferior trend in the others. This is 
unsurprising as viral replication has been inversely correlated to the extent to which it 
has been genetically manipulated (58). A feature confirmed by the fact that there was a 
further attenuation of the replication of cytokine transgene armed recombinants. Despite 
this, all novel recombinant viruses remained replication competent and were able to 
detectably express their relevant transgene.  
 
Effective immunotherapeutics are likely to be those that generate a response against 
multiple TAAs. A logistically simple way to do this would be to try and enhance the 
simultaneous presentation of different TAAs within an in situ syngeneic tumour. 
Intratumoural injections of virus into a syngeneic flank tumour would theoretically 
release multiple TAAs (through oncolysis), the combination of which would be unique 
to the host and tumour at that particular time.  
 
The generation of an adaptive antitumour immune response was initially investigated by 
comparing IFNγ release from ex vivo stimulated splenocytes. IFNγ production in vivo 
occurs mainly from cells of lymphoid origin; namely T and NK cells. The contribution 
from the former would be expected to be relatively high particularly after ex vivo 
selection with whole tumour cells or immunodominant T cell stimulating epitopes. 
Using these assays, we have shown that VVL15∆N1L was superior to VVL15 at 
priming adaptive tumour specific immunity. In contrast, antiviral immunity (measured 
by the response to an immunogenic VV B8R epitope) was not significantly altered. As 
expected, after a single dose of IT virus, both antitumour and antiviral responses in LLC 
and DT6606 tumour bearing mice waned with time, so that by day 21 there were no 
significant differences between treatment groups. Unsurprisingly therefore, boosting 
strategies will be required for more prolonged antitumour responses. 
 
 
208 
 
IFNγ released from splenocytes harvested from virally treated DT6606 tumour bearing 
mice were consistently higher than from their LLC bearing counterparts. This may 
again reflect differences in immunogenicity between the oncolysed TAAs or the ease 
with which tolerance to TAAs may be reversed. Thus the TME of LLC tumours may be 
more immunosuppressive than DT6606 tumours. There were higher numbers of CD4+ 
(in comparison to CD8+) cells in histological sections of LLC tumours post treatment; 
the reverse was true in DT6606 tumour sections. T regulatory cells of the CD4+ subset 
are naturally more abundant and have been more extensively studied than those of a 
CD8+ phenotype (363, 364). It is tempting to think that LLC tumours may therefore 
contain a higher ratio of T-regs to CTLs than DT6606 tumours, but this assumption 
would need to be confirmed by formal investigation. Furthermore, it is unclear from this 
explanation why the strength of the antiviral (anti VV B8R) response in LLC tumour 
bearing mice was not lower than in DT6606 tumour bearing mice.  
 
At the time of testing, the immunodominant TAA profile of DT6606 pancreatic tumour 
cells (331, 332) had not been established. An “artificial” TAA, like chicken ovalbumin 
is foreign to the host in this context and likely to be highly immunogenic; but we felt it 
should suffice in a comparative study.  Intratumoural VVL15∆N1L enhanced anti-Ova 
immunity in comparison to VVL15. Once again, the relatively high IFNγ levels upon 
splenocyte co-culture with the B8R epitope was not statistically different between 
groups treated with either viral platform. 
 
Fluorescence cytometric analysis of splenic T cells following IT viral administration 
into tumour bearing mice provided some preliminary data on the nature of the T cell 
response. At relatively early time points i.e. seven and 14 days post injection, 
VVL15∆N1L generated significantly higher levels of CD44+CD62Llo, CD8+ T cells in 
comparison to VVL15 or PBS.  
 
Memory T cells, both CD4+ and CD8+ may be categorised into at least two different 
functional groups: effector and central memory (reviewed in (365)). Whilst both subsets 
are positive for CD44 (a hyaluronate receptor that has been associated with “activated” 
memory cells), effector memory cells lose the lymphoid homing receptors CCR7 and 
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CD62L; they are thought to circulate throughout the periphery, being capable of rapidly 
maturing into IFNγ producing cells and in the case of CD8+ T cells, immediately 
effecting target cell cytotoxicity.  Central memory T cells are CCR7 and CD62Lhi and 
remain within lymphoid tissue, producing mainly IL2 in their native state. Although 
they are capable of proliferation upon meeting their cognate antigen, they can only do 
so in lymphoid tissue and therefore rely on APCs for delivery of antigen. In addition, 
they take longer than effector memory T cells to differentiate into an activated effector 
phenotype. As the surface expression of CCR7 mirrors that of CD62L, our chosen 
definitions of effector or central memory T cells were CD44+ and CD62Llo or hi 
respectively. Based on this definition, in both LLC and DT6606 tumour bearing mice, 
VVL15∆N1L (in comparison to the other treatment arms) enhanced splenic effector 
memory CD8+ T cells at early time points following infection. As previous IFNγ 
immunoassays revealed non-significant differences in antiviral adaptive immunity 
between viral groups, it was possible that the enhanced number of CD8+ effector 
memory cells reflected an enhanced antitumour memory pool. The enhanced generation 
of mesothelin pentamer specific CD8+ T cells following treatment of DT6606 tumour 
bearing mice with multiple doses of VVL15∆N1L corroborated this notion.  
 
Measurement of IFNγ levels from ex-vivo activated T cells can only act as a surrogate 
marker for the potency of a tumour specific cytotoxic response. A demonstration of 
direct T cell mediated cytotoxicity would be desirable. To this effect, a non-radioactive 
CTL assay, based on LDH release from lysed cells, confirmed the ability of 
VVL15∆N1L (in comparison to VVL15) to induce a greater number of tumour specific 
cytotoxic splenocytes. In parallel to the previous results, antitumour cytotoxicity was 
superior following viral treatment of DT6606 as opposed to LLC tumour bearing mice.   
 
A number of SC syngeneic flank models were used to assess whether the induced 
adaptive antitumour immunity translated into efficacy. Treatment with VVL15∆N1L 
slowed tumour growth to a significant degree in DT6606 and CT26 tumour bearing 
mice. The replication and cellular cytotoxicity of VVL15∆N1L in DT6606 and CT26 
cells in vitro were not enhanced in comparison to VVL15, so viral oncolysis must have 
been augmented, probably by a boost in antitumour immunity in vivo. Indeed the 
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complete abrogation of the efficacy of VVL15∆N1L against DT6606 tumours in mice 
depleted of CD8+ cells confirmed the critical role of antitumour CTLs. Surprisingly, 
depletion of NK or CD4+ cells made little difference in this regard. 
 
The next group of experiments were designed to establish whether VVL15∆N1L could 
be delivered to tumours following IV administration, as well as its off-target infectivity.  
The use of two syngeneic flank models derived from different strains of mice, C57BL/6 
(LLC) and BALB/c (CT26) would confirm the validity of any conclusions. Note that 
although non-invasive imaging (measuring luminescence and fluorescence) was 
available and from previous studies was capable of detecting viral replication within 
tumour, this investigative modality was not sensitive enough to detect virus in organs 
other than the lungs (Ferguson, unpublished data).  
 
Following a single IV dose of either VVL15 or VVL15∆N1L (1x108 PFUs), live virus 
could be recovered from tumour for at least 10 days. In mice carrying CT26 tumours, 
there was no significant difference between viral tires at any time point, although there 
did appear to be a trend for the enhanced clearance of VVL15∆N1L. VVL15∆N1L titres 
in the LLC model were significantly worse after day three. Viral titres rose and peaked 
between three and seven days post injection implying that virus was able to amplify 
within tumours. Significant titres of live virus were recovered from filtering organs 
(lungs, liver, spleen and kidneys) during the first 24 hours. The highest titre outside of 
tumour was seen in the lungs, with live virus present for at least three days. Importantly, 
VVL15∆N1L was cleared by the host to a greater extent than VVL15 in off-target 
organs. There was no live virus in the brains of CT26 tumour bearing mice and although 
live virus was demonstrated in the brains of LLC bearing animals, deletion of the N1L 
gene appeared to moderately reduce titres as expected from the literature (see section 
1.5.7)  
 
Despite enhanced host clearance of live VVL15∆N1L virus from LLC tumours, IV 
delivery did retain the capacity to stimulate a superior antitumour immune response in 
comparison VVL15.  However, as with the IT treatment of flank LLC tumour bearing 
mice, this enhancement did not translate into superior efficacy upon IV treatment of its 
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orthotopic counterpart. The LLC model is extremely aggressive and the time needed to 
generate an efficacious effector immune response is likely to far exceed that required to 
cause the demise of the animal by tumour dissemination. Nonetheless, given the 
reduced off-target replication of VVL15∆N1L it may be possible to safely administer 
higher IV doses compared to VVL15. LD50 (dose for lethality in 50% of animals) 
experiments using escalating doses of IV virus will need to be performed in order to 
establish a safe dosage window; which could then be extrapolated to the first in-human 
trials. 
 
One of the “hallmarks” of cancer is their ability to metastasize (47). The next 
experiment demonstrated that although IT VVL15∆N1L was unable to restrict the 
growth of primary tumour, it did reduce metastases from the primary. Histological 
examination of murine lungs at the end point of the experiment, demonstrated a higher 
proportion of tumour free lungs following treatment with VVL15∆N1L. Explanations 
could include blockage of peritumour vasculature by leucocyte (granulocyte in 
particular) infiltrates, enhanced numbers and activity of circulating NK cells and/ or 
indeed enhanced adaptive anti-tumour surveillance. Regardless of the mechanisms, 
given the above result, we postulated that VVL15∆N1L might be a good neoadjuvant to 
conventional antitumour therapy, including surgery.  
 
Interestingly, numerous animal studies have demonstrated that surgical manipulation 
can enhance post-operative metastases (288, 307). As detailed in the introduction, there 
may be a number of reasons for this including intraoperative seeding, enhanced 
secretion of pro-metastatic growth factors and immune suppression. Surgical damage is 
inflammatory and should theoretically release cellular “danger signals”, but other sub-
components of the innate immune response may be dampened e.g. the NK response 
(288, 307, 310). Neoadjuvant virotherapy could tip the balance into one that favours 
eradication of in situ microscopic disease. In one study the concurrent administration of 
WRDD, reversed the dampened NK response associated with major surgery and was 
able to reduce metastatic dissemination (310). In that experiment virus was 
administered just a few hours prior to surgery. This may cause two problems upon 
translation to human patients: a) systemic high dose virotherapy may be hazardous in 
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the setting of prolonged surgery under general anaesthesia, and b) excision of the 
tumour bed (and thus virally released TAAs) so soon following OVT may preclude the 
priming of long term tumour specific adaptive immunity.  
 
Our preliminary results demonstrated a significant short term survival benefit for mice 
pre-treated with VVL15∆N1L prior to surgical excision of their primary tumour. This 
effect was mediated by the elevation of circulating NK cells as demonstrated by the 
complete abrogation of response when the experiment was repeated in mice in which 
NK cells were depleted. A further important experiment that should be performed is to 
test whether VVL15∆N1L treatment also enhances the activation of NK cells. 
 
Tumour regrowth after re-implantation of primary cancer cells in survivors from the 
neoadjuvant surgical cohort was positively associated with diminished antitumour 
immunity. Indeed only 20% of total mice treated with VVL15∆N1L could overturn the 
immune dampening effect of surgery (see figure 3.49) and developed the ability to 
reject a novel tumour challenge, so there remained significant room for improvement. 
 
In a bid to explore some of the mechanisms responsible for the efficacy of 
VVL15∆N1L, biological time-point experiments were performed following the IT 
injection of syngeneic flank LLC tumour models. Intratumoural neutrophil infiltration 
following virotherapy was not unexpected from the literature and VVL15∆N1L 
appeared to enhance this response (see below). The prolonged presence of neutrophils 
within TMEs have been associated with tumour progression via multiple mechanisms 
(366) and it is interesting to note that KC, a murine neutrophil chemoattractant was 
constitutively secreted by LLC and DT6606 tumour cells in vitro. Analogous to 
GMCSF, in the resting state KC may act as an autocrine growth factor in these models. 
In contrast, hyper recruitment and stimulation of neutrophils, as occurs following 
virotherapy, has been associated with tumour cell cytotoxicity and suppression (367). 
The latter has been attributed to mechanisms such the mechanical blockage of tumour 
vessels, excess release of cytotoxic agents, enhanced antigen dependent cellular 
cytotoxicity (ADCC) in the presence of antitumour antibodies, or indeed through a 
phenotypic switch of neutrophils to being able to present antigens (368-370).     
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Interestingly there was a reciprocal reduction in the IT macrophage pool following 
administration of VVL15∆N1L (and to a lesser extent VVL15) in DT6606 tumours. 
This may have been an artefactual consequence of the flow cytometric gating strategy 
used to quantify intra-tumour leucocytes. The monocyte pool, expressed as a percentage 
of CD45+ cells may have been artificially lowered by the disproportionately large 
neutrophil response following VVL15∆N1L administration. Immunohistochemical 
scrutiny of tumour sections following VVL15∆N1L treatment did confirm substantial 
infiltration by (F4/80+) macrophages (figure 4.1) although qualitatively less so in 
comparison to other treatment groups.  
 
 
 
Figure 4.1 Qualitative reduction of IT macrophages following IT VVL15∆N1L  
Syngeneic LLC flank tumours were treated with 1x108 PFUs of IT virus or the equivalent volume of PBS. 
Fourteen days later, frozen sections of harvested tumour were immunostained with anti F4/80 antibodies 
(x200 magnification).  
 
 
Until recently it was thought that monocytes, macrophages and DCs could not support 
VV replication, although early genes like N1L could still be expressed (262, 371-374). 
However Byrd et al. (375) recently confirmed that tissue macrophages may indeed be a 
significant source of viral load in vivo and that VV can in fact replicate in and lyse 
monocytes and macrophages, particularly those of the tumour promoting M2 
phenotype. There is an abundance of literature documenting the role of these 
macrophages in tumour progression (376). A relatively select reduction of this pool 
through infection with VVL15∆N1L might have been an additional mechanism 
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responsible for the efficacy seen with VVL15∆N1L in this project. This hypothesis will 
obviously require formal investigation.    
 
Thus far, IT administered VVL15∆N1L appeared to enhance the stimulation of anti-
tumour adaptive immunity without altering antiviral immunity. One explanation might 
be that presentation of TAAs in this context is predominantly mediated by activated 
DCs, whereas viral epitopes could additionally be presented by monocytes/ 
macrophages. In our studies, VVL15∆N1L enhanced splenic DCs in vivo as well as 
their activation in vitro. In vivo, the consequent rise in viral epitope presentation may 
have been offset by the reduction in viral antigen presentation by the reduced pool of 
monocytes/ macrophages. Again further detailed studies will be required to test this 
hypothesis; although it should be noted that some groups have contrastingly 
demonstrated the importance of CD169+ intra-nodal macrophages in the presentation of 
TAAs from dead tumour cells, albeit in a non-viral context (377, 378).   
 
Another explanation for the selective enhancement of antitumour immunity might relate 
to the expression of IL10. IL10 is widely regarded as an immunosuppressive cytokine 
and in the current context may supress the potentially toxic antiviral immune response, 
ensuring host and therefore viral survival. Infection with VVL15∆N1L enhanced IL10 
production from DCs and monocytes in particular, a result that was originally reported 
with a WR strain of VV (262). Furthermore, we have recently shown that IT 
administration of a different (N1L intact) VVL15 recombinant, armed with an IL10 
transgene similarly enhanced the generation of antitumour adaptive immunity at the 
expense of antiviral immunity (379). The rise in local IL10, associated with deletion of 
the N1L gene may therefore have caused a relative dampening of the vastly 
immunodominant antiviral immune response. 
 
A screen of inflammatory cytokines and chemokines within virally infected LLC flank 
tumours revealed the selective enhancement of KC, GCSF, IL1α/β and MIP1α. These 
are all regulated by NF-κB transcription factors and their expression might have been 
expected to be enhanced given the suppressive effect of the N1L protein on this 
pathway (247).  
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Based on their well characterised functions, enhanced production of KC (mainly from 
infected tumour cells) and GCSF were most likely to be responsible for the enhanced 
infiltration of intratumoural neutrophils seen in vivo following VVL15∆N1L infection. 
MIP1α is a chemo attractant produced mainly by infected/ activated monocytes, 
macrophages and dendritic cells. In addition to DCs and monocytes, it also recruits NK 
and T cells (190, 342). It is possible that that this cytokine may have been responsible 
for the elevation of circulating NK cells following IT VVL15∆N1L. Further studies 
using inhibitory molecules, mRNA silencing techniques and/or transgenic mice will be 
required to confirm this.  
 
Interestingly, VVL15∆N1L infection upregulated the expression of the IL1 family of 
cytokines from both DCs and APCs:  IL1α, IL1β and IL18. The latter two are surrogate 
markers for the activation of inflammasome platforms. Inflammasomes are a group of 
multimeric protein complexes (consisting of a pattern recognition receptor molecule, the 
adaptor protein ASC and caspase-1, that form in response to a range of exogenous and 
endogenously generated pathogen or damage associated molecules (247, 346). 
Activated caspase-1, in turn cleaves and activates IL1β and IL18 precursor molecules 
which are subsequently secreted. Interestingly, hyperactivation of inflammasome 
complexes may lead to a particularly immunogenic form of cell death called pyroptosis 
(344). On the other hand, chronic signalling through both NF-κB pathways and 
inflammasome complexes have been associated with  perpetuation and growth of 
tumour (344).  
 
Although transcription of the precursor, pro IL1β gene is under the control of NF-κB 
transcription factors, pro-IL18 mRNA is constitutively expressed and appears to have 
different regulatory controls (346). The fact that in our studies IL18 was also 
upregulated by VVL15∆N1L infection, suggests that the N1L protein may additionally 
regulate inflammasome signalling. Interestingly, the F1L protein, another VV 
antiapoptotic Bcl-2 structural homologue, has recently been shown to specifically 
inhibit the NLRP1 inflammasome complex (345). In the defining study, the authors 
utilised a re-constituted in vitro model to isolate the activity this particular 
inflammasome complex. They also noted the inability of the N1L protein to alter 
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signalling through this complex. However there are numerous other candidate 
inflammasomes; for example the largest inflammasome (NLRP3) is oligomerised by a 
wide range of stimuli including viruses and bacteria and would be a good starting point 
for further functional studies of the N1L protein. It would also be intriguing to 
investigate whether VVL15∆N1L could induce pyroptotic cell death, an established 
form of ICD.  
 
To summarize, thus far VVL15∆N1L retained its ability to replicate in and lyse a range 
of tumour cells and has the potential to convert an immunosuppressive TME into one 
that favours the generation of an antitumour immune response (both innate and 
adaptive). This translated into tumour growth reduction in a primary model of 
pancreatic cancer and a prolongation of post-operative survival when used as 
neoadjuvant therapy to surgery in a spontaneously metastasising lung cancer model. 
The former was mediated by CD8+ cells whereas the latter by enhanced circulating NK 
cells.  
 
The data obtained has recently encouraged a switch by our research group from the use 
of VVL15 to the VVL15∆N1L platform, upon which other VVL based therapeutics will 
be constructed in the future.  
 
The final results chapter included some preliminary experiments with murine GMCSF 
or IL12 transgene armed VVL15∆N1L viruses. Intratumoural injection of VVL15-
mIL12 into syngeneic DT6606 flank models boosted tumour specific adaptive 
immunity above that afforded by VVL15-mGMCSF and VVL15∆N1L. IFNγ 
production from whole DT6606 cell/ mesothelin peptide stimulated splenocytes was 
enhanced, as was the percentage of effector memory CD8+ T cells following both 
single and multiple doses of VVL15-mIL12. VVL15-mIL12 appeared to globally 
enhance the CD8+ pool of T cells.  
 
As with previous experiments, there was no enhancement of the antiviral (anti B8R) 
immune response. Given the dramatic elevation in IFNγ following splenocyte 
stimulation with growth arrested DT6606 cells, it is likely therefore that a significant 
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proportion of elevated CD8+ effector memory T cells were clones with specificity for 
tumour epitopes, although on this occasion, flow cytometric analysis did not reveal a 
significant enhancement in a mesothelin peptide specific pool of CD8+ T cells. 
Assuming this was a true result, it may have reflected the disproportionate expansion of 
other more immunogenic TAA specific CD8+ T cells. 
 
The percentage of in vivo splenic DCs, as well as their in vitro activation was enhanced 
by treatment with VVL15-mGMCSF, which also expressed its transgene following the 
in vitro infection of DCs and monocytes. Theoretically, early treatment of tumours with 
VVL15-mGMCSF followed by the sequential administration of VVL15-mIL12 should 
have provided optimal boosts to afferent and efferent arms of a developing immune 
response respectively. Such a sequence of administration into syngeneic flank DT6606 
tumours surprisingly did not translate into the most efficacious regime. Instead, early 
and prolonged administration of VVL15-mIL12 was most efficacious. The effects of 
IL12 on enhancing innate as well as adaptive immunity are well established, i.e. the 
cytokine has been shown to enhance APC activation and the proliferation and activation 
of NK cells (141, 226). 
  
Of note, VVL15-mGMCSF was unable to enhance antitumour immunity or efficacy 
above that due to VVL15∆N1L. Its replication in DT6606 tumour cells was comparable 
to VVL15-mIL12 and it was able to express its cytokine armed transgene in this cell 
line to even greater levels than its IL12 armed counterpart. mGMCSF was functional as 
demonstrated by its ability to enhance DC or monocyte activation in vitro as well as 
enhance the splenic pool of DCs in vivo.  
 
Cytotoxicity assays however, revealed that VVL15-mGMCSF was significantly worse 
than VVL15-mIL12 at killing murine tumour cell lines in vitro and this may have been 
a contributing factor to its poorer response. A reduction in oncolysis implies a reduced 
burden of TAAs and danger signals. Additionally, DT6606 cells constitutively secrete 
low levels of mGMCSF and in the corresponding in vivo tumour model this cytokine 
may play a role in promoting tumour growth (380, 381). This is of translational 
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significance given the fact that some of the most clinically advanced viral therapeutics 
(i.e. T-Vec (287), JX-594 (92)) carry the human version of this transgene. 
 
VVL15-mIL12 retained its parent platform’s capacity to reduce metastatic 
dissemination from primary flank LLC tumours. However, unlike VVL15∆N1L or 
VVL15-mGMCSF, it was also able to slow the growth of the primary tumour. 
Furthermore, its use in a neoadjuvant setting appeared to prolong the long term survival 
of mice following surgical resection of the primary. Seven out of eight mice were alive 
at 90 days post-operatively. Although not explicitly tested, the latter result could have 
either been due to a vastly enhanced NK response and/or the generation of longer term 
antitumour T cell mediated immune surveillance. These fundamentally different 
mechanisms of action will be imminently investigated by our group; in the first instance 
through biological time-point and immune cell subset depletion experiments analogous 
to those already performed in this project. 
 
A note of caution must be made with regards the systemic administration of 
VVL15∆N1L based recombinant viruses. Although substantial efficacy was seen 
following IT delivered VVL15∆N1L, particularly against the DT6606 pancreatic 
tumour model, IV delivered virus however was not able to slow tumour growth (data 
not shown). The IV dosage however in the latter experiment was limited to only three 
alternate-daily doses. We found that daily administration of 1x108 PFUs of virus was 
too toxic for the mice (especially with the cytokine transgene armed recombinants) and 
more practically, mouse tail veins were completely thrombosed after the third IV dose.  
 
The current project and previous work by our group revealed that a substantial quantity 
of VV virion is sequestered upon “first-pass” in the reticuloendothelial system 
following IV administration. Splenic macrophages in particular appeared to be a 
significant barrier for delivery to peripherally located tumours (Ferguson et al. 
unpublished data). Interestingly, temporary inhibition of macrophage function (through 
selective PI3Kinase inhibition) enhanced tumour uptake of IV administered VVL15 and 
slowed tumour growth (Ferguson et. al. unpublished data). Intravenous VVL15∆N1L 
based viruses will be incorporated into a similar protocol in the near future. 
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Although systemic administration has yet to be optimised, VVL15-mIL12 when 
administered via the IT route was the most promising of all the VVL platforms tested in 
this project. Before conducting human trials with its human cytokine armed counterpart, 
further animal studies will be required. Indeed, using data from this project, our group 
has recently secured a Developmental Pathway Funding Scheme grant from the Medical 
Research Council, to further evaluate and optimise vaccination strategies using these 
and other recombinant viruses in a neoadjuvant surgical setting. We plan to use a 
syngeneic subcutaneous mouse model of a spontaneously metastasising head and neck 
cancer (SCCVII) as a prelude to treating a histologically similar orthotopic model in 
Syrian hamsters. The HCPC-1 cell line is a Syrian hamster cheek pouch derived 
epidermoid carcinoma that can metastasise to lungs following its orthotopic 
implantation (382, 383). These oral tumours are morphologically closer to their human 
counterparts than the equivalent mouse or rat alternatives (383). Hamster immunity is 
also functionally closer to humans than rodent species and importantly is able to 
respond to some human cytokines like GMCSF (384, 385). Indeed we have recently 
demonstrated that human IL12 is capable of inducing antitumour immunity in a 
syngeneic Syrian hamster pancreatic cancer model but not in a murine counterpart 
(Wang et al., unpublished data). 
 
It is hoped that the above will lead to an investigational new drug (IND) application 
followed by early phase clinical trials, which in the first instance, due to our group’s 
strong collaboration with local and regional head and neck cancer units, will likely 
involve this patient population.                 
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 Future strategies to realise the anticancer potential of oncolytic viruses  4.2
 
Waning optimism for OVT has recently been re-ignited by novel strategies to realise 
their potential to cross stimulate an antitumour effector immune response. 
 
Two notable GMCSF cytokine transgene armed viruses are amongst the most advanced 
in stages of clinical testing.  
 
T-Vec is a γ134.5 gene deficient HSV (386). Monotherapeutic treatment of advanced 
malignant melanoma led to complete remission of primary and distant metastatic 
nodules in eight of 50 patients (287). This led to a phase three trial of advanced 
malignant melanoma patients, which demonstrated a six-month response rate of 16% 
(compared to 2% for patients treated with GMCSF alone) (387). A phase one/two trial 
with ipilimumab (an anti-CTLA4 inhibitory antibody) in patients with malignant 
melanoma was underway at the time of writing (146). In head and neck cancer, an 
uncontrolled phase two trial of T-Vec in combination with chemo-radiotherapy led to a 
93% complete pathological response (388).  
 
The vaccinia viral platform has also shown promise as an anticancer therapeutic in 
clinical trials (6). JX-594, a Wyeth strain recombinant, armed with a human GMCSF 
transgene, is the most advanced of these (92). It has recently demonstrated a dose 
dependent survival advantage following IT injection into hepatocellular carcinomas 
(HCC) in a randomised phase two, dose finding trial (median survival 14.1 months in 
the high dose, versus 6.7 months in the low dose group) (389). Additionally, it also 
demonstrated tumour-targeted replication following IV administration (282). This 
occurred in some cases despite the pre-existence of neutralizing antibodies. In these 
trials efficacious responses were only consequent to very high doses of viruses and long 
term survival data have yet to be accrued.  
  
Wild type reovirus (serotype 3-Dearing, Reolysin® Oncolytics Biotech), a dsRNA virus 
is another promising platform that features prominently in the literature. Its selectivity is 
based on defects in the RAS pathway in tumour cells. Its segmental dsRNA genome 
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does not lend itself to genetic manipulation, although it is systemically active and can 
promote protective antitumour immunity (194). An important phase three trial involving 
IV Reolysin® in combination with paclitaxel and carboplatin for patients with platinum 
refractory head and neck cancers has just been completed according to the Oncolytics 
Biotech website (http://www.oncolyticsbiotech.com/clinical-trials/default.aspx). The 
data has yet to be publically released.  
 
GL-ONC1 (GLV-1h68) is the first recombinant Lister strain virus to enter clinical trials. 
At the time of writing recruitment was ongoing for four dose escalating phase one trials. 
Two were designed to examine the effect of IV administered virus in patients with 
either advanced disseminated solid tumours of various types 
(http://www.clinicaltrials.gov; trial identifier: NCT00794131) or in combination with 
cisplatin and radiotherapy of head and neck cancer (http://www.clinicaltrials.gov; trial 
identifier: NCT01584284). Early reports from both trials indicated that IV virus was 
well tolerated, with some evidence of viral delivery to tumour (390, 391). The other two 
were aimed at treating patients with malignant pleural or peritoneal carcinomatosis via 
intrapleural (http://www.clinicaltrials.gov; trial identifier: NCT01766739) and 
intraperitoneal (http://www.clinicaltrials.gov; trial identifier: NCT01443260) routes 
respectively.  
 
Although some clinical trials with OVT have produced exciting results, many have 
ultimately disappointed and indeed none of the viral platforms have yet to achieve 
United States Food and Drug Administration (FDA) approval. OVs as monotherapy are 
unlikely to cure advanced tumours, but may find a role in the potentiation of existing 
therapeutic agents or be one component of novel immunotherapeutic strategies; some of 
which are discussed below. 
 
4.2.1 Combination with chemotherapeutic agents 
 
In many clinical trials, OVTs have been introduced in conjunction with the current 
standard of care in advanced cancers: usually chemotherapeutic agents. We introduced a 
discussion of the use of VVL derivatives in conjunction with chemotherapeutic agents 
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in section 1.4.2. This section elaborates that discussion in an attempt to stimulate further 
avenues of investigation to improve the therapeutic potential of our novel recombinant 
viruses.  
 
Chemotherapeutic agents inhibit mitosis, damage DNA, and ultimately cause cell death 
via a multitude of mechanisms. Given they may directly damage the viral genome or 
prematurely eliminate the host cell; combination with OVs should theoretically not be 
synergistic. However, the efficacy of such combinations may not solely be due to the 
potentiation of cellular cytotoxicity (99, 392). In some situations chemotherapeutics 
may remove barriers to successful viral infection, weaken immunosuppressive forces or 
even enhance antitumour immune priming.  
 
Chemotherapeutics may inadvertently supress antiviral immunity and therefore enhance 
viral spread. For example, histone deacetylase inhibitors (HDACIs), as well as 
enhancing histone acetylation and thus chromatin modulation, often cause the 
acetylation and inhibition of proteins involved in key antiviral pathways, for example 
the type 1 IFN response (393). In one study their concurrent use with HSV reduced the 
infiltration and activation of NK cells (394). Cyclophosphamide, a DNA alkylating 
agent induces apoptotic cell death. At high doses, for example it was shown to limit host 
antiviral immunity (especially neutralising antiviral antibodies) and enhanced the 
persistence, dissemination and therapeutic benefit of a recombinant VV (395).  
 
Chemotherapeutic agents may also enhance the ability of OVs to reverse immune 
tolerance to TAAs. One mechanism might operate through the selective inhibition of 
immune suppressive cells within the TME. Thus cyclophosphamide, paclitaxel and 
temozolomide can successfully reduce T-regs when delivered in repeated low doses 
(396-398), which in the case of cyclophosphamide mitigates the toxic effects of global 
immunosuppression following high solitary doses. Low repeated dosing of 
cyclophosphamide has also been shown to restore T and NK cell effector function in 
advanced cancer patients (399). In the context of OVT, preconditioning of mice with 
either cyclophosphamide or anti-CD25 monoclonal antibodies to deplete T-regs, 
enhanced the efficacy of reovirus, VSV and adenovirus therapy (400-402). 
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 In healthy tissue, MDSCs protect the host by dampening the inflammatory response to 
pathogens; but in the TME they are tumour promoting and may supress induced 
antitumour effector T cells (403). Furthermore, they may promote the expansion of T-
regs and M2 macrophages (404, 405). MDSCs can be depleted by treatment with 
chemotherapeutic agents such as gemcitabine, sunitinib, 5-FU and docetaxel (392) 
which if administered concurrently with OVT appears to enhance the survival of 
preclinical animal models (406).  
 
Some chemotherapy drugs may have multiple non-canonical effects within the 
transformed cell that may benefit concurrent OVT e.g. paclitaxel treatment causes the 
up regulation of class I MHC and indeed other components of the antigen presentation 
pathway (407) and may reduce the threshold for immune activation. Interestingly, 
others such as doxorubicin may decrease the expression of immune checkpoint ligands 
PD-L1, reducing their inhibition of TILs (408).  
 
Like OVTs, certain chemotherapeutics (e.g. anthracyclines and platinum based drugs) 
may induce a state of “pre mortem” cellular stress, associated with the surface 
expression of and release of DAMPs characteristic of immunogenic cell death (see 
section 1.5.5) (409) and may ultimately lead to the generation of potent tumour specific 
immunity (410). The combination of such drugs with OVT may synergistically boost 
antitumour immunogenicity (411).  
 
Although appealing, combination therapy with OVTs may not be beneficial in all 
circumstances. For example, low dose CPA may clear T-regs, but this may promote 
antiviral immunity leading to viral clearance. Conversely, high dose cyclophosphamide 
mediated immunosuppression may prolong viral survival and thus oncolysis, but may 
impair the development of antitumour immunity (125, 166).  
 
Although potentially exciting a great deal of translational research needs to be 
performed in order to determine the optimal combination(s) of chemo-OVT and in 
particular chemo-VVL recombinant viral therapy. This is certainly one line of 
investigation that our group intends to perform in the near future.   
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4.2.2 Other immunomodulatory strategies 
 
As previously discussed, a potential problem with using a single viral platform in both 
prime and boost phases of a tumour vaccination regime, even with a loaded autoantigen 
(that would be expressed at high levels within the TME), is that the secondary 
antitumour immune response may be swamped by an even greater magnitude antiviral 
response (44). The use of different viral vectors in priming and booster phases of 
therapy has been previously discussed in the context of generating an immune response 
to a single tumour antigen and remains a very promising strategy. Our group has 
recently demonstrated the complete eradication of a syngeneic subcutaneous pancreatic 
tumour model in a hamster host using a heterologous prime-boost regime with a 
recombinant adenovirus followed by VVL15  (412). Antitumour immune memory was 
generated as evidenced by no tumour regrowth following subsequent tumour cell re-
challenge, whilst immune cell subset depletion experiments confirmed the critical role 
of T cells. Unlike other similar studies, these viruses were not armed with a tumour 
antigen-encoding transgene and therefore illustrated for the first time that a 
heterologous prime-boost regime tailored to whole tumour cells (as opposed to a single 
tumour antigen) was indeed possible in the face of two antigenically different but 
strongly immunogenic OVs, administered in a favourable sequence. Although similar 
results were obtained by our group in other syngeneic murine and hamster tumour 
models, complete abrogation of tumour was not universal. The therapeutic regime being 
developed in the current project might ideally fit into the “vaccinia” slot of this 
heterologous prime boost strategy. 
 
The relative clinical success of immune checkpoint inhibition, confirmed the curative 
potential of tumour immunotherapy. Thus a CTLA4 blocking antibody ipilimumab 
demonstrated promise in a phase three trial in patients with advanced malignant 
melanoma (413) and was the first in class to obtain FDA approval. A small proportion 
of patients were completely cured. CTLA4 on the surface of T cells acts as an “off 
switch” upon binding the costimulatory molecules CD80 or CD86 found on APCs. 
CTLA4 is abundantly expressed on T-regs, but interestingly in this pool of cells anti 
CTLA4 antibodies can lead to their depletion (414, 415). 
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Immune checkpoint inhibition lends itself to augment the antitumour immunogenic 
potential of OVT and indeed vice versa. This was tested recently with Newcastle 
Disease Virus (NDV) in a preclinical model of malignant melanoma. NDV injection 
into B16 tumours channelled the infiltration of CD4+ and CD8+ lymphocytes into both 
injected and uninjected tumours and thereby loosely focussed the systemically 
administered CTLA4 antibodies to the TME (416). T-Vec is currently being used in 
conjunction with ipilimumab in a randomised phase two clinical trial 
(http://www.clinicaltrials.gov; trial identifier: NCT01740297). 
 
An immune checkpoint that has hitherto received little investigation in the context of 
virotherapy is PD-1(on T cells)/ PD-L1. This could be directly inhibited by PD1 
antibodies or indirectly via the sequestration of PD-L1 by soluble PD1 receptor 
molecules. Genes coding for the inhibitory antibody (against CTLA4 or PD1) or the 
decoy PD1 receptor, could be transcribed into an OV and hence the disinhibition of 
antigen triggered T cells would be localised to the TME following administration of the 
virus. Our group is currently investigating this strategy with VVL recombinant viruses. 
  
Regardless of whether we ultimately chose to translate our work with single viral or 
heterologous viral platforms, or indeed in combination with other 
immunochemotherapeutics, OVT may find most success if it is used early on in the 
disease process, perhaps in a neoadjuvant setting; in patients whose immune systems 
have not been compromised by advanced cancer or treatment. The therapeutic could be 
administered with little hindrance to existing patient treatment protocols. Recombinant 
VVL15∆N1L mediated oncolysis could commence the priming of antitumour immunity 
to establish long term surveillance, as well as to combat MRD following eradication of 
the primary tumour by other modalities. A significant cause of cancer mortality is due to 
recurrence of tumour following apparent eradication, often many years later. It is this 
group of patients that may be the ultimate beneficiaries of our and other groups work 
with OVT.   
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 Conclusion 4.3
 
The results from experiments conducted in this project provide optimism for the 
potential use of VVL15∆N1L as a platform upon which to build a novel set of 
immunogenic oncolytic VVL recombinants; a set of viruses that could potentially focus 
both innate and adaptive arms of a developing host antitumour immune response into 
the TME. The IL12 armed VVL15∆N1L recombinant holds particular promise as a 
treatment modality against pancreatic and other solid cancers. Excitingly VVL15-IL12 
has also demonstrated dramatic efficacy as a neoadjuvant to oncologic surgery, where 
its properties may minimise post-operative tumour metastasis and prevent long term 
recurrence; from which many patients with solid cancers ultimately succumb. 
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Appendix  
 
Sequences of pUC19 based VV super-shuttle vectors 
 
 
 
1. The sequenced insert cassette between L024 and L026 genes in  
pUC19- LA-H5-H5-RFP-H5- RA 
 
Key:  
L024-Overlap-L025(remnant)-H5-H5-RFP-H5-L025(remnant)-L026 
See section 3.1 for further details and abbreviations 
 
AATGTTTCTTTGGTTATACTAGTATAGTCACTATCGGACAAATAAAGAAAAT
CAGATGATCGATGAATAATACATTTAAATTCATCATCTGTAAGATTTTTGAG
ATGTCTCATTAGAATATTATTAGGGTTAGTACTCATTATCATTCGGCAGCTA
TTACTTATTTTATTATTTTTCACCATATAGATCAATCATTAGATCAAAAATTG
AAAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAAT
AATCATAAATAGTCGACAATCGAATTCCCGCGGCCGGGAATTCGATTAGAT
CTAAAAATTGAAAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAA
AGCGAGAAATAATCATAAATAGCTACCGGACTCAGATCCACCGGTCGCCAC
CATGGCCTCCTCCGAGGACGTCATCAAGGAGTTCATGCGCTTCAAGGTGCG
CATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCG
AGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAG
GGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCCCAGTTCCAGTACG
GCTCCAAGGTGTACGTGAAGCACCCCGCCGACATCCCCGACTACAAGAAGC
TGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACG
GCGGCGTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCTCCTTCAT
CTACAAGGTGAAGTTCATCGGCGTGAACTTCCCCTCCGACGGCCCCGTAATG
CAGAAGAAGACTATGGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCCGC
GACGGCGTGCTGAAGGGCGAGATCCACAAGGCCCTGAAGCTGAAGGACGG
CGGCCACTACCTGGTGGAGTTCAAGTCCATCTACATGGCCAAGAAGCCCGT
GCAGCTGCCCGGCTACTACTACGTGGACTCCAAGCTGGACATCACCTCCCAC
AACGAGGACTACACTATCGTGGAGCAGTACGAGCGCGCCGAGGGCCGCCAC
CACCTGTTCCTGTAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACAT
TTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCT
GAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTAT
AATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTT
TTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGG
CGAAAAATTGAAAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAA
AGCGAGAAATAATCATAAATAAAGCTTCCCGGGACGCGTATCTAATAAGTA
GAGTCCTCATGCTTAGTTAACAACTATTTTTTATGTTAAATCAATTAGTACA
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CCGCTATGTTTAATACTTATTCATATTTTAGTTTTTAGGATTGAGAATCAATA
CAAAAA_TTAATGCATCATTAATTTTAGAAATACTTAGTTTCCACGTAGTCA
ATGAAACATTTGAACTCATCGTACAGGACGTTCTCGTACAGGACGTAACTAT
AAACCGGTTTATATTTGTTCAAGATAGATACAAATCCGATAACTTTTTTTAC
GAATTCTACG 
 
 
 
 
2. The sequenced insert cassette between L024 and L026 genes in  
pUC19- LA-H5- mGMCSF -H5- RFP –H5 RA 
 
Key:  
L024-Overlap-L025(remnant)-H5-mGMCSF -H5-RFP-H5-L025(remnant)-L026 
See section 3.1 for further details and abbreviations 
 
 
TTTGGTTATACTAGTATAGTCACTATCGGACAAATAAAGAAAATCAGATGA
TCGATGAATAATACATTTAAATTCATCATCTGTAAGATTTTTGAGATGTCTC
ATTAGAATATTATTAGGGTTAGTACTCATTATCATTCGGCAGCTATTACTTA
TTTTATTATTTTTCACCATATAGATCAATCATTAGATCAAAAATTGAAAATA
AATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAATAATCAT
AAATAGTCGACAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCT
GAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGG
TGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGA
CCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCT
CCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCT
GTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCACC
GGTAGAGGGCCAACATGTGGCTGCAGAATTTACTTTTCCTGGGCATTGTGGT
CTACAGCCTCTCAGCACCCACCCGCTCACCCATCACTGTCACCCGGCCTTGG
AAGCATGTAGAGGCCATCAAAGAAGCCCTGAACCTCCTGGATGACATGCCT
GTCACGTTGAATGAAGAGGTAGAAGTCGTCTCTAACGAGTTCTCCTTCAAG
AAGCTAACATGTGTGCAGACCCGCCTGAAGATATTCGAGCAGGGTCTACGG
GGCAATTTCACCAAACTCAAGGGCGCCTTGAACATGACAGCCAGCTACTAC
CAGACATACTGCCCCCCAACTCCGGAAACGGACTGTGAAACACAAGTTACC
ACCTATGCGGATTTCATAGACAGCCTTAAAACCTTTCTGACTGATATCCCCT
TTGAATGCAAAAAACCAGGCCAAAAATGAGGAAGCCCAGCTAGCTCGACAT
GATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAA
AAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTGAAATTTG
TGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAAC
AACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAG
GTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAGATCCATTTAAATGT
TAATTAGATCTAAAAATTGAAAATAAATACAAAGGTTCTTGAGGGTTGTGTT
AAATTGAAAGCGAGAAATAATCATAAATAGCTACCGGACTCAGATCCACCG
GTCGCCACCATGGCCTCCTCCGAGGACGTCATCAAGGAGTTCATGCGCTTCA
AGGTGCGCATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCG
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AGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTG
ACCAAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCCCAGTTCC
AGTACGGCTCCAAGGTGTACGTGAAGCACCCCGCCGACATCCCCGACTACA
AGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCG
AGGACGGCGGCGTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCT
CCTTCATCTACAAGGTGAAGTTCATCGGCGTGAACTTCCCCTCCGACGGCCC
CGTAATGCAGAAGAAGACTATGGGCTGGGAGGCCTCCACCGAGCGCCTGTA
CCCCCGCGACGGCGTGCTGAAGGGCGAGATCCACAAGGCCCTGAAGCTGAA
GGACGGCGGCCACTACCTGGTGGAGTTCAAGTCCATCTACATGGCCAAGAA
GCCCGTGCAGCTGCCCGGCTACTACTACGTGGACTCCAAGCTGGACATCAC
CTCCCACAACGAGGACTACACTATCGTGGAGCAGTACGAGCGCGCCGAGGG
CCGCCACCACCTGTTCCTGTAGCGGCCGCGACTCTAGATCATAATCAGCCAT
ACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCC
TGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGC
AGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAA
AGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTAT
CTTAAGGCGAAAAATTGAAAATAAATACAAAGGTTCTTGAGGGTTGTGTTA
AATTGAAAGCGAGAAATAATCATAAATAAAGCTTCCCGGGACGCGTATCTA
ATAAGTAGAGTCCTCATGCTTAGTTAACAACTATTTTTTATGTTAAATCAAT
TAGTACACCGCTATGTTTAATACTTATTCATATTTTAGTTTTTAGGATTGAGA
ATCAATACAAAAA_TTAATGCATCATTAATTTTAGAAATACTTAGTTTCCAC
GTAGTCAATGAAACATTTGAACTCATCGTACAGGACGTTCTCGTACAGGAC
GTAACTATAAACCGGTTTATATTTGTTCAAGATAGATACAAATCCGATAACT
TTTTTTACGAATTCTACG 
 
 
 
 
3. The sequenced insert cassette between L024 and L026 genes in  
pUC19-LA-H5-H5-RFP-H5-mIL12- RA  
 
Key:  
L024-Overlap-L025(remnant)-H5-H5-RFP-H5-mIL12-L025(remnant)-L026 
See section 3.1 for further details and abbreviations 
 
 
TTTGGTTATACTAGTATAGTCACTATCGGACAAATAAAGAAAATCAGATGA
TCGATGAATAATACATTTAAATTCATCATCTGTAAGATTTTTGAGATGTCTC
ATTAGAATATTATTAGGGTTAGTACTCATTATCATTCGGCAGCTATTACTTA
TTTTATTATTTTTCACCATATAGATCAATCATTAGATCAAAAATTGAAAATA
AATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAATAATCAT
AAATAGTCGACAATCGAATTCGATTAGATCTAAAAATTGAAAATAAATACA
AAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAATAATCATAAATAG
CTACCGGACTCAGATCCACCGGTCGCCACCATGGCCTCCTCCGAGGACGTC
ATCAAGGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCGTGAACGGC
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CACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCAC
CCAGACCGCCAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCCTTCGCCTG
GGACATCCTGTCCCCCCAGTTCCAGTACGGCTCCAAGGTGTACGTGAAGCA
CCCCGCCGACATCCCCGACTACAAGAAGCTGTCCTTCCCCGAGGGCTTCAA
GTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACCCA
GGACTCCTCCCTGCAGGACGGCTCCTTCATCTACAAGGTGAAGTTCATCGGC
GTGAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACTATGGGCTGG
GAGGCCTCCACCGAGCGCCTGTACCCCCGCGACGGCGTGCTGAAGGGCGAG
ATCCACAAGGCCCTGAAGCTGAAGGACGGCGGCCACTACCTGGTGGAGTTC
AAGTCCATCTACATGGCCAAGAAGCCCGTGCAGCTGCCCGGCTACTACTAC
GTGGACTCCAAGCTGGACATCACCTCCCACAACGAGGACTACACTATCGTG
GAGCAGTACGAGCGCGCCGAGGGCCGCCACCACCTGTTCCTGTAGCGGCCG
CGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTT
TAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAA
TTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAA
TAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGT
GGTTTGTCCAAACTCATCAATGTATCTTAAGGCGAAAAATTGAAAATAAAT
ACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAATAATCATAAA
TAAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTG
AGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGT
GCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGAC
CGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTC
CACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTG
TTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACGTAAGTGATATC
TACTAGATTTATCAAAAAGAGTGTTGACTTGTGAGCGCTCACAATTGATACT
TAGATTCATCGAGAGGGACACGTCGACTACTAACCTTCTTCTCTTTCCTACA
GCTGAGATCACCGGCGAAGGAGGGCCACCATGGGTCAATCACGCTACCTCC
TCTTTTTGGCCACCCTTGCCCTCCTAAACCACCTCAGTTTGGCCAGGGTCATT
CCAGTCTCTGGACCTGCCAGGTGTCTTAGCCAGTCCCGAAACCTGCTGAAGA
CCACAGATGACATGGTGAAGACGGCCAGAGAAAAGCTGAAACATTATTCCT
GCACTGCTGAAGACATCGATCATGAAGACATCACACGGGACCAAACCAGCA
CATTGAAGACCTGTTTACCACTGGAACTACACAAGAACGAGAGTTGCCTGG
CTACTAGAGAGACTTCTTCCACAACAAGAGGGAGCTGCCTGCCCCCACAGA
AGACGTCTTTGATGATGACCCTGTGCCTTGGTAGCATCTATGAGGACTTGAA
GATGTACCAGACAGAGTTCCAGGCCATCAACGCAGCACTTCAGAATCACAA
CCATCAGCAGATCATTCTAGACAAGGGCATGCTGGTGGCCATCGATGAGCT
GATGCAGTCTCTGAATCATAATGGCGAGACTCTGCGCCAGAAACCTCCTGT
GGGAGAAGCAGACCCTTACAGAGTGAAAATGAAGCTCTGCATCCTGCTTCA
CGCCTTCAGCACCCGCGTCGTGACCATCAACAGGGTGATGGGCTATCTGAG
CTCCGCCGTTCCTGGAGTAGGGGTACCTGGAGTGGGCGGATCTATGTGGGA
GCTGGAGAAAGACGTTTATGTTGTAGAGGTGGACTGGACTCCCGATGCCCC
TGGAGAAACAGTGAACCTCACCTGTGACACGCCTGAAGAAGATGACATCAC
CTGGACCTCAGACCAGAGACATGGAGTCATAGGCTCTGGAAAGACCCTGAC
CATCACTGTCAAAGAGTTTCTAGATGCTGGCCAGTACACCTGCCACAAAGG
AGGCGAGACTCTGAGCCACTCACATCTGCTGCTCCACAAGAAGGAAAATGG
AATTTGGTCCACTGAAATTTTAAAAAATTTCAAAAACAAGACTTTCCTGAAG
TGTGAAGCACCAAATTACTCCGGACGGTTCACGTGCTCATGGCTGGTGCAA
AGAAACATGGACTTGAAGTTCAACATCAAGAGCAGTAGCAGTCCCCCCGAC
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TCTCGGGCAGTGACATGTGGAATGGCGTCTCTGTCTGCAGAGAAGGTCACA
CTGGACCAAAGGGACTATGAGAAGTATTCAGTGTCCTGCCAGGAGGATGTC
ACCTGCCCAACTGCCGAGGAGACCCTGCCCATTGAACTGGCGTTGGAAGCA
CGGCAGCAGAATAAATATGAGAACTACAGCACCAGCTTCTTCATCAGGGAC
ATCATCAAACCAGACCCGCCCAAGAACTTGCAGATGAAGCCTTTGAAGAAC
TCACAGGTGGAGGTCAGCTGGGAGTACCCTGACTCCTGGAGCACTCCCCAT
TCCTACTTCTCCCTCAAGTTCTTTGTTCGAATCCAGCGCAAGAAAGAAAAGA
TGAAGGAGACAGAGGAGGGGTGTAACCAGAAAGGTGCGTTCCTCGTAGAG
AAGACATCTACCGAAGTCCAATGCAAAGGCGGGAATGTCTGCGTGCAAGCT
CAGGATCGCTATTACAATTCCTCATGCAGCAAGTGGGCATGTGTTCCCTGCA
GGGTCCGATCCTAGGATGCAACGGATGCTAGCTCGACATGATAAGATACAT
TGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTAT
TTGTGAAATTTGTGATGCTATTGCTTTATTTGTGAAATTTGTGATGCTATTGC
TTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGC
ATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCA
AGTAAAACCTCTACAAATGTGGTAGATCATTTGGGACGCGTATCTAATAAG
TAGAGTCCTCATGCTTAGTTAACAACTATTTTTTATGTTAAATCAATTAGTAC
ACCGCTATGTTTAATACTTATTCATATTTTAGTTTTTAGGATTGAGAATCAAT
ACAAAAA_TTAATGCATCATTAATTTTAGAAATACTTAGTTTCCACGTAGTC
AATGAAACATTTGAACTCATCGTACAGGACGTTCTCGTACAGGACGTAACT
ATAAACCGGTTTATATTTGTTCAAGATAGATACAAATCCGATAACTTTTTTT
ACGAATTCTACG 
 
 
 
 
4. The sequenced insert cassette between L024 and L026 genes in  
pUC19- LA-H5-H5-RFP-H5-hGMCSF- RA 
 
Key: 
L024-Overlap-L025(remnant)-H5-H5-RFP-H5-hGMCSF-L025(remnant)-L026 
See section 3.1 for further details and abbreviations 
 
 
TTTGGTTATACTAGTATAGTCACTATCGGACAAATAAAGAAAATCAGATGA
TCGATGAATAATACATTTAAATTCATCATCTGTAAGATTTTTGAGATGTCTC
ATTAGAATATTATTAGGGTTAGTACTCATTATCATTCGGCAGCTATTACTTA
TTTTATTATTTTTCACCATATAGATCAATCATTAGATCAAAAATTGAAAATA
AATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAATAATCAT
AAATAGTCGACAATCGAATTCCCGCGGCCGGGAATTCGATTAGATCTAAAA
ATTGAAAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAG
AAATAATCATAAATAGCTACCGGACTCAGATCCACCGGTCGCCACCATGGC
CTCCTCCGAGGACGTCATCAAGGAGTTCATGCGCTTCAAGGTGCGCATGGA
GGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCC
GCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGCGGC
CCCCTGCCCTTCGCCTGGGACATCCTGTCCCCCCAGTTCCAGTACGGCTCCA
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AGGTGTACGTGAAGCACCCCGCCGACATCCCCGACTACAAGAAGCTGTCCT
TCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCG
TGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCTCCTTCATCTACAA
GGTGAAGTTCATCGGCGTGAACTTCCCCTCCGACGGCCCCGTAATGCAGAA
GAAGACTATGGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCCGCGACGG
CGTGCTGAAGGGCGAGATCCACAAGGCCCTGAAGCTGAAGGACGGCGGCC
ACTACCTGGTGGAGTTCAAGTCCATCTACATGGCCAAGAAGCCCGTGCAGC
TGCCCGGCTACTACTACGTGGACTCCAAGCTGGACATCACCTCCCACAACG
AGGACTACACTATCGTGGAGCAGTACGAGCGCGCCGAGGGCCGCCACCACC
TGTTCCTGTAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGT
AGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAA
CATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATG
GTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTC
ACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGCGAA
AAATTGAAAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCG
AGAAATAATCATAAATAAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCG
CCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCC
GCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTA
AAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTA
GACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGT
CTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGC
CTACGTAAGTGATATCTACTAGATTTATCAAAAAGAGTGTTGACTTGTGAGC
GCTCACAATTGATACTTAGATTCATCGAGAGGGACACGTCGACTACTAACCT
TCTTCTCTTTCCTACAGCTGAGATCACCGGCGAAGGAGGGCCACCATGTGGC
TGCAGAGCCTGCTGCTCTTGGGCACTGTGGCCTGCAGCATCTCTGCACCCGC
CCGCTCGCCCAGCCCCAGCACGCAGCCCTGGGAGCATGTGAATGCCATCCA
GGAGGCCCGGCGTCTCCTGAACCTGAGTAGAGACACTGCTGCTGAGATGAA
TGAAACAGTAGAAGTCATCTCAGAAATGTTTGACCTCCAGGAGCCGACCTG
CCTACAGACCCGCCTGGAGCTGTACAAGCAGGGCCTGCGGGGCAGCCTCAC
CAAGCTCAAGGGCCCCTTGACCATGATGGCCAGCCACTACAAGCAGCACTG
CCCTCCAACCCCGGAAACTTCCTGTGCAACCCAGACTATCACCTTTGAAAGT
TTCAAAGAGAACCTGAAGGACTTTCTGCTTGTCATCCCCTTTGACTGCTGGG
AGCCAGTCCAGGAGTGAATTCGCTAGCTCGACATGATAAGATACATTGATG
AGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTG
AAATTTGTGATGCTATTGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTAT
TTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTC
ATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTA
AAACCTCTACAAATGTGGTAGATCATTTGGGACGCGTATCTAATAAGTAGA
GTCCTCATGCTTAGTTAACAACTATTTTTTATGTTAAATCAATTAGTACACCG
CTATGTTTAATACTTATTCATATTTTAGTTTTTAGGATTGAGAATCAATACAA
AAA_TTAATGCATCATTAATTTTAGAAATACTTAGTTTCCACGTAGTCAATG
AAACATTTGAACTCATCGTACAGGACGTTCTCGTACAGGACGTAACTATAA
ACCGGTTTATATTTGTTCAAGATAGATACAAATCCGATAACTTTTTTTACGA
ATTCTACG 
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5. The sequenced insert cassette between L024 and L026 genes in  
pUC19- LA-H5-H5-RFP-H5-hIL12-RA 
 
Key: 
L024-Overlap-L025(remnant)-H5-H5-RFP-H5-hIL12-L025(remnant)-L026 
See section 3.1 for further details and abbreviations 
 
 
TTTGGTTATACTAGTATAGTCACTATCGGACAAATAAAGAAAATCAGATGA
TCGATGAATAATACATTTAAATTCATCATCTGTAAGATTTTTGAGATGTCTC
ATTAGAATATTATTAGGGTTAGTACTCATTATCATTCGGCAGCTATTACTTA
TTTTATTATTTTTCACCATATAGATCAATCATTAGATCAAAAATTGAAAATA
AATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAATAATCAT
AAATAGTCGACAATCGAATTCCCGCGGCCGGGAATTCGATTAGATCTAAAA
ATTGAAAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAG
AAATAATCATAAATAGCTACCGGACTCAGATCCACCGGTCGCCACCATGGC
CTCCTCCGAGGACGTCATCAAGGAGTTCATGCGCTTCAAGGTGCGCATGGA
GGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCC
GCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGCGGC
CCCCTGCCCTTCGCCTGGGACATCCTGTCCCCCCAGTTCCAGTACGGCTCCA
AGGTGTACGTGAAGCACCCCGCCGACATCCCCGACTACAAGAAGCTGTCCT
TCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCG
TGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCTCCTTCATCTACAA
GGTGAAGTTCATCGGCGTGAACTTCCCCTCCGACGGCCCCGTAATGCAGAA
GAAGACTATGGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCCGCGACGG
CGTGCTGAAGGGCGAGATCCACAAGGCCCTGAAGCTGAAGGACGGCGGCC
ACTACCTGGTGGAGTTCAAGTCCATCTACATGGCCAAGAAGCCCGTGCAGC
TGCCCGGCTACTACTACGTGGACTCCAAGCTGGACATCACCTCCCACAACG
AGGACTACACTATCGTGGAGCAGTACGAGCGCGCCGAGGGCCGCCACCACC
TGTTCCTGTAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGT
AGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAA
CATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATG
GTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTC
ACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGCGAA
AAATTGAAAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCG
AGAAATAATCATAAATAAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCG
CCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCC
GCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTA
AAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTA
GACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGT
CTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGC
CTACGTAAGTGATATCTACTAGATTTATCAAAAAGAGTGTTGACTTGTGAGC
GCTCACAATTGATACTTAGATTCATCGAGAGGGACACGTCGACTACTAACCT
TCTTCTCTTTCCTACAGCTGAGATCACCGGCGAAGGAGGGCCACCATGGGTC
ACCAGCAGTTGGTCATCTCTTGGTTTTCCCTGGTTTTTCTGGCATCTCCCCTC
GTGGCCATATGGGAACTGAAGAAAGATGTTTATGTCGTAGAATTGGATTGG
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TATCCGGATGCCCCTGGAGAAATGGTGGTCCTCACCTGTGACACCCCTGAA
GAAGATGGTATCACCTGGACCTTGGACCAGAGCAGTGAGGTCTTAGGCTCT
GGCAAAACCCTGACCATCCAAGTCAAAGAGTTTGGAGATGCTGGCCAGTAC
ACCTGTCACAAAGGAGGCGAGGTTCTAAGCCATTCGCTCCTGCTGCTTCACA
AAAAGGAAGATGGAATTTGGTCCACTGATATTTTAAAGGACCAGAAAGAAC
CCAAAAATAAGACCTTTCTAAGATGCGAGGCCAAGAATTATTCTGGACGTT
TCACCTGCTGGTGGCTGACGACAATCAGTACTGATTTGACATTCAGTGTCAA
AAGCAGCAGAGGCTCTTCTGACCCCCAAGGGGTGACGTGCGGAGCTGCTAC
ACTCTCTGCAGAGAGAGTCAGAGGGGACAACAAGGAGTATGAGTACTCAGT
GGAGTGCCAGGAGGACAGTGCCTGCCCAGCTGCTGAGGAGAGTCTGCCCAT
TGAGGTCATGGTGGATGCCGTTCACAAGCTCAAGTATGAAAACTACACCAG
CAGCTTCTTCATCAGGGACATCATCAAACCTGACCCACCCAAGAACTTGCA
GCTGAAGCCATTAAAGAATTCTCGGCAGGTGGAGGTCAGCTGGGAGTACCC
TGACACCTGGAGTACTCCACATTCCTACTTCTCCCTGACATTCTGCGTTCAG
GTCCAGGGCAAGAGCAAGAGAGAAAAGAAAGATAGAGTCTTCACGGACAA
GACCTCAGCCACGGTCATCTGCCGCAAAAATGCCAGCATTAGCGTGCGGGC
CCAGGACCGCTACTATAGCTCATCTTGGAGCGAATGGGCATCTGTGCCCTGC
AGTGTTCCTGGAGTAGGGGTACCTGGGGTGGGCGCCAGAAACCTCCCCGTG
GCCACTCCAGACCCAGGAATGTTCCCATGCCTTCACCACTCCCAAAACCTGC
TGAGGGCCGTCAGCAACATGCTCCAGAAGGCCAGACAAACTCTAGAATTTT
ACCCTTGCACTTCTGAAGAGATTGATCATGAAGATATCACAAAAGATAAAA
CCAGCACAGTGGAGGCCTGTTTACCATTGGAATTAACCAAGAATGAGAGTT
GCCTAAATTCCAGAGAGACCTCTTTCATAACTAATGGGAGTTGCCTGGCCTC
CAGAAAGACCTCTTTTATGATGGCCCTGTGCCTTAGTAGTATTTATGAAGAC
TTGAAGATGTACCAGGTGGAGTTCAAGACCATGAATGCAAAGCTGCTGATG
GATCCTAAGAGGCAGATCTTTCTAGATCAAAACATGCTGGCAGTTATTGATG
AGCTGATGCAGGCCCTGAATTTCAACAGTGAGACTGTGCCACAAAAATCCT
CCCTTGAAGAACCGGATTTTTATAAAACTAAAATCAAGCTCTGCATACTTCT
TCATGCTTTCAGAATTCGGGCAGTGACTATTGATAGAGTGATGAGCTATCTG
AATGCTTCCTAAAAAGCGAGGTCCCTCCAAACCGTTGTCATTTTTATAAAAC
TTTGAAATGAGGAAACTTTGATAGGATGTGGATTAAGAACTAGGGAGGGGC
TAGCTCGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGA
ATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTAT
TTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATA
AACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGA
GGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAGATC
CATTTGGGACGCGTATCTAATAAGTAGAGTCCTCATGCTTAGTTAACAACTA
TTTTTTATGTTAAATCAATTAGTACACCGCTATGTTTAATACTTATTCATATT
TTAGTTTTTAGGATTGAGAATCAATACAAAAA_TTAATGCATCATTAATTTT
AGAAATACTTAGTTTCCACGTAGTCAATGAAACATTTGAACTCATCGTACAG
GACGTTCTCGTACAGGACGTAACTATAAACCGGTTTATATTTGTTCAAGATA
GATACAAATCCGATAACTTTTTTTACGAATTCTACG 
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